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Abstract	
Synthetic	 polymers	 represent	 a	 versatile	 class	 of	 biomaterials	 applied	 for	 tissue	 engineering,	
drug	 delivery,	 and	 biosensors.	 Among	 the	 polymer	 systems	 developed,	 polyethylene	 glycol	
(PEG)	 is	 the	 gold	 standard	 in	 the	 field	 thanks	 to	 its	 excellent	 biocompatibility,	 high	 water	
solubility,	and	low	toxicity.	Despite	its	popularity,	health	concerns	originating	from	the	presence	
of	PEG	antibodies	in	humans	have	increased	the	interest	in	alternative	polymers	for	biomedical	
applications.	Among	these,	poly(oligo(ethylene	glycol)	methyl	ether	methacrylate)	 (POEGMA),	
poly(N-acryloyl	morpholine)	(PNAM),	and	poly(2-alkyl-2-oxazoline)s	(PAOx)	were	investigated	in	
the	present	thesis.		
The	first	two	parts	of	the	thesis	describe	the	α-	or	ω-end	chain	functionalization	of	PAOx	during	
initiation	 or	 termination	 of	 the	 cationic	 ring-opening	 polymerization	 (CROP)	 of	 2-ethyl-2-
oxazoline	 (EtOx).	 In	 Chapter	 3,	 new	 nosylate	 initiators	 were	 synthesized	 and	 used	 to	 obtain	
maleimide-	or	 thiol-functional	PAOx.	After	 respective	optimization	of	 the	 reaction	conditions,	
well-defined	polymers	with	molar	masses	relevant	for	either	bioconjugation	to	a	model	protein	
or	 surface	patterning	were	obtained	 from	 the	 synthesized	 initiators.	 Chapter	 4	 describes	 the	
synthesis	 of	 the	 first	 PEtOx-based	 macromonomers	 (MM)	 for	 ring-opening	 metathesis	
polymerization	 (ROMP)	 to	 develop	 a	 metal-free	 PEtOx-based	 MRI	 probe.	 PEtOx	 MM	 were	
obtained	by	termination	of	the	CROP	of	EtOx	with	norbornene	moieties.	Bivalent	alkyne-PEtOx	
MM	were	 functionalized	 with	 a	 paramagnetic	 nitroxide,	 used	 as	MRI	 contrast	 enhancement	
agent,	by	CuAAC	click	 reaction.	The	 synthesis	of	bottlebrush	polymers	and	BASPs	 from	 linear	
and	 nitroxide-functionalized	 PEtOx	MMs	 by	 graft-through	 ROMP	was	 carried	 out	with	 nearly	
quantitative	 conversion.	 The	 new	 PEtOx-based	 MRI	 probe	 showed	 an	 improved	 transverse	
relaxivity	 (r2)	 of	 up	 to	∼13.5	 times	 higher	when	 compared	 to	 common	 nitroxides,	 indicating	
potential	for	further	development	as	an	alternative	to	the	previously	reported	PEG-based	MRI	
probes.		
In	the	last	part	of	the	thesis,	a	method	to	evaluate	the	influence	of	polymer	type,	molar	mass,	
and	 conjugation	 degree	 on	 the	 physicochemical	 properties	 of	 polymer-conjugated	 lysozyme	
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was	developed.	Low	molar	mass	(3	kDa)	mono-conjugates	(both	PNAM	and	POEGMA)	showed	
an	 increased	 or	 equal	 activity	 to	 that	 of	 the	 native	 protein,	 combined	 with	 an	 increased	
equilibrium	 solubility	 in	 high	 salt	 concentrations	 at	 pH	 3	 compared	 to	 native	 lysozyme.	
POEGMA7.5kDa	 showed	 the	 highest	 increase	 in	 solubility	 of	 all	 tested	 conjugates,	 but	 also	 a	
minimal	activity	 (less	 than	10%).	The	results	obtained	 indicate	 that	depending	on	the	desired	
application	for	the	conjugate,	a	compromise	should	be	found	between	enhanced	solubility	and	
activity.	 The	 high-throughput	method	 developed	 allows	 the	 potential	 extrapolation	 to	 assess	
the	physicochemical	properties	of	other	available	biocompatible	polymers.	
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Zusammenfassung	
Synthetische	Polymere	stellen	eine	vielseitige	Klasse	von	Biomaterialien	dar,	die	im	Bereich	des	
Tissue	 Engineering,	 der	 Wirkstoffabgabe	 und	 Biosensoren	 eingesetzt	 werden.	 Unter	 den	
entwickelten	 Polymersystemen	 stellt	 Polyethylenglykol	 (PEG)	 dank	 seiner	 ausgezeichneten	
Biokompatibilität,	 hohen	 Wasserlöslichkeit	 und	 geringen	 Toxizität	 den	 (Gold)Standard	 auf	
diesem	 Gebiet	 dar.	 Trotz	 seiner	 Popularität	 haben	 gesundheitliche	 Bedenken,	 aufgrund	 der	
Anwesenheit	von	PEG-Antikörpern	bei	Menschen,	das	Interesse	an	alternativen	Polymeren	für	
biomedizinische	 Anwendungen	 erhöht.	 Zwei	 von	 ihnen	 sind	 Poly(oligo(ethylen	
glykol)methylethermethacrylat)	 (POEGMA),	 Poly(N-acryloylmorpholin)	 (PNAM)	 und	 Poly(2-
alkyl-2-oxazolin)	(PAOx)	welche	in	der	vorliegenden	Arbeit	untersuchtwurden.	
Die	 ersten	 beiden	 Kapitel	 der	 Doktorarbeit	 beschäftigen	 sich	 mit	 der	 α-	 oder	 ω-	
Endkettenfunktionalisierung	 von	 PAOx	 während	 der	 Initiierung	 oder	 Terminierung	 der	
kationischen	 Ringöffnungspolymerisation	 (CROP)	 von	 2-Ethyl-2-oxazolin	 (EtOx).	 In	 Kapitel	 3	
wurden	 neue	 Nosylat-Initiatoren	 synthetisiert	 und	 verwendet,	 um	 PAOx	mit	Maleimid-	 oder	
Thiolfunktionalität	 zu	 erhalten.	Nach	 entsprechender	Optimierung	 der	 Reaktionsbedingungen	
wurde	 aus	 den	 synthetisierten	 Initiatoren	 wohldefinierte	 Polymere	 erhalten,	 dessen	
Molmassen	 entweder	 für	 eine	 Biokonjugation	 an	 ein	 Modellprotein	 oder	 eine	
Oberflächenstrukturierung	relevant	sind.	Kapitel	4	beschreibt	die	Synthese	einer	ringöffnenden	
Metathese-Polymerisation	 (ROMP),	 die	 erstmalig	 auf	 PEtOX	Makromonomeren	 (MM)	basiert,	
für	 die	 Entwicklung	 einer	 metallfreien	 PEtOx-basierten	 Magnetresonanztomographie-Sonde	
(MRT).	 PEtOx-MM	wurden	 durch	 Terminierung	 der	 CROP	 von	 EtOx	mit	 Norbornen	 erhalten.	
Bivalente	 Alkin-PEtOx-MM	 wurden	 mit	 dem	 paramagnetischen	 Nitroxid,	 das	 als	 MRT-
Kontrastverstärkungsmittel	 verwendet	 wurde,	 durch	 CuAAC	 im	 Rahmen	 der	 Click-Chemie	
funktionalisiert.	 Die	 Synthese	 von	 „Bottlebrush“-Polymeren	 und	 BASPs	 aus	 linearen	 und	
Nitroxid-funktionalisierten	 PEtOx-MM	 durch	 graft-through	 ROMP	 wurde	 mit	 nahezu	
quantitativem	Umsatz	durchgeführt.	Die	neue	PEtOx-basierte	MRT-Sonde	wies	eine	verbesserte	
transversale	Relaxivität	(r2)	von	bis	zum	ca.	13-Fachen	im	Vergleich	zu	Nitroxid	CP-3	auf,	was	auf	
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eine	mögliche	Weiterentwicklung	 als	 Alternative	 zu	 den	 bisher	 beschriebenen	 PEG-basierten	
MRT-Sonden	hinweist.	
Im	 letzten	 Kapitel	 der	 Arbeit	 wurde	 eine	 Methode	 zur	 Bestimmung	 des	 Einflusses	 von	
Polymertyp,	 Molmasse	 und	 Konjugationsgrad	 auf	 die	 physikalisch-chemischen	 Eigenschaften	
von	PNAM-	und	POEGMA-konjugiertem	Lysozym	entwickelt.	Der	Satz	von	Monokonjugaten	mit	
niedriger	Molmasse	(3	kDa)	(sowohl	PNAM	als	auch	POEGMA)	zeigte	eine	erhöhte	oder	gleiche	
Aktivität	zu	der	des	nativen	Proteins,	kombiniert	mit	einer	erhöhten	Gleichgewichtslöslichkeit	in	
hohen	 Salzkonzentrationen	 bei	 pH	 3	 im	Vergleich	mit	 nativem	 Lysozym.	 POEGMA7.5kDa	 zeigte	
den	 höchsten	 Anstieg	 der	 Löslichkeit	 aller	 getesteten	 Konjugate,	 aber	 auch	 eine	 minimale	
Aktivität	 (weniger	 als	 10%).	 Abhängig	 von	 der	 gewünschten	Anwendung	 des	 Konjugats	 sollte	
ein	Kompromiss	zwischen	erhöhter	Löslichkeit	und	Aktivität	gefunden	werden.	Die	entwickelte	
Hochdurchsatzmethode	 erlaubt	 die	mögliche	 Extrapolation	 andere	 verfügbare	 biokompatible	
Polymere	zu	bewerten.	
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1	
Introduction		
The	use	of	synthetic	polymers	to	develop	biomaterials	such	as	scaffolds	for	tissue	engineering,	
drug-delivery	vehicles,	or	biomedical	 sensors,	has	encountered	significant	advance	during	 the	
last	decades.1–3	Polyethylene	glycol	(PEG)	is	the	most	widely	investigated	polymer	system	and	
the	 gold	 standard	 in	 the	 field.	 PEG	 exhibits	 a	 number	 of	 excellent	 properties	 such	 as	
biocompatibility,	 high	 water	 solubility,	 and	 low	 toxicity	 and	 immunogenicity.4	 Thanks	 to	 its	
approval	by	the	Food	and	Drug	Administration	(FDA)	as	food	additive	and	in	medicine,	PEG	has	
been	widely	used	not	only	as	drug	carriers,	but	also	 for	 the	 fabrication	of	 implants,	as	 tablet	
surface	coatings,	and	for	daily	use	products	such	as	oral	hygiene	products	and	cosmetics.5–8	The	
popularity	of	this	polymer	has	led	not	only	to	research	on	further	biomedical	applications,	but	
also	deeper	understanding	of	the	side	effects	PEG	has	on	the	human	body.	For	instance,	cases	
of	hypersensitivity	and	allergic	reactions	to	PEG	have	been	reported	with	increasing	frequency.9	
Immunogenicity	 studies	 show	 that	 PEGylated	 proteins	 can	 induce	 the	 formation	 of	 PEG	
antibodies.10–12	 In	 fact,	 in	 2009,	 antibodies	 against	 PEG	were	 found	 in	 25%	 of	 healthy	 blood	
donors,	compared	to	0.2%	only	20	years	before.13	This	can	be	attributed	to	the	better	detection	
methods	 recently	 developed,	 but	 also	 to	 the	 large	 exposure	 of	 humans	 to	 PEG.	 Another	
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controversial	aspect	 is	the	non-biodegradability	of	PEG,	that	can	result	 in	accumulation	in	the	
body	as	vacuoles	in	organs	such	as	kidneys,	liver,	or	spleen.14		
Unequivocally,	 PEG	 has	 the	 advantage	 of	 decades	 of	 research,	 and	 a	 number	 of	 PEGylated	
drugs	already	 in	 the	market	 to	back	 it	up.15	However,	 the	 findings	on	adverse	 side	effects	of	
PEG	 have	 increased	 the	 interest	 in	 alternative	 polymer	 systems	 that	 could	 serve	 in	 the	
biomedical	 field.13,16	 In	 addition,	 recent	 advances	 on	 polymerization	 techniques	 provide	 the	
possibility	 to	 develop	 polymer	 systems	 with	 tunable	 properties	 by	 careful	 selection	 of	
(co)monomers,	 the	 availability	 of	 a	 number	 of	 functionalization	 strategies,	 and	 access	 to	
different	 architectures	 with	 well-defined	 polymer	 sizes,	 as	 well	 as	 the	 possibility	 to	 obtain	
narrow	dispersities.17–20	Among	the	pool	of	hydrophilic	biocompatible	polymers	already	being	
investigated	 are	 poly(amino	 acid)s,21	 poly(oligo(ethylene	 glycol)	 methyl	 ether	 methacrylate)	
(POEGMA),22–24	 poly(N-acryloyl	 morpholine)	 (PNAM),25	 polyglycerol	 (PG),26	 poly(N-(2-
hydroxypropyl)methacrylamide)	 (PHPMA),27	 poly(vinylpyrrolidone)	 (PVP),28	 and	 poly(2-alkyl-2-
oxazoline)s	(PAOx).29	Among	these,	PAOx,	POEGMA,	and	PNAM	are	of	utter	relevance	for	the	
development	of	this	thesis.		
Although	PAOx	were	first	reported	in	1966,30–33	it	is	only	in	the	last	couple	of	decades	that	the	
interest	in	these	polymers	has	increased,	proved	by	an	exponential	growth	in	published	reports	
and	 patents	 of	 PAOx	 with	 promising	 applications	 in	 biomedical	 fields.	 PAOx	 share	 some	
characteristics	with	PEG	such	as	high	solubility	in	water,	biocompatibility,	and	low	toxicity,	but	
with	 the	 great	 advantage	 of	 synthetic	 versatility	 that	 comes	 from	 the	 polymerization	
mechanism.34,35	 PAOx	 are	 synthesized	 by	 living	 cationic	 ring-opening	 polymerization	 (CROP),	
which	allows	the	tailoring	of	the	properties	of	the	resulting	polymer	depending	on	the	choice	of	
2-oxazoline	 monomers,	 and	 the	 addition	 of	 functional	 groups	 at	 the	 α	 or	 ω	 end	 chains,	
depending	on	 the	 initiator	and	 terminating	agent	used.36	The	polymerization	mechanism	also	
allows	the	formation	of	random	and	block	copolymers,	and	a	variety	of	architectures,	with	well-
defined	polymer	sizes	and	narrow	distributions.37	In	the	scope	of	the	present	thesis,	a	number	
of	end-functionalized	PAOx	were	synthesized	taking	advantage	of	the	living	CROP	mechanism.		
	 Introduction	 1.	
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Chapter	3	describes	 the	design	and	synthesis	of	maleimide-	and	thiol-	α-functionalized	PAOx,	
obtained	using	novel	functional	initiators	for	the	CROP	of	2-ethyl-2-oxazoline	(EtOx)	(Figure	1).	
The	synthesis	and	characterization	of	the	new	initiators	are	presented,	as	well	as	kinetic	studies	
of	 the	 polymerization	 of	 EtOx	 with	 the	 newly	 synthesized	 initiators.	 The	 resulting	 polymers	
were	characterized	to	prove	end-group	fidelity	and	reactivity	with	model	molecules.	For	each	
initiator,	an	application	relevant	to	the	potential	of	PAOx	either	as	polymer-protein	conjugate	
or	as	passivating	materials	for	surfaces	is	presented.			
Chapter	4	deals	with	the	synthesis	of	new	PAOx	macromonomers	for	ring-opening	metathesis	
polymerization	 (ROMP),	 to	 produce	 a	 new	 type	 of	 organic-radical	 based	magnetic	 resonance	
imaging	(MRI)	contrast	agent	as	alternative	to	PEG.	The	new	macromonomers	were	developed	
using	 the	 termination	 step	 as	 a	 functionalization	 strategy	 to	 introduce	 either	 norbornene	 or	
dual	norbornene-alkyne	groups,	 for	 further	 functionalization	 (Figure	1).	 The	macromonomers	
were	characterized	and	used	for	the	first	time	for	the	formation	of	bottlebrush	polymers	and	
brush-arm	 star	 polymers	 by	 ROMP.	 The	 reduction-resistant	 spirocyclohexyl	 nitroxide	 chex,	
which	provides	MRI	contrast	enhancement,	was	incorporated	to	the	macromonomers	by	click	
reaction,	resulting	in	a	PAOx-based	metal-free	MRI	probe.	Relaxivity	studies	were	carried	out	to	
test	its	potential	use	as	an	alternative	to	already	existing	PEG-based	MRI	probes.	
	
Figure	1.	General	strategies	for	the	functionalization	of	PAOx	and	aim	of	the	project.	
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Chapter	5	describes	the	synthesis	and	conjugation	of	the	biocompatible	polymers	POEGMA	and	
PNAM	to	a	model	protein,	for	the	evaluation	of	the	influence	of	a	series	of	parameter	on	the	
physicochemical	 properties	 of	 the	 resulting	 conjugates.	 The	 conjugation	 of	 polymers	 to	
proteins,	 generally	brings	 advantages	 such	as	better	 solubility	 and	 longer	 circulation	 times	 in	
vivo.	 However,	 there	 is	 no	 available	 tool	 to	 evaluate	 the	 influence	 of	 parameters	 such	 as	
polymer	 type,	 molar	 mass,	 or	 the	 number	 of	 chains	 attached	 to	 the	 conjugate	 on	
physicochemical	properties.	Here,	sets	of	POEGMA	and	PNAM	of	different	molar	masses	were	
synthesized,	characterized,	and	conjugated	to	lysozyme.	A	systematic	assessment	of	the	effects	
of	 polymer	 size	 and	 conjugation	 degree	 on	 aggregation	 behavior,	 solubility,	 and	 remaining	
activity	was	performed	(Figure	2).			
	
	
Figure	 2.	 Strategy	 for	 the	 formation	 of	 polymer-protein	 conjugates	 and	 its	 separation	 for	 high-
throughput	screening	of	physicochemical	properties.		
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2	
Theory	and	Background	
	
2.1. 	Biocompatible	polymers:	Poly(ethylene	glycol)	and	alternatives	
Synthetic	biocompatible	polymers	enable	the	development	of	materials	for	modern	biomedical	
applications	 such	 implants,	 biosensors,	 drug	 delivery,	 gene	 therapy,	 and	 regenerative	
medicine.3,38	To	achieve	this,	stimuli-responsive	polymers,	water-soluble	polymers,	or	polymer	
conjugates	 have	 to	 be	 developed.39	 Considering	 the	 advances	 on	 living	 polymerization	
techniques,	 it	 is	possible	 to	obtain	highly	defined	materials	with	 the	necessary	 functionalities	
for	the	desired	application.		
Polymers	 for	 drug	 delivery	 are	 used	 in	 a	 number	 of	 ways,	 including	 the	 formation	 of	 drug	
complexes	 by	 direct	 attachment	 to	 the	 pharmaceutical	 active,40	 lipid-polymer	 conjugates	 to	
become	part	of	the	liposomal	delivery	system,41	or	nucleic	acid-polymer	complexes	attached	via	
cationic	interactions.42,43	These	polymer	carriers	provide	a	shielding	effect	on	the	drug	to	avoid	
fast	 recognition	 by	 the	 immune	 system	 and	 clearance	 from	 the	 body.	 The	 suppression	 of	
interactions	 with	 blood	 components	 in	 the	 body	 is	 known	 as	 the	 stealth	 effect.44,45	 Other	
advantages	of	the	use	of	a	polymer	for	conjugation	include	protection	against	degradation	by	
enzymes,	an	increased	solubility	in	water,	and	selective	tumor	accumulation.46	
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Structural	parameters	of	the	polymer,	such	as	molar	mass	and	dispersity	have	an	influence	on	
the	 biological	 and	 stabilizing	 effects	 of	 the	 polymer	 carrier,	 affecting	 biocompatibility	 and	
stealth	behavior.47	For	instance,	a	low	dispersity	(Ð)	is	desired	for	most	biomedical	applications	
since	 it	provides	 the	homogeneity	necessary	 to	ensure	 reproducibility	 in	body-residence	 time	
and	immunogenicity.	
Examples	 of	 synthetic	 biocompatible	 polymers	 tested	 for	 drug-delivery	 applications	 include	
poly(ethylene	glycol)	(PEG),48	polylactic	acid	(PLA),49	polysialic	acid	(PSA),50	N-(2-hydroxypropyl)	
methacrylamide	(HPMA),27	polyglutamic	acid	(PGA),21	and	polyvinylpyrrolidone	(PVP).28	Among	
these,	poly(ethylene	glycol)	(PEG)	is	the	most	widely	used	non-ionic,	hydrophilic	polymer	with	
stealth	 behavior.	 PEG	 is	 considered	 the	 gold	 standard	 in	 polymer-based	 biomedical	
applications.	Despite	 its	success,	 it	has	relevant	 limitations	that	have	recently	raised	concerns	
regarding	its	use,	and	there	is	an	ongoing	search	for	potential	synthetic	polymer	alternatives.3,47		
In	this	section,	a	description	of	the	main	characteristics	of	PEG	will	be	addressed,	as	well	as	the	
main	 raised	 concerns	 of	 its	 use	 in	 therapeutics.	 Examples	 of	 synthetic	 polymers	 that	 have	
shown	potential	to	be	alternatives	to	PEG	in	biomedical	applications	will	be	given.		
	
2.1.1. Advantages	and	disadvantages	of	PEG	
PEG	is	the	most	studied	and	applied	synthetic	polymer	in	the	biomedical	field.	Among	the	many	
advantages	of	PEG	claimed	so	far	are	its	nontoxicity	and	low	immunogenicity.51	In	addition,	the	
anionic	polymerization	of	ethylene	oxide	can	provide	defined	polymers	with	narrow	dispersities	
showing	 Ð	 <	 1.1.	 Its	 high	 solubility	 in	 both	 organic	 and	 aqueous	 solvents	 make	 end-group	
modifications	possible	while	at	the	same	time	ensuring	biocompatibility.47		
In	1977,	the	first	covalent	attachment	of	PEG	to	bovine	serum	albumin	(BSA)	and	liver	catalase	
was	 reported.52	 It	 was	 found	 that	 the	 attachment	 of	 the	 polymeric	 chain	 increased	 the	
circulation	 time	 in	 blood	 vessels	 and	 decreased	 the	 immunogenicity	 of	 the	 proteins,	 while	
retaining	the	activity	of	the	enzymes.	PEG	conjugates	show	high	water	solubility,	physical	and	
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thermal	 stability,	 reduced	 aggregation,	 less	 immunogenicity,	 and	 long	 storage	 capability.44	
Pharmacokinetic	studies	of	PEG	in	humans	have	shown	that	gastrointestinal	absorption	of	PEG	
decreases	as	the	molar	mass	increases,	with	excretion	in	humans	of	85%	and	96%	in	12	h	after	
intravenous	injection	of	1	g	of	1	kDa	and	6	kDa	PEG,	respectively.	Toxicology	tests,	carcinogen	
studies,	and	mutagen	assays	did	not	show	adverse	effects	from	low	molar	mass	PEG.53		
In	1990,	Adagen	was	the	first	PEGylated	protein	to	be	approved	by	the	FDA.15	This	conjugate	is	
used	for	enzyme	replacement	therapy	in	the	treatment	of	severe	combined	immunodeficiency	
disease.	Over	40	years	after	 the	 first	PEGylation,	a	number	of	PEG	conjugated	proteins,	DNA,	
RNA,	and	polypeptides	have	been	developed,	showing	more	stable	and	efficient	performances	
when	compared	 to	using	only	 to	 the	pharmaceutical	active.	Table	1	 summarizes	some	of	 the	
FDA-approved	PEG	conjugates	already	available	on	the	market.54		
	
Table	1.	Examples	of	FDA	approved	PEGylated	drug	carriers.	
PEGylated	protein	 Molar	mass	 Protein	name	
Adagen	 5	kDa	 Adenosine	deaminase	
Cimzia	 40	kDa	 Antibody	TNF	
Neulasta	 20	kDa	 Filgrastim	G-CSF	
Oncaspar	 5	kDa	 L-asparaginase	
PEGASYS	 40	kDa	 Interferon	alfa-2a	
PEG-INTRON	 12	kDa	 Interferon	alfa-2b	
Somavert	 5	kDa	
Human	growth	hormone	receptor	
antagonist	B2036	
Krystexxa	 10	kDa	 Mammalian	urate	oxidase	
Mircera	 30	kDa	
Continuous	erythropoietin	receptor	
activator	
	
The	 mentioned	 characteristics	 make	 PEG	 useful	 for	 a	 number	 of	 applications	 besides	 drug	
carrier.	PEG	is	currently	used	for	blood	and	organ	storage,55	the	fabrication	of	stents,56	and	as	
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excipient	 for	 nasal	 and	 ocular	 applications.57	 On	 daily	 use	 products,	 PEG	 can	 be	 found	 in	
shampoos,	fragrances,	cleansing	agents,	and	contact	lenses,	among	many	others.	
The	large	and	continuous	exposure	to	PEG	in	cosmetics,	food	processing,	and	pharmaceuticals	
that	 has	 taken	 place	 for	 a	 few	 decades	 now,	 has	 also	 lead	 to	 more	 findings	 regarding	
unfavorable	side	effects	of	PEG	carriers.	
The	non-immunogenicity	of	PEG	is	one	of	the	controversial	aspects	surrounding	the	use	of	PEG	
conjugates.10	 Studies	 have	 shown	 that	 the	 use	 of	 PEGylated	 proteins	 such	 as	 uricase,	 or	
ovalbumin,	 can	 induce	 the	 formation	 of	 antibodies	 against	 PEG	 (anti-PEG).58	 In	 the	 human	
body,	the	main	consequence	of	anti-PEG	presence	is	limiting	the	efficacy	of	the	peptide,	protein	
or	drug	used,	or	reducing	the	tolerance	to	the	conjugate.	However,	keeping	in	mind	that	most	
proteins	 or	 drugs	 used	 are	 immunogenic	 themselves,	 the	 use	 of	 PEG	 can	mask	 the	 immune	
system	response	to	these	therapeutics.48	An	important	consequence	of	the	constant	exposure	
of	humans	to	PEG	for	the	last	decades	is	evident	in	a	study	conducted	in	2009,	where	in	25%	of	
healthy	blood	donors	PEG	antibodies	were	found,	whereas	only	20	years	before	the	occurrence	
was	only	0.2%.11	
The	 non-biodegradability	 of	 PEG	 is	 another	 disadvantage	 in	 biomedical	 applications.	 Control	
over	 the	molar	mass	of	 the	polymer	dictates	 toxicity	and	excretion	of	 the	body.59	For	certain	
applications,	the	size	requirements	of	the	polymer	include	exceeding	the	renal	clearance	limit	
to	increase	the	circulation	time	of	the	drug.	However,	the	longer	circulation	of	these	polymers	
results	in	their	excretion	through	the	liver	or	deposition	in	other	tissues,	inducing	the	formation	
of	 vacuoles	 in	 the	 liver,	 kidneys,	or	 spleen.14	On	 the	other	hand,	polymers	below	400	Da	are	
found	toxic.	These	small	size	PEG	chains	can	go	through	oxidative	degradation	by	alcohol	and	
aldehyde	dehydrogenase	and	produce	diacid	and	hydroxyl	acid	metabolites.60		
The	 toxicity	of	 the	 side	products	obtained	during	PEG	synthesis	 is	 another	 concern.	Both	 the	
remaining	ethylene	oxide	of	 the	polymerization,	 and	1,4-dioxane,	 the	main	 side	product,	 are	
considered	 carcinogenic	 in	 humans.	 Therefore,	 strict	 content	 limits	 of	 the	 mentioned	
compounds	in	PEG	are	required	for	biomedical	applications.47		
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The	 described	 limitations	 have	 boosted	 efforts	 to	 find	 other	 potential	 polymers	 that	 can	 be	
used	 for	 therapeutics,	 either	 by	 addressing	 the	 disadvantages	 previously	 described,	 or	 by	
bringing	 additional	 benefits	 to	 the	 function	 of	 the	 formed	 conjugates.	 Some	 of	 the	 relevant	
results	 and	 possibilities	 of	 synthetic	 polymeric	 systems	 will	 be	 described	 in	 the	 following	
section.		
	
2.1.2. Alternatives	to	PEG	
2.1.2.1. Degradable	polymers	
Poly(glutamic	 acid)	 (PGA),61	 poly(hydroxyethyl-L-asparagine)	 (PHEA),62	 poly(hydroxyethyl-L-
glutamine)	 (PHEG),63	and	poly(sarcosine)	 (pSar),64	are	 some	poly(amino	acid)s	 currently	being	
tested	as	alternatives	 to	PEG	(Figure	3A-D).	The	biodegradability	of	 these	polymers	 into	their	
corresponding	amino	acids,	which	can	then	be	metabolized	in	the	body,	represents	the	major	
advantage	over	other	biocompatible	polymers.61,65,66	Out	of	the	mentioned	poly(amino	acid)s,	
PGA	has	already	been	approved	to	use	as	thickener	 in	food,	wetting	agent	for	cosmetics,	and	
additive	 for	 fertilizers.61	 Importantly,	 a	 PGA	 conjugate	 for	 cancer	 treatment	 is	 currently	 on	
phase	 III	 of	 clinical	 trials.	 On	 preliminary	 studies,	 the	 paclitaxel-PGA	 conjugate	 showed	 high	
water	solubility,	improved	safety,	enhanced	antitumor	efficacy,	and	produced	less	side	effects,	
when	compared	to	native	paclitaxel.67	
Poly(oligo(ethylene	 glycol)	 methyl	 ether	 methacrylate)	 (POEGMA),	 a	 hydrophilic,	 PEG-based	
comb-like	polymer,	has	been	extensively	studied	 for	potential	biomedical	applications	 (Figure	
3E).	 POEGMA	 can	 be	 synthesized	 by	 reversible-deactivation	 radical	 polymerization	 (RDRP)	
techniques	 such	 as	 atom	 transfer	 radical	 polymerization	 (ATRP),	 or	 reversible	 addition-
fragmentation	 chain	 transfer	 (RAFT)	 polymerization.	 The	 resulting	 polymers	 not	 only	 present	
defined	sizes	and	narrow	dispersities,	but	can	be	modified	to	add	special	functionalities	to	the	
polymeric	 chain	 depending	 on	 the	 initiator	 or	 transfer	 agent	 used.22–24	 POEGMA	 has	 been	
grafted	from	model	proteins	using	modified	ATRP	initiators	in	aqueous	medium	with	high	yields	
and	 low	 dispersities.23,68,69	 The	 resulting	 conjugates	 have	 the	 advantage	 of	 specificity	 on	 the	
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conjugation	site	(either	N	or	C	terminus).	In	addition,	in	vivo	studies	of	the	conjugates	showed	
an	 increased	 circulation	 time	of	 15-50	 times,	 as	well	 as	 increased	 tumor	 accumulation	when	
compared	 to	 the	 native	 protein.13	 POEGMA	 brushes	 are	 degradable,	 since	 these	 are	 linked	
through	a	methacrylate	backbone,	connected	by	ester	bonds	that	are	susceptible	to	hydrolysis	
and	enzymatic	breakdown.		
Among	other	relevant	degradable	synthetic	polymers	studied	as	potential	alternatives	to	PEG	
are	 poly(zwitterions),	 such	 as	 poly(carboxybetaine	 methacrylate)	 (PCBMA)	 and	
poly(sulfobetaine	methacrylate)	 (PSBMA)	 (Figure	 3F-G).	 Either	 as	 self-assembled	monolayers,	
or	as	brush	copolymers	on	surfaces,	this	type	of	polymers	show	protein	resistant	properties.70,71	
Conjugation	of	PCBMA	to	a	model	enzyme	showed	an	increased	stability	similar	to	PEGylation,	
but	with	an	improvement	in	the	binding	affinity.72	This	can	be	achieved	thanks	to	the	properties	
of	 zwitterionic	 polymers	 to	 regulate	 ionic	 structuring	 of	 water.	 By	 drawing	 water	 molecules	
away	 from	 hydrophobic	 regions	 of	 the	 protein,	which	 is	 generally	 the	 catalytic	 site,	 protein-
substrate	 interactions	are	enhanced.	Similar	 to	POEGMA,	when	the	backbone	of	 the	polymer	
brushes	studied	is	methacrylate-based,	degradability	is	possible.	However,	the	biocompatibility	
in	vivo	of	the	degradation	products,	e.g.,	polymethacrylic	acid,	should	also	be	considered.	
	
Figure	 3.	 Structures	 of	 a)	 poly(glutamic	 acid)	 (PGA),	 b)	 poly(hydroxyethyl-L-glutamine)	 (PHEG),	 c)	
poly(hydroxyethyl-L-asparagine)	 (PHEA),	d)	poly(sarcosine)	 (pSar),	e)	poly(oligo(ethylene	glycol)	methyl	
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ether	methacrylate)	(POEGMA)	f)	poly(carboxybetaine	methacrylate)	(PCBMA),	and	g)	poly(sulfobetaine	
methacrylate)	(PSBMA).	
2.1.2.2. Nondegradable	polymers	
Polyglycerol	(PG)	is	structurally	very	similar	to	PEG	and,	as	expected,	its	properties	are	also	very	
similar,	 including	 an	 excellent	 biocompatibility	 (Figure	 4A).	 However,	 PG	 also	 shares	 the	
disadvantage	of	non-degradability	with	PEG.	An	advantage	of	PG	is	the	possibility	to	synthesize	
a	number	of	architectures,	including	linear	and	hyperbranched	polymers,	with	a	wide	range	of	
defined	molar	 masses	 and	 added	 functionalities.26	 A	 study	 of	 linear	 and	 hyperbranched	 PG	
showed	 superior	 blood	 and	 cell	 compatibility	 and	 longer	 circulation	 times	 from	 both	 PG	
architectures,	 when	 compared	 to	 PEG.73	 The	 first	 PG-protein	 conjugate	 was	 developed	 by	
grafting	 branched	 PG	 to	 the	model	 protein	 BSA,74	 and	 since	 then	 conjugates	 using	 different	
architectures	of	PG	have	been	reported.	An	activity	comparison	among	linear,	mid-functional,	
hyperbranched,	and	 linear	hyperbranched	architectures	 conjugated	 to	 lysozyme,	 showed	 the	
linear	PG	conjugate	showed	the	lowest	remaining	activity	among	the	set	of	conjugates.75		
Poly(N-(2-hydroxypropyl)methacrylamide)	 (PHPMA)	 is	 a	 non-toxic,	 neutral,	 hydrophilic,	
biocompatible	 polymer	 (Figure	 4B).76	 It	 has	 been	 investigated	 for	 over	 four	 decades	 for	
biomedical	 applications,	 since	 its	 characteristics	make	 it	 suitable	 for	 drug	 delivery.	 After	 the	
synthesis	 of	 well-defined	 PHPMA	was	 reported,77	 the	 number	 of	 PHPMA-protein	 conjugates	
developed	 has	 been	 increasing.	 Promising	 conjugates	 include	 a	 28	 kDa	 PHPMA-doxorubicin	
copolymer	and	a	25	kDa	PHPMA-platinate,	which	are	already	on	clinical	trials.47		
Poly(N-acryloylmorpholine)	 (PNAM)	 is	 a	 bi-substituted	 acrylamide	 derivative	 with	 properties	
including	solubility	in	water	and	other	polar	solvents,	and	low	toxicity	(Figure	4C).	It	has	been	
synthesized	by	RAFT	polymerization	and	modified	for	selective	attachment	to	surfaces,	as	well	
as	enzymes,	 showing	a	 reduced	 immunogenicity.78	For	 instance,	drug-PNAM	conjugates	have	
been	 reported	 for	 doxorubicin	 and	 amoxicillin,	 although	 without	 further	 evaluation.79	 In	
addition,	PNAM	conjugation	to	the	enzyme	Candida	lipase	resulted	in	conjugates	with	a	higher	
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solubility	in	organic	solvents	and	higher	remaining	activity	when	compared	to	its	reported	PEG	
analogue.79	
Polyvinylpyrrolidone	(PVP)	is	a	commercially	available	polymer,	already	used	for	a	wide	range	
of	 applications	 including	 adhesives,	 coatings,	 photoresists,	 photography,	 and	 textiles	 (Figure	
4D).47,80	Until	 recently,	PVP	was	 synthesized	by	 free	 radical	polymerization.	The	possibility	 to	
synthesize	 defined	 molecular	 weight	 PVP	 with	 narrow	 dispersities	 opened	 a	 number	 of	
possibilities	for	pharmaceutical	applications.81	PVP	has	been	tested	for	drug-delivery	systems,	
where	it	has	shown	increased	circulation	time,	as	well	as	higher	solubility	and	stability	towards	
denaturation.82	
Poly(2-alkyl-2-oxazoline)s	 (PAOx)	 are	 synthetic	 polymers	 which	 have	 gathered	 increasing	
popularity	 in	 the	 last	 couple	 of	 decades,	 especially	 in	 the	 biomedical	 field	 (Figure	 4E).	 The	
interest	 in	 PAOx	 comes	 from	 their	 versatility,	 since	 properties	 such	 as	 solubility	 and	
thermoresponsiveness	 can	 be	 tuned	 depending	 on	 the	 2-alkyl	 substituent	 selected.36,37	
Another	 advantage	 of	 PAOx	 over	 PEG	 is	 the	 easy	 access	 to	 copolymers,	 allowing	 the	
introduction	of	functional	groups	on	the	side	chain.35	Poly(2-methyl-2-oxazoline)	(PMeOx)	and	
poly(2-ethyl-2-oxazoline)	 (PEtOx)	 are	 the	 most	 popular	 PAOx,	 thanks	 to	 their	 high	 water	
solubility,	biocompatibility,	and	non-cytotoxicity.34	Despite	the	very	recently	renewed	interest	
in	PAOx,	the	first	PEtOx	conjugate	for	treatment	of	Parkinson’s	disease	already	entered	phase	II	
of	 clinical	 trials.83	 A	 more	 detailed	 description	 of	 the	 polymerization	 mechanism,	 different	
approaches	to	functionalization,	and	recent	advances	of	its	use	on	biomedical	research	will	be	
addressed	in	the	following	section.		
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Figure	 4.	 a)	 Polyglycerol	 (PG),	 b)	 poly(N-(2-hydroxypropyl)methacrylamide)	 (PHPMA),	 c)	 poly(N-
acryloylmorpholine)	(PNAM),	d)	poly(vinylpyrrolidone)	(PVP),	and	e)	poly(2-alkyl-2-oxazoline)s	(PAOx).	
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2.2. 	Poly(2-oxazoline)s	
The	 synthesis	 of	 poly(2-alkyl/aryl-2-oxazoline)s	 (PAOx)	 by	 polymerization	 of	 2-oxazolines	was	
first	described	in	the	1960s	by	four	independent	groups.30–33	However,	it	is	only	in	recent	years	
that	 interest	 in	 these	 polymers	 has	 rapidly	 increased,	 thanks	 to	 their	 potential	 biomedical	
applications29,34,84,85	 and	 the	 thermoresponsive	 properties	 of	 certain	 PAOx.86,87	 Particularly,	
PMeOx	 and	 PEtOx	 share	 properties	 such	 as	 biocompatibility,	 low	 toxicity,	 and	 anti-fouling	
behavior	with	PEG,	the	gold	standard	for	stealth	polymers.88,89		
PAOx	are	a	type	of	synthetic	polyamides	with	a	structure	that	is	isomeric	to	natural	peptides,90	
and	are	therefore	considered	pseudo	polypeptides	(Figure	5).		
	
	
Figure	5.	Structures	of	2-alkyl-2-oxazoline,	its	corresponding	polymer,	and	a	polypeptide.	
	
2.2.1. Cationic	ring-opening	polymerization	of	2-oxazolines	
PAOx	are	prepared	by	cationic	ring-opening	polymerization	(CROP).	This	type	of	polymerization	
enables	access	to	polymers	with	functional	end	groups	by	the	utilization	of	functional	initiators	
or	 terminating	 agents,	 as	 well	 as	 block	 copolymers	 by	 the	 sequential	 addition	 of	 different	
monomers.91	 The	 versatility	 of	 this	method	 allows	 the	 preparation	 of	 well-defined	 polymers	
with	 tunable	 properties.	 The	 CROP	 of	 2-oxazolines	 follows	 a	 chain-growth	 polymerization	
mechanism,	 where	 the	main	 steps	 are	 initiation,	 propagation,	 and	 termination,	 as	 shown	 in	
Scheme	1.	
Under	 the	 appropriate	 conditions,	 the	 CROP	 of	 2-oxazolines	 can	 proceed	 in	 a	 living	manner,	
which	 means	 that	 no	 chain	 transfer	 or	 undesired	 termination	 should	 occur	 during	 the	
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polymerization.36	To	achieve	this	 living	character,	the	purity	and	dryness	of	all	components	of	
the	system	is	of	utter	importance.	
	
	
Scheme	1.	General	mechanism	of	the	cationic	ring-opening	polymerization	of	2-alkyl-2-oxazolines.	
	
The	initiation	step	occurs	by	a	nucleophilic	attack	of	the	cyclic	imino	ether	to	the	electrophilic	
initiator	 resulting	 in	 the	 formation	 of	 an	 oxazolinium	 cation	 (Scheme	 1).	 When	 initiation	 is	
incomplete	 or	 slow,	 it	 leads	 to	 a	 deviation	 of	 the	 desired	 first-order	 kinetics.	 This	 results	 in	
broad	 molar	 mass	 distributions	 and	 high	 dispersities.36	 The	 CROP	 of	 2-oxazolines	 has	 been	
reported	 using	 a	 variety	 of	 initiators	 including	 Lewis	 acids	 such	 as	 boron	 trifluoride,	
trihalogenobismuthine,92	 and	 zirconium/tris(pentafluorophenyl)borate;	 alkyl	 esters	 such	 as	
tosylates,18	triflates,18	nosylates;19	and	halides	including	chlorides,16	bromides,16	and	iodides.17	
Some	 of	 the	 most	 commonly	 used	 initiators	 are	 alkylating	 agents,	 such	 as	 methyl	 triflate,	
methyl	tosylate,	methyl	iodide,	and	benzyl	bromide.	Among	these	possibilities,	methyl	tosylate	
is	 the	 most	 popular	 and	 preferred	 initiator	 for	 the	 CROP	 of	 2-oxazolines	 due	 to	 its	 higher	
stability,	 low	 price,	 and	 commercial	 availability.	When	modifying	 the	 initiator,	 alkyl	 tosylates	
may	 show	 slow	 initiation,	 and	 in	 these	 cases	 it	 is	 best	 to	 use	 an	 alternative	 counter	 ion.	
Although	triflates	provide	the	fastest	 initiation	when	compared	to	tosylates	and	nosylates,	 its	
inherent	 instability,	 along	 with	 a	 problematic	 synthesis	 and	 purification	 become	 a	 relevant	
disadvantage.93	 In	 such	 cases,	 nosylates	become	a	more	 suitable	possibility	 for	 the	design	of	
functional	initiators	due	to	their	stability	and	easier	synthesis.	
The	propagation	step	occurs	in	a	two-step	fashion	(Scheme	2).	The	first	(and	rate	determining)	
step	 is	 the	 addition	 of	 the	 first	 monomer	 to	 the	 product	 of	 initiation	 (kp,1).	 After	 that,	 the	
propagation	rate	constant	(kp)	increases	dramatically	because	of	a	neighboring,	intra-molecular	
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dipole-ion	polarization	effect	that	results	in	the	stabilization	of	the	transition	state.94	The	kp	for	
the	 CROP	 of	 2-oxazolines	 depends	 on	 a	 number	 of	 parameters	 such	 as	monomer	 structure,	
monomer	 concentration,	 solvent	 used,	 and	 temperature.95,96	 Optimized	 conditions	 for	 the	
CROP	of	2-oxazolines	are	140	°C	in	acetonitrile	using	a	microwave	reactor.	At	this	temperature,	
it	 was	 shown	 that	 theoretical	 and	 experimental	 values	 of	 molecular	 weight	 were	 almost	
perfectly	 close.97	However,	microwave	 irradiation	 is	not	necessary,	 and	 similar	 results	 can	be	
obtained	using	superheated	conditions	in	pressure	reactors	or	flow	reactors.98,99	
	
	
Scheme	2.	Propagation	mechanism	for	the	CROP	of	2-oxazolines.	
	
As	 previously	 mentioned,	 one	 of	 the	 conditions	 of	 a	 living	 polymerization	 is	 that	 no	 side	
reactions	occur.	For	the	CROP	of	2-oxazolines,	however,	two	possible	chain	transfer	reactions	
are	known	to	happen	(Scheme	3).100	The	main	side	reaction	is	a	β-elimination	process,	with	an	
imine-enamine	rearrangement	that	results	 in	the	formation	of	 two	species:	a	proton-initiated	
oxazolinium	 cation,	 and	 an	 enamine	 ether-terminated	 polymer	 chain.	 The	 second	 possible	
chain	 transfer	 reaction	 is	 only	 relevant	 at	 higher	 conversion,	 where	 the	 enamine	 ether-
terminated	 chain	 can	 act	 as	 nucleophile	 leading	 to	 chain	 coupling	 and	 the	 formation	 of	
branching	 points.101	 The	main	 problem	 with	 the	 proton-initiated	 oxazolinium	 cation	 created	
during	 chain	 transfer	 is	 the	 creation	 of	 a	 new	 growing	 center.	More	 growing	 chains	 present	
result	in	lower	molar	mass	polymers.	This	additional	and	unwanted	polymer	population	can	be	
detected	 using	 mass	 spectrometry,	 for	 example.	 It	 has	 been	 reported	 that	 chain	 transfer	
constants	 are	 200	 to	 800	 times	 smaller	 than	 propagation	 constants,	 depending	 on	 the	
conditions	and	monomer	used.94	This	means	chain	transfer	occurs	at	a	much	slower	rate	than	
propagation,	and	low	dispersities,	as	well	as	end	group	fidelity,	are	still	achievable.		
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Scheme	3.	Chain	 transfer	 reaction	 via	β-elimination.	 Top:	 enamine-functionalized	 chain	 and	a	proton-
initiated	growing	center.	Bottom:	Coupling	of	a	living	polymer	chain	to	an	enamine-functionalized	chain.	
Adapted	from	reference	36	with	permission	from	Elsevier.	
	
To	terminate	the	polymerization,	a	nucleophilic	agent	is	required	to	stop	the	propagation	of	the	
oxazolinium	ion	(Scheme	4).	There	are	two	possible	termination	mechanisms:	the	attack	on	the	
2-position	of	the	oxazolinium	ring	that	yields	the	kinetic	product,	or	the	nucleophilic	attack	on	
position	5,	which	is	thermodynamically	controlled.102,103		
	
	
Scheme	 4.	 Termination	 possibilities	 for	 the	 CROP	 of	 2-oxazolines.	 Left:	 Kinetic	 product	 obtained	 by	
termination	with	water.	Right:	Thermodynamic	product	by	nucleophilic	attack	on	position	5.	
	
Terminating	agents	based	on	oxygen,	nitrogen,	and	sulfur	are	normally	used.	One	of	the	most	
widely	used	terminating	agent	is	water,	that	attacks	on	the	2-position	of	the	oxazolinium	ions	
to	 form	 an	 amine	 ester	 end	 group	 that	 is	 then	 hydrolyzed	 to	 afford	 the	 hydroxyl-terminal	
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kinetically	 controlled	 product.104	 An	 alternative	 strategy	 for	 the	 introduction	 of	 a	 primary	
alcohol	end	group	 is	 the	use	of	a	methanolic	potassium	or	 sodium	hydroxide	 solution,	which	
gives	 the	 termination	on	 the	5-position.105	 The	nucleophilic	 character	of	 amines	makes	 them	
suitable	for	the	termination	reaction,	as	well.	Primary,	secondary,	and	tertiary	amines,	as	well	
as	 ammonia	 and	 azides	 have	 been	 reported	 to	 terminate	 the	 polymerization.106–109	 Although	
the	use	of	some	amines	can	possibly	terminate	more	than	one	chain	per	terminating	agent,	this	
can	be	 suppressed	using	a	 large	excess	of	 the	 terminating	molecule.	Aniline,110	 long	aliphatic	
amines,108	 derivatives	 of	 piperidine,111	 piperazine,112	 pyrrole,113	 among	 others	 have	 been	
reported	 as	 terminating	 agents	 for	 PAOx.	 Carboxylic	 acids	 such	 as	 maleic	 acid,114	 glutaric	
acid,115	 cinnamic	 acid,116	 among	 others	 have	 also	 been	 used	 to	 terminate	 the	 CROP	 of	 2-
oxazolines,43,117,118	as	well	as	sulfur-based	derivatives	such	as	sodium	thiolates,	that	 introduce	
terminal	carboxylic	acid	end	groups.119	
	
2.2.2. Functionalization	of	poly(2-oxazoline)s	
Depending	 on	 the	 desired	 application	 for	 the	 polymer,	 it	 is	 possible	 to	 tune	 a	 number	 of	
parameters.	 Physical	 properties,	 architecture,	 size,	 added	 functionalities,	 among	 other	
properties,	can	be	modified	to	achieve	the	established	goal.	The	versatility	of	PAOx	allows	the	
use	of	different	functionalization	strategies,	whether	that	means	modifying	end	groups	or	the	
side	chain.	Examples	of	these	strategies	are	described	in	the	following	section.		
	
2.2.2.1. Functional	initiators	
A	relevant	advantage	of	the	polymerization	mechanism	is	that	during	initiation,	an	α-terminal	
functionality	can	be	incorporated	into	the	PAOx	chains	using	a	functional	initiator.	The	desired	
functionality	 needs	 to	be	 compatible	with	 the	CROP	of	 2-oxazolines	 to	provide	 fast	 initiation	
and	ensure	the	living	character	of	the	polymerization.	Otherwise,	protection	strategies	for	the	
functionality	can	be	utilized.		
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A	number	of	initiators	bearing	functional	moieties	been	reported.	Among	these	functionalities	
are	 allyl120	 and	 alkyne	 groups,121	 for	 the	 possibility	 to	 introduce	 functional	 blocks	 by	 click	
reactions.	 For	 instance,	 an	 α-alkyne	 PMeOx	 was	 used	 to	 form	 graft	 copolymers	 of	 poly(ε-
caprolactone)-graft-poly(2-MeOx)	by	 copper-catalyzed	azide–alkyne	 cycloaddition	 (CuAAC)	 for	
potential	application	as	drug	carriers.122	Initiators	that	add	amine,123	hydroxyls,124	or	carboxylic	
acid	based	on	esters,125	and	other	specific	functionality	to	the	polymeric	chain	allow	for	further	
functionalization.	 Other	 types	 of	 initiators	 introduce	 functionality	 by	 structure,	 containing	
moieties	 such	as	 lipids,	porphyrins,	or	 saccharides.35,85	Some	examples	of	 functional	 initiators	
are	shown	in	Figure	6.		
	
	
Figure	6.	Functionalized	initiators	for	the	CROP	of	2-alkyl-2-oxazolines	(Adapted	from	reference	92	with	
permission	from	John	Wiley	and	Sons).	
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An	initiator	with	antimicrobial	activity	(N,N-dimethyldodecylammonium	bromide)	was	also	used	
for	the	polymerization	of	MeOx,	proving	that	the	PAOx	system	can	be	used	as	an	alternative	to	
PEGylated	 antimicrobial	 polymers.126	 The	one-step	 synthesis	 of	 amphiphilic	 block	 copolymers	
with	 narrow	 molar	 masses	 was	 done	 using	 a	 dual	 RAFT-CROP	 initiator	 4-	 cyano-4-
(dodecylthiocarbonothioylthio)pentyl-4-methylbenzenesulfonate	 (CDPS).127	 This	 dual	 initiator	
allows	 the	 possibilities	 to	 tune	 the	 hydrophobic	 block	 depending	 on	 the	 monomer	 used,	
keeping	a	biocompatible	hydrophilic	PEtOx	block.	Functional	initiators	also	open	the	possibility	
to	synthesize	polymers	with	different	architectures.	For	example,	a	tetratosylate	initiator,	with	
a	porphyrin	core	was	synthesized	and	used	to	produce	well-defined	star-shaped	PEtOx.128	
Many	 common	 end-chain	 functionalization	 methods	 make	 use	 of	 the	 ω	 end	 chain,	 since	
incompatible	functionalities	can	be	added	once	the	polymerization	is	over.	However,	the	use	of	
functional	 initiators	 brings	 the	 advantage	 that	 ideally	 one	 functional	 group	 will	 initiate	 one	
polymeric	chain,	and	there	 is	no	need	to	add	an	excess	of	 the	 functional	moiety.	 In	addition,	
functional	 initiators	 can	give	direct	 access	 to	heterotelechelic	 PAOx,	when	 combined	with	 an	
appropriate	termination	strategy.	
	
2.2.2.2. Functionalization	of	the	R-group	
The	 choice	 of	 R-group	 of	 the	 2-alkyl-2-oxazoline	 has	 an	 impact	 on	 the	 solubility,	mechanical	
properties,	 and	 thermal	 properties	 of	 the	 resulting	 polymer.	 The	 possibility	 to	 tune	 the	
properties	 of	 the	 polymer	 based	 on	 the	 type	 of	 monomer	 used,	 along	 with	 the	 use	 of	 R	
functional	pendant	groups	is	one	of	the	most	important	advantages	of	PAOx	over	PEG.92	
Hydrophilicity	can	be	tuned	depending	on	the	size	of	the	R	substituent	used.	PMeOx	and	PEtOx	
are	the	most	popular	monomers	for	biomedical	applications,	since	both	are	very	hydrophilic.	By	
increasing	the	 length	of	 the	R	groups	or	using	aromatic	groups,	 the	hydrophobic	character	of	
the	resulting	polymer	is	increased.	
In	 general	 terms,	 the	 lower	 critical	 solution	 temperature	 (LCST)	 of	 PAOx	 depends	 on	 a)	 the	
molar	mass,	and	b)	the	addition	of	comonomers	to	influence	the	balance	of	hydrophobicity	and	
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hydrophilicity.129–131	 Finely	 tuned	 LCSTs	 can	 be	 obtained	 by	 the	 random	 or	 gradient	
copolymerization	 of	 monomers	 with	 different	 R	 groups.	 For	 instance,	 a	 study	 varying	 the	
composition	 and	 molar	 mass	 of	 three	 different	 2-oxazoline	 monomers,	 with	 either	 ethyl,	
isopropyl,	or	n-propyl	side	chains,	whose	homopolymer	exhibits	a	different	LCST	(60	°C,	36	°C,	
and	24	°C,	respectively),132–134	showed	that	it	is	possible	to	obtain	a	range	of	LCSTs	from	24	°C	
to	 97	 °C,	 depending	on	 the	molar	mass	 and	 composition	of	 the	polymer	 system.135,136	 These	
copolymers	 could	 potentially	 be	 used	 in	 biomedical	 applications	 for	 the	 preparation	 of	
thermosensitive	bioconjugates.	
The	 addition	of	 unsaturated	monomers	 such	 as	 2-isopropenyl-2-oxazoline,137	 2-(9-decenyl)-2-
oxazoline,138	soy-based	2-oxazoline,139	and	2-oxazolines	bearing	cycloaliphatic	R-side	chains	and	
aromatic	 systems	have	been	 reported.140–143	Monomers	 that	bear	nitrogen-containing	groups	
on	 the	 pendant	 chain	 such	 as	 azetidinyl,	 azepanyl,	 piperidine,	 1-azocanyl,	 1-morpholine,	 1-
pyrrolidinyl,	and	pyrrolidonylethyl	have	also	been	reported.144–146	Hydroxyl-	end	groups	on	the	
pendant	chains	can	be	obtained	using	esters	or	acetals	as	protecting	groups.147,148	Modified	2-
oxazolines	 with	 polystyrene	 or	 poly(ethylene	 oxide)	 as	 the	 R	 group	 can	 be	 used	 as	
macromonomers	for	the	synthesis	of	graft	copolymers.149,150	
Taking	advantage	of	the	possibility	to	directly	copolymerize	2-ethyl-2-oxazoline	with	functional	
side	 chain	 monomers	 such	 as	 2-methoxycarbonylethyl-2-oxazoline,151	 that	 can	 be	 easily	
modified	 to	 add	 bioactive	 molecules	 (or	 other	 specific	 groups),	 creates	 the	 possibility	 to	
develop	functional	biocompatible	polymers,	such	as	drug	carriers	or	conjugates.83		
	
2.2.2.3. Functional	terminating	agents	
During	 the	 termination	 step,	 a	 variety	 of	 functionalities	 can	 be	 added	 on	 the	ω-chain	 end.	
Adding	a	 functionality	during	 termination	has	 the	advantage	 that	 the	addition	of	groups	 that	
are	not	compatible	with	the	polymerization	mechanism	is	possible,	since	these	are	added	at	the	
end	of	the	reaction.	
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Some	 functional	 terminating	 agents	 include	 silane-containing	 amines	 for	 surface	
functionalization,152,153	 sodium	 azide,107	 and	 hexynoic	 acid154	 for	 click	 reactions.	 	 Carboxylate	
derivatives	 to	 add	 polymerizable	 end	 groups	 such	 as	 styrenics,155	 acrylates,156	 and	
methacrylates118	 have	 also	 been	 reported	 for	 the	 synthesis	 of	 macromonomers	 for	 graft	
copolymerization	by	free	radical	polymerization	(Figure	7).		
	
	
Figure	 7.	 Terminating	 agents	 for	 the	 CROP	 of	 2-alkyl-2-oxazolines	 (Adapted	 from	 reference	 92	 with	
permission	from	John	Wiley	and	Sons).	
	
Other	 examples	 of	 functional	 terminating	 groups,	 such	 as	 carboxylic	 acid-containing	 RAFT	
agents,	 or	 norbornene,	 transform	 PAOx	 into	 macromonomers	 for	 the	 synthesis	 of	 graft	
copolymers.	
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2.2.3. Poly(2-oxazoline)s	as	biomaterials	
A	number	of	PAOx	have	already	been	studied	to	use	as	drug	carriers	 in	the	form	of	polymer-
protein	 conjugates,119,157	 polymer-drug	 conjugates,83	 or	 polymeric	 micelles.158,159	 PAOx	
hydrogels	 for	 tissue	engineering,	and	PAOx	grafted	onto	surfaces	 to	obtain	a	protein	and	cell	
repelling	effect	have	also	been	developed.	Currently,	PEtOx	is	approved	by	the	FDA,	yet	only	as	
an	 indirect	 food	 additive.	 However,	 recently,	 the	 first	 PAOx-drug	 conjugate	 entered	 phase	 II	
clinical	 trials.	Although	 the	necessary	 in	 vivo	 research	has	 to	 verify	 the	 safety	of	PAOx	 in	 the	
human	body,	 the	 amount	 of	 available	 data	 gathered	 in	 such	 relatively	 short	 amount	 of	 time	
provides	promising	results.		
Poly(2-oxazoline)s,	 as	 homopolymers	 or	 copolymers,	 have	 been	 conjugated	 to	 a	 number	 of	
proteins,	giving	similar	resulting	properties	as	PEG	conjugates.119,157	An	extensive	study,	made	
by	Veronese	and	coworkers,	compared	the	biological	and	chemical	properties	of	PAOx,	and	its	
conjugates	 with	 model	 proteins,	 to	 the	 PEG	 analogues.43	 Three	 monomers	 with	 different	 R	
groups	were	used	(methyl,	ethyl,	and	propyl),	with	hydroxyl	or	carboxylic	acid	end	groups	for	
further	 functionalization	 via	 activation	 with	 p-nitrophenylchloroformate,	
disuccinimidylcarbonate,	 or	N-hydroxysuccinimide.	 In	 all	 cases,	 as	 expected,	 defined	 polymer	
sizes	with	narrow	distributions	were	produced	and	functionalized	for	protein	conjugation.	The	
repeatability	 and	 ease	 of	 functionalization	 of	 the	 polymer	 were	 highlighted,	 and	 the	 lower	
viscosity	shown	in	all	PAOxs,	compared	to	PEG.	Important	finding	of	this	study	include	a	lower	
immune	 response	 by	 the	 PAOx	 conjugates	 (Figure	 8,	 right),	 a	 similar	 activity,	 and	 better	
pharmacokinetics	 as	 observed	 from	 longer	 circulation	 times	 of	 the	 PAOx-conjugate	 in	 vivo	
(Figure	8,	left).	
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Figure	8.	Left:	Effect	of	 subcutaneous	 injection	of	 insulin,	 insulin	glargine,	and	10kDa	PEtOx-insulin	on	
the	blood	glucose	levels	in	male	Sprague–Dawley	rats.	Right:	Relative	immunogenicity	of	BSA,	PEG-BSA,	
and	PEtOx-BSA	in	rabbits,	measured	by	anti-BSA	antibody	levels.	Adapted	from	reference	43.	Copyright	
2018	American	Chemical	Society.	
	
Polymer-drug	 conjugates	 represent	 a	 strategy	 to	 increase	 the	 solubility	of	drugs	 in	water,	 as	
well	 as	 to	 improve	 the	 drug	 pharmacokinetics.160	 Although	 the	 number	 of	 PAOx-drug	
conjugates	 is	 reduced,	 compared	 to	 PEG,	 a	 significant	 advance	 has	 been	 achieved.	 A	 very	
recent	 and	 relevant	 report	 was	 the	 development	 of	 the	 first	 anti-cancer	 drug-PAOx	
conjugate.83	In	this	study,	taking	advantage	of	the	living	character	of	the	CROP	of	2-oxazolines,	
copolymers	 of	 mainly	 2-ethyl-2-oxazoline	 and	 the	 functional	 2-methoxycarboxyethyl-2-
oxazoline,	terminated	with	methanolic	ammonia	were	synthesized	with	defined	molar	masses	
and	narrow	distributions.	The	selected	anti-cancer	drug,	doxorubicin,	was	loaded	using	an	acid-
degradable	 hydrazone	 linker	 attached	 to	 the	 functional	 side	 chain	 (Figure	 9).	 Additionally,	 a	
radiolabel	was	attached	after	functionalization	of	the	ω-chain	end.	In	vivo	experiments	in	mice	
showed	prolonged	blood	circulation,	 increased	 tumor	accumulation	and	enhanced	antitumor	
efficacy	of	 the	PEtOx	 conjugate.	An	 in	 vivo	 comparison	 to	 the	PHPMA-doxorubicin	 analogue,	
did	not	show	substantial	differences	in	biodistribution	and	antitumor	efficacy.	This	report	is	a	
clear	 example	 of	 the	 versatility	 of	 the	 synthesis	 of	 PAOx,	 and	 the	 possibility	 of	 tuning	 the	
properties	of	the	system	depending	on	the	desired	application.	
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Figure	 9.	 Structure	 of	 the	 studied	 PEtOx-doxorubicin	 conjugate.	 Adapted	 from	 reference	 83	 with	
permission	from	Elsevier.	
	
Polymeric	micelles	based	on	PAOx	have	also	been	used	as	effective	delivery	systems	for	anti-
cancer	drugs.	Micelles	with	a	hydrophilic	PEtOx	shell	and	hydrophobic	drug	core	(doxorubicin)	
for	controlled	released	by	pH	changes	have	been	developed.158	In	another	contribution,	a	pH-
sensitive	 copolymer	 of	 poly(2-ethyl-2-oxazoline)-b-poly(D,L-lactide)	 was	 used	 to	 load	 the	
hydrophobic	drug	paclitaxel	into	the	micellar	core	by	non-covalent	hydrophobic	interactions.159	
In	both	 cases,	 the	drug-loaded	micelles	demonstrated	effective	antitumor	effect	 in	 vivo	 over	
the	free	drug,	also	showing	low	toxicity.	
The	 functionalization	 of	 surfaces	 is	 another	 approach	 to	 tackle	 biomedical	 challenges.	
Biofouling	of	proteins,	cells,	or	bacteria	on	surfaces	represents	a	major	problem	in	devices	such	
as	stents,	catheters,	and	joint	implants,	among	many	others.	Coatings	provide	a	stealth	effect	
to	 these	 materials,	 making	 the	 surface	 undetectable	 by	 the	 organism	 and	 preventing	
infections.161	PEtOx	has	been	photo-immobilized	on	surfaces	widely	used	in	analytical	devices	
such	as	silicon	wafers,	glass	slides,	and	Au	films.162	The	protein-resistant	properties	of	the	films	
were	evaluated	by	treatment	with	BSA,	providing	the	expected	repealing	effect.		
The	 exceptional	 properties	 of	 PAOx,	 such	 as	 biocompatibility,	 high	 stability,	 structural	 and	
functional	diversity,	along	with	the	possibility	to	obtain	high	controlled	and	defined	polymers,	
make	 this	 class	 of	 polymers	 an	 attractive	 option	 to	 develop	 biomaterials	 and	 polymer	
therapeutics.	 Over	 the	 last	 20	 years,	 publications	 and	 patents	 of	 PAOx	 for	 biomedical	
applications	 have	 exponentially	 increased,	 positioning	 this	 polymeric	 system	 as	 an	 emerging	
alternative	to	PEG.		 	
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2.3. Living	ring-opening	metathesis	polymerization		
Ring-opening	metathesis	polymerization	(ROMP)	 is	a	powerful	and	broadly	applicable	method	
for	the	synthesis	of	macromolecular	materials	with	unique	architectures	and	useful	functions.	
The	 origin	 of	 ROMP	 can	 be	 traced	 to	 1955,	 when	 the	 first	 carbon-carbon	 double	 bond	
rearrangement	reaction	in	polymerization	of	norbornene,	catalyzed	by	titanium,	was	reported	
by	 Anderson	 and	 Merckling.163	 About	 ten	 years	 later,	 this	 metal-catalyzed	 redistribution	 of	
carbon-carbon	 double	 bonds	was	 named	 olefin	metathesis.164	 Initially,	 olefin	metathesis	was	
regarded	as	an	odd	reaction,	but	since	then	it	has	been	established	as	one	of	the	most	powerful	
transformations	in	chemical	synthesis	of	a	wide	variety	of	useful	products,	both	in	industry	and	
academia.165,166	The	development	of	defined	catalysts	enabled	the	synthesis	of	a	wide	range	of	
polymers	with	complex	architectures	and	useful	applications.167		
In	this	section,	a	description	of	the	ROMP	mechanism	will	be	provided,	as	well	as	a	brief	history	
of	a	variety	of	relevant	catalysts	that	have	been	used	for	olefin	metathesis.		
	
2.3.1. Mechanism	
ROMP	 is	 a	 chain-growth	 polymerization	 that	 converts	 cyclic	 olefins	 into	 linear	 polymers	
containing	 olefinic	 bonds	 in	 the	 main	 chain	 as	 shown	 in	 Figure	 10.	 The	 polymerization	
mechanism	 is	 based	 on	 a	 metal-mediated	 carbon–carbon	 (C–C)	 double	 bond	 exchange	
processes.168	Contrary	 to	other	olefin	addition	polymerizations,	 in	ROMP	 the	unsaturation	of	
the	monomer	is	conserved	as	it	is	converted	to	a	polymer.		
	
Figure	10.	The	general	ROMP	reaction.	
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In	 1970,	Chauvin	proposed	 the	 commonly	 accepted	ROMP	mechanism,	 illustrated	 in	Scheme	
5.169	 The	 initiation	 step	 involves	 the	 coordination	 of	 a	 cyclic	 olefin	 to	 a	 metal	 alkylidene	
complex.	 A	 [2+2]	 cycloaddition	 produces	 a	 metallacyclobutane	 intermediate	 that	 forms	 the	
beginning	of	a	growing	polymer	chain.	This	intermediate	undergoes	cycloreversion	to	obtain	a	
new	metal	 alkylidene.	 As	monomers	 are	 incorporated	 to	 the	 chain,	 the	 size	 of	 the	 resulting	
complex	increases.	Despite	the	size	increase,	its	reactivity	toward	cyclic	olefins	remains	similar	
to	 the	 initiator.	 Thus,	 during	 propagation,	 analogous	 steps	 are	 repeated	 until	 either	 a)	 all	
monomer	 is	consumed,	b)	a	 reaction	equilibrium	 is	 reached,	or	c)	 the	 reaction	 is	 terminated.	
ROMP	is	commonly	quenched	by	the	addition	of	a	reagent,	e.g.	ethyl	vinyl	ether	(EVE),	which	
reacts	 with	 the	metal	 carbene	 species	 of	 the	 growing	 polymer	 chain	 end,	 and	 removes	 the	
metal	from	the	polymer.170,171	
	
Scheme	5.	General	mechanism	 of	 the	 ROMP	 reaction	 (Adapted	 from	 reference	 170	with	 permission	
from	Elsevier).	
	
In	 addition	 to	 the	 general	 ROMP	 mechanism	 already	 illustrated	 in	 Scheme	 5,	 inter	 and	
intramolecular	 chain-transfer	 reactions	 can	 occur,	 also	 considered	 secondary	 metathesis	
reactions	(Scheme	6).170,167	 In	an	 intermolecular	chain	transfer,	a	polymer	chain	that	contains	
the	 active	metal	 alkylidene	 on	 its	 terminus,	 can	 react	 with	 an	 olefin	 along	 the	 backbone	 of	
another	 polymer	 chain.	 This	 intermolecular	 reaction	 keeps	 the	 number	 of	 polymer	 chains	
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unchanged,	however,	there	 is	a	change	 in	molar	mass	of	the	 individual	chains	 involved	 in	the	
reaction.	The	intramolecular	chain-transfer	reaction,	also	known	as	backbiting,	occurs	when	the	
active	 terminus	 of	 a	 polymer	 chain	 reacts	 with	 itself	 to	 form	 a	 cyclic	 polymer	 chain	 with	 a	
reduced	molar	mass.	Overall,	 both	 types	of	 chain-transfer	 reactions	broaden	 the	molar	mass	
distribution	of	the	system.		
	
Scheme	6.	Secondary	metathesis	reactions	in	ROMP.	(Adapted	from	reference	170	with	permission	from	
Elsevier).	
	
The	ROMP	reaction	is	driven	by	a	decrease	in	entropy	that	comes	from	the	release	of	strain	of	
the	cyclic	olefin	as	it	goes	from	monomer	to	polymer.	Strained	cyclic	olefins	that	do	not	contain	
bulky	groups	around	the	double	bond	are	commonly	used	as	monomers	for	ROMP	(Figure	11).	
These	include	cyclobutene,	cyclopentene,	cis-cyclooctene,	and	norbornene.	All	of	these	have	a	
degree	 of	 strain	 >	 5	 kcal	 mol–1.172	 Cyclohexene,	 for	 instance,	 has	 a	 lower	 ring	 strain,	 which	
makes	 it	 an	exception	of	polymerizable	monomers	by	ROMP.	Norbornene	and	 its	derivatives	
are	the	most	commonly	used	monomers	due	to	their	high	reactivity	 for	ROMP,	and	relatively	
easy	functionalization	for	further	applications.			
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Figure	11.	Examples	of	ROMP	monomers.	
	
2.3.2. Catalysts	
The	requirements	of	a	living	polymerization	include	the	rapid	consumption	of	initiating	species,	
a	 linear	 relation	between	 the	degree	of	polymerization	and	monomer	 consumption,	 and	 low	
dispersities	(Ð).173	 	Evidently,	the	catalysts	developed	for	ROMP	must	satisfy	these	conditions.	
Progress	on	the	development	of	metal-based	catalysts	has	led	to	catalyst	systems	that	exhibit	
fast	initiation	kinetics,	reduce	the	occurrence	of	intramolecular	or	intermolecular	chain	transfer	
reactions,	show	solubility	in	a	wide	range	of	organic	(or	even	aqueous)	solvents,	show	stability	
towards	 air,	 moisture,	 and	 some	 organic	 functional	 groups,	 and	 can	 be	 used	 at	 room	
temperature.	 These	 advances	 are	 the	 result	 of	 decades	 of	 research	 dedicated	 to	 the	
development	of	robust	catalytic	systems	suitable	for	olefin	metathesis.		
Since	the	discovery	of	olefin	metathesis	many	decades	ago,	extensive	work	was	put	to	identify,	
isolate,	 and	 characterize	 the	 key	 intermediates	 involved	 in	 the	 metathesis,	 metal-carbene	
complexes	and	metallacyclobutanes.168	The	first	reported	catalysts	were	based	on	mixtures	of	a	
range	of	 transition	metals.	A	heterogeneous	 catalyst	mixture	of	 Ti	 and	W	halides	with	Al	 co-
catalysts	 was	 used	 to	 obtain	 a	 high	 molar	 mass	 polymers	 from	 norbornene	 for	 the	 first	
time.174,168	Soon	after,	the	development	of	homogeneous	catalyst	systems	that	polymerized	a	
wider	 variety	 of	 monomers	 (i.e.	 cyclobutene,	 cycloheptene,	 cyclooctene,	 and	 norbornene),	
showed	 the	potential	of	 this	 type	of	polymerization	 to	 synthesize	new	macromolecules.175,176	
These	first	 investigations	required	demanding	conditions	(e.g.	moisture-	and	air-free),	and	did	
not	completely	satisfy	the	living	polymerization	conditions.		
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Single-component	 catalysts	 allowed	 for	 the	 first	 time	 the	 possibility	 to	 define	 the	 relation	
between	structure	and	reactivity.	Catalyst	systems	that	provide	a	living	character	to	ROMP	are	
developed	 based	 on	 titanium,	 tantalum,	 tungsten,	 molybdenum,	 or	 ruthenium.177	 Titanium-
based	catalysts	were	the	first	to	add	a	living	character	to	the	polymerization,178	also	providing	
the	 possibility	 to	 add	 functional	 end	 groups	 during	 initiation	 and	 termination,179	 and	 the	
formation	of	block	copolymers.180	However,	its	low	reactivity	soon	focused	the	attention	on	the	
more	 reactive	 tantalum-based	 catalysts.	 For	 instance,	 a	 tantalum-based	 catalyst	 with	 bulky,	
electron-rich	ligands	was	used	to	successfully	polymerized	norbornene	to	high	conversion	with	
dispersity	 values	 below	 1.1.181,182	 Despite	 these	 advances,	 the	 high	 oxidation	 state	 and	
reactivity	 towards	 functional	 groups	 with	 heteroatoms	 and	 carbonyls	 limited	 the	 living	
character	of	the	ROMP	reaction.	
A	 significant	 advance	was	made	by	 Schrock	 in	 the	preparation	of	 tungsten	 and	molybdenum	
catalysts.183–185	 Especially	 relevant,	 the	 molybdenum-based	 alkylidenes,	 shown	 in	 Figure	 12	
brought	 advantages	 such	 as	 a	 relatively	 simple	 synthesis	 and	 higher	 stability	 towards	
decomposition.185	Importantly,	these	catalysts	were	tolerant	to	monomers	containing	a	variety	
of	 functionalities	 including	 amide,	 ketal,	 cyano,	 ester,	 trifluoromethyl,	 halogen,	 and	 imide	
groups,	and	were	able	to	provide	stereoregular	polymers.	The	activity	of	these	catalysts	could	
be	 tuned	 through	 modification	 of	 the	 alkoxide	 ligand.	 Fluorinated	 derivatives,	 for	 example,	
showed	 increased	activities	and	were	 found	 to	 rapidly	 isomerize	2-pentene	and	other	acyclic	
olefins.186	 It	was	also	 found	that	molybdenum-based	catalysts	are	able	 to	polymerize	a	wider	
range	of	cyclic	olefins	with	varying	degrees	of	ring	strain	and	functionality	such	as	norbornene,	
cyclopentene,	cyclobutenes,	and	cyclopropenes.187,188	The	great	disadvantage	of	these	catalysts	
is	the	high	oxophilicity	of	the	metal	center,	which	makes	it	sensitive	to	oxygen	and	moisture.	
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Figure	12.	Molybdenum-based	alkylidenes	(Adapted	from	reference	170	with	permission	from	Elsevier).	
	
The	 field	of	 olefin	metathesis	was	 for	 a	 really	 long	 time	dominated	by	 the	 Schrock	 catalysts,	
until		another	breakthrough	was	made	by	Grubbs	in	1992,	when	he	synthesized	a	group	of	Ru-
based	 catalysts	 with	 unique	 properties	 (Figure	 13).189,190	The	 first	 generation	 of	 this	 catalyst	
system,	Grubbs	 1	 or	 G1,	 allowed	 the	 polymerization	 reactions	 to	 happen	 in	 the	 presence	 of	
oxygen,	 but	 with	 the	 disadvantage	 of	 a	 lower	 activity	 compared	 to	 Schrock’s	 catalysts.	 The	
change	 of	 one	 of	 the	 phosphine	 ligands	 in	 G1	 for	 an	 N-heterocyclic	 carbene	 produced	 the	
second	 generation	 Grubbs	 catalyst,	 G2.	 In	 this	 case,	 Grubbs	 2	 has	 a	 higher	 tolerance	 to	
functional	groups	when	compared	to	G1,	but	with	a	rather	slower	initiation.	The	3rd	generation	
of	Grubbs	catalysts	contains	strongly	ligating	N-heterocyclic	carbenes	with	weakly	coordinating	
pyridines.	 These	 catalysts	 display	 extremely	 high	 activities	 and	 fast	 initiation	 kinetics.	 A	wide	
range	 of	 monomers	 can	 be	 polymerized	 with	 this	 catalyst	 resulting	 in	 polymers	 with	 low	
dispersities.	Additionally,	the	catalyst	can	initiate	metathesis	in	the	presence	of	alcohol,	water,	
and	carboxylic	acids,	and	is	also	stable	in	air.	
	
Figure	13.	Ruthenium-based	ROMP	catalysts	(Adapted	from	reference	191	with	permission	from	
Elsevier).	
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2.3.3. Applications	of	polymers	synthesized	by	ROMP	
ROMP	 is	 capable	of	producing	 functionally	diverse	and	 structurally	 complex	polymers	 from	a	
diverse	 range	 of	 monomers	 through	 the	 implementation	 of	 well-defined	 catalysts.	 The	
architectures	of	polymers	synthesized	using	ROMP	generally	 fall	under	 four	broad	categories:	
linear,	 cross-linked,	 branched,	 and	 dendritic.192	 The	 wide	 range	 of	 polymers	 that	 can	 be	
synthesized	 with	 unique	 architectures	 and	 useful	 functions	 make	 ROMP	 a	 relevant	 tool	 in	
industry,	 as	 well	 in	 academia,	 in	 fields	 like	 life	 sciences,	 optics	 and	 electronics,	 sensors,	 or	
energy	storage.167,193	
ROMP	can	be	used	to	synthesize	defined	bioactive	polymers	with	structural	features	optimized	
for	 the	 biologically	 relevant	 applications.	 The	 developed	 polymers	 have	 diverse	 functions,	
including	 inhibitors	 of	 receptor–ligand	 interactions,	 novel	 drug	 delivery	 agents,	 innovative	
imaging	agents,	and	incisive	mechanistic	probes	of	multivalent	interactions.193–198		
The	 nanoscopic	 size	 and	 multivalence	 of	 bottlebrushes,	 bivalent	 bottlebrushes,	 and	
dendronized	polymers	synthesized	using	a	graft-through	ROMP	make	them	attractive	for	in	vivo	
drug	delivery	applications.3,199	For	instance,	a	bivalent-brush	polymer	for	use	in	chemotherapy	
delivery	 reported	 by	 the	 Grubbs	 group	 was	 synthesized	 by	 graft-through	 ROMP	 of	
poly(ethylene	 glycol)	 (PEG)	 based	 macromonomers	 (MMs)	 that	 were	 loaded	 with	 photo	
cleavable	anticancer	drugs	doxorubicin	(DOX)	and	camptothecin	(CT)	(Figure	14).194	The	graft-
through	ROMP	approach	has	the	advantage	that	it	ensures	that	the	weight	percentage	of	drug	
loaded	onto	the	brush	polymers	is	the	same	as	the	weight	percentage	of	drug	on	the	MM.		
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Figure	14.	Bivalent	macromonomer	and	bivalent-brush	polymer.	Adapted	from	reference	194.	Copyright	
2018	American	Chemical	Society.	
	
In	diagnostic	imaging,	for	example,	polymers	can	exhibit	enhanced	sensitivity.	The	relaxivity	of	
an	 MRI	 contrast	 agent	 can	 be	 augmented	 through	 its	 incorporation	 into	 a	 polymer.200,201	
Likewise,	 polymers	 can	 bear	 many	 copies	 of	 an	 imaging	 agent,	 which	 can	 lead	 to	 signal	
enhancement.	ROMP	is	an	ideal	polymerization	method	for	this	purpose	because	it	can	give	rise	
to	polymers	with	multiple	sites	that	can	be	simultaneously	functionalized	with	contrast	agents,	
or	 targeting	 probes.	 In	 2006,	 a	 monomer	 for	 ROMP	 that	 also	 functions	 as	 a	 portion	 of	 a	
GdIII	chelating	moiety	for	an	MRI	contrast	agent	was	developed.196	An	increase	in	relaxivity	per	
GdIII	was	 shown	 upon	 transition	 from	 monomer	 to	 polymer,	 and	 extremely	 large	 molecular	
relaxivities	were	achieved	through	incorporation	of	multiple	GdIII	ions	per	polymer.	In	another	
contribution,	the	Johnson	group	reported	a	metal-free	nitroxide-based	MRI	probe	that	showed	
increased	 relaxivity	 per	 nitroxide	 (up	 to	 44	 times	 higher)	 compared	 to	 common	 nitroxides,	
higher	 stability,	 and	 low	 toxicity.197	 The	 probe	 was	 synthesized	 by	 ROMP	 of	 functionalized	
branched	 PEG	 macromonomers	 containing	 the	 nitroxide,	 to	 form	 brush-arm	 star	 polymers	
(BASP)	(Figure	15).	The	particular	architecture	of	the	BASP,	with	a	dense	layer	of	nitroxides	at	
the	 interface	of	 a	 rigid	polyacetal	 core	 and	a	hydrophilic	 PEG	 shell,	 resulted	 in	 the	 improved	
performance	for	MRI.		
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Figure	 15.	 Schematic	 representation	 of	 a	 PEG-based	 MRI	 probe	 synthesized	 by	 ROMP.	 Branched	
macromonomers	functionalized	with	a	nitroxide	are	combined	with	an	acetal	crosslinker	(Adapted	from	
reference	197).	
	
Another	 relevant	 application	 of	 polymers	 synthesized	 by	 ROMP	 is	 its	 use	 to	 mimic	 the	
molecular	architecture	and	activity	of	natural	antimicrobial	peptides	(NAP).	NAPs	are	one	of	the	
first	compounds	produced	after	an	infection,	and	vital	components	of	the	immune	system.	The	
natural	amphiphilicity	of	antimicrobial	peptides	was	mimicked	using	ROMP	copolymers	made	of	
amphiphilic	 oxanorbornene-capped	 macromonomers	 (Figure	 16).195	 Through	 ROMP,	 the	
hydrophilic	 and	 hydrophobic	 components	 were	 varied	 independently,	 which	 produced	 an	
extensive	library	of	antibacterial	polymers.		
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Figure	16.	The	synthetic	approach	allows	the	combination	of	a	hydrophilic	(blue),	a	hydrophobic	(green),	
and	 a	 polymerizable	 (yellow)	 part	 of	 the	 monomer,	 producing	 an	 extensive	 library	 of	 antimicrobial	
polymers.	Adapted	from	reference	195.	Copyright	2018	American	Chemical	Society.	
	
Applications	of	polymers	synthesized	by	ROMP	are	providing	new	materials	for	understanding	
and	 tuning	 biological	 responses.	 Further	 advances	 in	 ROMP	 will	 undoubtedly	 fuel	 new	 and	
imaginative	applications	of	bioactive	polymers.	
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2.4. Radical	polymerization	
Radical	 polymerization	 is	 generally	 used	 for	 the	 commercial	 production	 of	 high	 molar	 mass	
polymers,	due	to	its	ability	to	polymerize	a	wide	variety	of	monomers	on	flexible	conditions	at	
an	industrial	scale.19	However,	the	lack	of	control	on	the	architecture	of	the	produced	polymer	
was	 a	 disadvantage	 for	 many	 years.	 The	 development	 of	 reversible-deactivation	 radical	
polymerization	 (RDRP)	 led	 to	 the	 possibility	 to	 synthesize	 advanced	 materials	 with	 precise	
control	 of	 the	 molecular	 architecture.202	 In	 this	 section,	 an	 overview	 on	 free	 radical	
polymerization,	and	three	approaches	to	control	radical	polymerization	will	be	given.	
	
2.4.1. Free-radical	polymerization	
Free-radical	 polymerization	 is	 the	 chosen	method	 for	many	 industrial	 applications	 due	 to	 its	
ability	 to	polymerize	a	 large	 variety	of	monomers	 (e.g.	 acrylates,	methacrylates,	 acrylamides,	
methacrylamides,	 styrenes,	 dienes,	 and	 vinyl	 monomers),	 its	 tolerance	 to	 many	 functional	
groups	and	reaction	conditions,	and	the	relative	simplicity	to	implement	this	process	compared	
to	other	technologies.20		
The	mechanism	of	free-radical	polymerization	involves	a	chain	polymerization,	where	initiation	
occurs	 by	 radicals,	 formed	 by	 an	 initiator,	 added	 to	 the	 monomer.	 Subsequent	 addition	 of	
monomer	 units	 to	 the	 radicals	 formed	 occurs,	 until	 the	 propagating	 radicals	 react	with	 each	
other,	terminating	the	reaction	(Scheme	7).	In	conventional	radical	polymerization,	the	process	
involves	polymer	chains	continuously	forming,	propagating,	and	terminating.	These	chains	grow	
for	5–10	s	before	terminating.20	At	early	stages	of	the	polymerization,	high	molar	mass	chains	
are	 formed,	 and	 as	 conversion	 progresses,	 the	 molar	 mass	 will	 decrease	 due	 to	 monomer	
depletion.	 In	 the	 end,	 the	 size	 and	 distribution	 of	 the	 resulting	 polymers	 are	 determined	 by	
statistical	factors,	where	dispersity	is	broad	(Ð	>	1.5).203	
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Scheme	7.	Free	radical	polymerization	mechanism.	
	
2.4.2. Reversible-deactivation	radical	polymerization	(RDRP)	
For	over	two	decades	after	its	discovery	in	1956	by	Szwarc,204	anionic	living	polymerization	was	
the	 only	 example	 of	 a	 living	 polymerization	 process.	 After	 its	 discovery,	 it	 facilitated	 major	
developments	in	synthetic	polymer	chemistry	with	advantages	that	included	the	high	degree	of	
control	 over	 the	 macromolecular	 structure,	 particularly,	 the	 molar	 mass	 distribution,	
composition,	 and	 architecture.	 However,	 living	 anionic	 polymerizations	 present	 demanding	
reaction	conditions	such	as	the	use	of	ultrapure	reagents,	and	high	vacuum	to	minimize	traces	
of	moisture	and	air.		
One	of	the	most	relevant	contributions	in	polymer	science	was	the	development	of	RDRP,	the	
general	 name	 for	 a	 family	 of	 pseudo-living	 radical	 polymerization	 techniques.	 In	 a	 living	
polymerization,	in	general,	all	chains	should	initiate	at	the	beginning	of	the	reaction,	and	grow	
at	 the	 same	 rate,	 without	 the	 occurrence	 of	 chain	 transfer	 reactions	 or	 termination,	 by	
establishing	an	equilibrium	between	active	and	dormant	species.91	
In	RDRP,	the	propagating	species	is	a	free	radical,	and	there	is	a	dynamic	equilibrium	between	
active	radicals	and	dormant	species	(Figure	17).	The	success	of	this	polymerization	is	based	on	
the	 decrease	 of	 irreversible	 termination	 by	 having	 the	 propagating	 polymer	 chains	 in	 the	
dormant	 state	 most	 of	 the	 time.	 This	 can	 be	 achieved	 using	 reagents	 that	 react	 with	 the	
propagating	 radicals	 by	 reversible	 deactivation	 or	 reversible	 chain	 transfer.	 Contrary	 to	
conventional	 radical	 polymerization,	 the	 lifetime	 of	 active	 chains	 in	 RDRP	 is	 much	 lower,	
allowing	 a	 rapid	 shift	 in	 the	 equilibrium	 from	 dormant	 to	 active	 species.	 As	 a	 result	 of	 this	
equilibrium,	all	chains	grow	at	the	same	rate	throughout	the	polymerization,	which	means	the	
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molar	 mass	 increases	 linearly	 with	 conversion,	 resulting	 in	 polymers	 with	 predetermined	
degree	of	polymerization	and	narrow	molar	mass	distribution.20		
RDRP	 is	 of	 particular	 interest	 in	 the	 synthesis	 of	 advanced	 architectures	 such	 as	 block	
copolymers,	 comb-shaped	 polymers,	 multi-armed	 polymers,	 cyclic	 polymers,	 telechelic	
polymers,	and	gradient	copolymers.17		
	
Figure	17.	General	mechanism	of	RDRP	techniques	(Adapted	from	reference	205	with	permission	from	
Elsevier).	
	
Derived	 from	these	concepts,	 there	are	well-defined	techniques	of	RDRP:	 reversible	addition-
fragmentation	chain	transfer	(RAFT)	polymerization,	nitroxide-mediated	polymerization	(NMP),	
and	atom-transfer	radical	polymerization	(ATRP).		
	
2.4.2.1. Nitroxide-mediated	polymerization	
NMP	is	historically	the	first	discovered	RDRP	technique	and	synthetically	perhaps	the	easiest	of	
them	to	apply.	Before	 the	development	of	NMP,	 it	was	known	that	nitroxides	efficiently	 trap	
carbon-centered	 radicals	 to	 form	 alkoxyamines.	 Nitroxides	 were	 used	 as	 radical	 traps	 in	
polymerization	reactions	of	some	monomers,	such	as	acrylates	and	styrene.206	It	was	observed	
that	under	some	conditions	the	trapping	of	propagating	radicals	by	the	nitroxide	was	reversible,	
which	 led	 to	 the	 exploration	 of	 alkoxyamines	 as	 polymerization	 initiators.	 In	 1985,	 the	 first	
report	of	NMP	as	a	living	polymerization	technique	was	published.	
The	NMP	mechanism	 is	 based	on	 the	 reversible	 termination	between	a	 growing	propagating	
radical	 chain	 and	 a	 nitroxide,	 that	 acts	 as	 a	 control	 agent,	 to	 yield	 the	 dormant	 and	
predominant	 species,	 an	 alkoxyamine-terminated	 chain	 (Scheme	 8).203	 When	 an	 external	
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stimulus	 is	applied,	 tipically	heat,	a	homolytic	 cleavage	of	 the	dormant	 species	 regenerates	a	
propagating	 radical	 chain	 and	 the	 nitroxide.	 This	 way,	 an	 equilibrium	 between	 dormant	 and	
active	 species,	 also	 described	 as	 the	 activation–deactivation	 equilibrium,	 is	 established	 with	
constants	kact	and	kdeac.	The	advantage	of	 this	equilibrium	over	other	RDRP	techniques,	 is	 the	
thermal	 nature	 of	 the	 process,	 where	 no	 catalyst	 is	 required.	 The	 polymerization	 kinetics	 is	
governed	 by	 both	 the	 activation–deactivation	 equilibrium	 and	 the	 persistent	 radical	 effect	
(PRE).		
	
Scheme	8.	Activation	–	deactivation	mechanism	of	NMP,	from	either	a	mono-	or	bicomponent	system	
(Adapted	from	reference	205	with	permission	from	Elsevier).	
	
The	 PRE	 is	 based	 on	 the	 occurrence	 of	 termination	 reaction	 at	 early	 stages	 of	 the	
polymerization,	 and	 can	 be	 explained	 considering	 a	 compound	 that	 can	 decompose	 in	 a	
transient	 radical	 and	 a	 persistent	 radical.	 At	 the	 beginning	 of	 the	 reaction,	 the	 initial	
concentration	 of	 both	 radicals	 is	 zero	 and	 increases	 with	 time	 in	 a	 linear	 fashion.	 As	 more	
radicals	are	 formed,	at	 some	point	 radical-radical	 termination	will	happen,	either	 terminating	
transient	radicals	irreversibly,	or	combining	the	transient	and	persistent	radicals	in	a	reversible	
manner.	 Irreversible	termination	of	transient	radicals	 leads	to	an	 increase	 in	concentration	of	
the	 persistent	 radicals,	 making	 the	 recombination	 of	 persistent	 and	 transient	 radicals	 more	
favored.	After	some	time,	the	concentration	of	transient	radicals	will	decrease	to	zero,	and	only	
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the	 persistent	 radicals	 will	 be	 controlling	 the	 reaction.205	 	 Scheme	 9	 provides	 a	 simple	
explanation.		
	
Scheme	 9.	 Persistent	 radical	 effect.	 The	 termination	 of	 transient	 radicals	 (R•)	 increases	 the	
concentration	of	persistent	radicals	(Y•),	favoring	the	recombination	of	transient	and	persistent	species	
(R-Y).		
	
A	wide	variety	of	nitroxides	and	alkoxyamines	have	been	exploited	in	NMP,	using	two	different	
strategies,	either	with	a	one-	or	two-component	setup.	This	means	the	initiator	can	be	either	an	
alkoxyamine,	or	a	thermal	initiator	that	is	mixed	with	a	free	nitroxide	to	form	the	alkoxyamine	
in	situ.		
Studies	on	the	influence	of	the	structure	of	the	nitroxide	or	alkoxyamine	over	the	kinetics	and	
mechanism	 of	 NMP	 have	 been	 conducted	 with	 a	 number	 of	 initiators	 to	 improve	 their	
performance.	 TEMPO	 is	 one	 of	 the	most	 common	 nitroxides	 used	 for	 the	 polymerization	 of	
styrene.	However,	it	is	not	efficient	for	acrylates.	By	tuning	the	structure	of	TEMPO,	a	broader	
range	of	monomers	can	be	polymerized.207	Some	NMP	initiators	are	shown	in	Figure	18.	
	
Figure	18.	Examples	of	nitroxides	used	for	NMP.	
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The	limitation	on	the	number	of	monomers	that	can	be	polymerized	using	NMP,	makes	other	
polymerization	 techniques,	 such	 as	 ATRP	 and	 RAFT,	 somewhat	 more	 attractive	 options	 to	
obtain	 a	wider	 range	 of	 polymers.	 However,	 the	 synthetic	 simplicity	 of	NMP,	 along	with	 the	
mono	 component	 system,	 and	 no	 extra	 steps	 required	 for	 purification	 still	 make	 NMP	 a	
plausible	 option	 to	 obtain	 certain	 functional	 and	 defined	 polymers.	 Furthermore,	 research	 is	
still	ongoing	to	develop	novel	nitroxides	which	can	give	access	to	a	broader	monomer	range.208		
	
2.4.2.2. Atom-transfer	radical	polymerization	(ATRP)	
Since	 its	discovery	 in	1995,	ATRP	has	become	a	powerful	and	versatile	RDRP	 technique.209	 In	
ATRP,	 the	 catalyst	 used	 for	 initiation	 and	 chain	 growth	 is	 a	 complex	 of	 a	 transition	 metal,	
generally	copper,	and	more	rarely	ruthenium,	iron,	osmium,	or	nickel.210	In	this	technique,	the	
chain	growth	is	controlled	by	an	equilibrium	between	a	low	concentration	of	macroradicals	and	
a	 large	 number	 of	 dormant	 species,	mainly	 in	 the	 form	of	 initiating	 alkyl	 halides.	 Transition-
metal	complexes	mediate	the	generation	of	radicals	through	a	reversible	redox	process.		
In	the	ATRP	mechanism,	the	dormant	species	periodically	react	with	transition-metal	complexes	
in	 their	 lower	 oxidation	 state,	Mtn-Y,	 acting	 as	 activators	 to	 intermittently	 form	 propagating	
radicals	 (Rn•).	 Deactivation	 occurs	when	 transition-metal	 complexes	 in	 their	 higher	 oxidation	
state,	coordinated	with	halide	ligands	X−Mtm+1-Y,	react	with	the	propagating	radical	in	a	reverse	
reaction	to	re-form	the	dormant	species	and	the	transition	metal	complex	in	its	lower	oxidation	
state	 (Scheme	 10).211,212	 This	 process	 occurs	 with	 rate	 constants	 of	 activation	 kact	 and	
deactivation	 kdeact.	 The	 concentration	 of	 radicals	 for	 ATRP	 is	 kept	 low,	 due	 to	 the	 persistent	
radical	 effect	 (similar	 to	NMP),	 resulting	 in	well-defined	polymers.	 Termination	 reactions	 can	
occur	 in	 ATRP,	 through	 radical	 coupling.	 However,	 due	 to	 the	 low	 concentration	 of	
macroradicals	and	large	amount		of	dormant	species,	termination	is	minimized.19		
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Scheme	10.	Mechanism	of	ATRP	(adapted	from	reference	212	with	permission	from	Elsevier).	
	
ATRP	 provides	 a	 number	 of	 advantages,	 similar	 to	 those	 of	 the	 other	 RDRP	 techniques:	 it	
enables	 precise	 control	 on	molar	 mass,	 narrow	 dispersities,	 and	 the	 possibility	 to	 introduce	
functionalities.	 In	 addition,	 reactions	 can	 be	 prepared	 in	 a	 variety	 of	 different	 solvents	 and	
conditions,	including	water	and	room	temperature,	and	is	tolerant	to	most	functional	groups.213	
Depending	 on	 the	 reaction	 conditions	 and	 parameters,	 control	 over	 reaction	 kinetics	 can	 be	
achieved.	 An	 important	 feature	 is	 that	 polymers	 can	 be	 grown	 from	 almost	 any	 surface	 or	
material	that	has	an	attached	ATRP	initiator,	including	proteins	for	the	formation	of	conjugates,	
and	organic	or	inorganic	materials,	such	as	nanoparticles.214	Particularly,	many	alkyl	halides	(i.e.	
potential	ATRP	initiators)	are	commercially	available	and	can	easily	be	modified.	
	
2.4.2.3. Reversible	addition-fragmentation	chain	transfer	(RAFT)	polymerization		
Contrary	 to	NMP	and	ATRP,	where	 control	over	 the	polymerization	 is	 achieved	via	 reversible	
deactivation	of	propagating	macroradicals	by	atom-transfer	or	radical-radical	reactions,	and	the	
dormant	 species	are	also	 the	 radicals	 source,	 in	RAFT	polymerization,	deactivation–activation	
equilibria	are	chain-transfer	reactions,	and	an	external	component	 is	the	source	of	radicals	to	
start	the	polymerization.		
RAFT	 is	 one	 of	 the	most	 convenient	 and	 versatile	 polymerization	methods,	 applicable	 to	 the	
majority	 of	 monomers	 that	 can	 undergo	 radical	 polymerization.	 In	 the	 mid-1980s,	 the	 first	
report	 on	 the	 use	 of	 addition-fragmentation	 reactions	 to	 control	 polymerization	 was	
published.215	 In	 1998,	 CSIRO	 reported	 the	 living	 radical	 polymerization	 using	 thicarbonylthio	
compounds,	 namely	 dithioesters	 and	 trithiocabonates,	 followed	 by	 a	 patent	 in	 1999,	 where	
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they	used	xanthate	and	dithiocarbamate	compounds	as	RAFT	agents,	also	called	chain	transfer	
agents	 (CTA).216,217	 Since	 then,	 many	 other	 CTA	 variations	 became	 available,	 and	 RAFT	
developed	into	one	of	the	most	used	methods	of	living	polymerization.		
	
	
Scheme	 11.	 RAFT	 polymerization	 mechanism	 (adapted	 from	 reference	 218	 with	 permission	 from	
Elsevier).	
	
The	process	of	RAFT	polymerization	is	based	on	addition-fragmentation	equilibria	that	establish	
control	over	the	radical	polymerization.	The	mechanism,	shown	in	Scheme	11,	starts	with	the	
generation	of	radicals	through	the	decomposition	of	an	initiator,	that	add	onto	monomer	units	
and	lead	to	propagation.	In	this	process,	the	addition	of	a	growing	polymer	chain	to	the	initial	
CTA,	yields	a	new	chain-transfer	agent	and	a	 free	radical	 for	propagation,	R•.	Re-initiation	by	
the	 free	 radical	 creates	 a	 new	 propagating	 radical.	 A	 rapid	 equilibrium	 between	 both	
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propagating	species,	distributes	equally	the	propagation	probability	among	all	polymer	chains,	
resulting	in	the	production	of	polymers	with	narrow	dispersities.	Importantly,	once	the	reaction	
is	 complete,	 the	 majority	 of	 chains	 retain	 the	 thiocarbonylthio	 end	 group,	 which	 can	
subsequently	be	used	 for	 the	 synthesis	of	block	 copolymers,	be	 removed,	or	used	 for	 a	post	
polymerization	modification	to	add	a	functionality.216		
Transfer	 agents	 are	 unsaturated	 compounds	 that	 can	 undergo	 a	 two-step	 addition-
fragmentation	 mechanism,	 and	 have	 the	 general	 structure	 shown	 in	 Figure	 19.	 The	
effectiveness	of	the	RAFT	agent	depends	on	the	substituents	R	and	Z,	and	on	the	monomer	to	
polymerize.	The	Z	group	determines	the	reactivity	toward	propagating	radicals	and	the	stability	
of	the	intermediate	radicals.	The	leaving	group	R	has	to	be	capable	of	efficiently	re-initiating	the	
polymerization.		
	
	
Figure	19.	General	structure	of	RAFT	agents.	
	
When	 designing	 chain	 transfer	 agents,	 the	 R	 group	 must	 have	 a	 balance	 of	 re-initiation	
efficiency	and	good	homolytic	 leaving	group	ability.	 In	 the	most	effective	RAFT	agents,	R	 is	a	
tertiary	cyanoalkyl	or	cumyl.18,216	The	Z	group	influences	the	rate	of	addition	of	radicals	to	the	
C=S	double	bond.	 In	a	general	trend,	this	rate	 is	higher	for	dithiobenzoates	and	decreases	for	
trithiocarbonates,	 dithioalkanoates,	 dithiocarbonates,	 and	 lastly	 dithiocarbamates.	 A	 set	 of	
guidelines	to	aid	on	the	selection	of	the	appropriate	CTA	to	use	with	respect	to	the	monomer	is	
shown	 in	 Figure	 20.	 In	 the	 end,	 the	 compatibility	 with	 reaction	 media,	 desired	 end-group	
functionality,	and	polymer	architecture	dictate	the	choice	of	the	RAFT	agent.	
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Figure	 20.	 Guidelines	 for	 selection	 of	 RAFT	 agents	 for	 various	 polymerizations.	 MMA	 =	 methyl	
methacrylate;	 VAc	 =	 vinyl	 acetate;	 S	 =	 styrene;	 	 MA	 =	 methyl	 acrylate;	 AM	 =	 acrylamide;	 AN	 =	
acrylonitrile	(Adapted	from	reference	218).	
	
One	 significant	 advantage	 of	 RAFT	 polymerization	 and	 other	 RDRP	 methods	 over	 other	
processes	 for	 living	 polymerization	 is	 its	 compatibility	 with	 protic	 solvents	 and	 other	
functionalities	present	 in	the	monomer	or	the	RAFT	agent.	This	makes	the	technique	suitable	
for	the	synthesis	of	end-functional	polymers	by	 incorporating	the	functionality	 into	the	Z	or	R	
groups	 of	 the	 RAFT	 agent.	 Alternatively,	 to	 add	 an	 end	 functionality,	 the	 transformation	 or	
removal	 of	 the	 thiocarbonylthio	 group	 via	 aminolysis,	 thermal	 elimination,	 and	 hydrolysis,	
among	many	others	techniques,	has	been	widely	used.		
RAFT	polymerization	 is	potentially	universal	and	can	be	applied	 to	a	wide	range	of	 functional	
monomers	 (styrenics,	 alkyl(meth)acrylates,	 acrylic	 acid,	 vinyl	 acetate,	 etc.),	 allowing	 the	
preparation	of	polymers	with	precisely	controlled	structural	parameters	such	as	random,	block,	
gradient,	graft,	and	star	copolymers.	RAFT	polymerization	can	be	performed	 in	homogeneous	
media	(bulk	and	solution)	as	well	as	in	ionic	liquids	and	aqueous	dispersed	systems.213	
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2.5. Protein	conjugation	
The	 conjugation	 of	 polymers	 to	 proteins	 results	 in	 higher	 physical	 and	 thermal	 stabilities,	
reduced	immunogenicity,	and	improved	solubility	of	the	biomolecule.		In	the	case	of	therapeutic	
proteins,	 the	 improved	 pharmacokinetics	 allow	 the	 possibility	 to	 reduce	 the	 amount	 and	
frequency	of	 the	doses	used	 for	patients.	A	number	of	biocompatible	polymers,	 such	as	PEG,	
HPMA,	 PLGA,	 and	 PEtOx	 are	 already	 used	 for	 clinical	 research.	 Already	 a	 variety	 of	 polymer-
protein	 conjugates,	 mainly	 using	 PEG,	 have	 been	 approved	 by	 the	 FDA	 and	 are	 used	 in	 the	
treatment	of	diabetes,	cancer,	and	hepatitis	C.16,213		
Important	 aspects	 in	 the	 design	 of	 a	 polymer-protein	 conjugate	 include	 the	 specificity	 of	 the	
conjugation	 site,	 steric	 hindrance	 created	 by	 the	 polymer,	 and	 the	 enhancement	 of	 the	
reactivity	of	the	drug.76		Since	the	location	of	the	polymer	chain	on	the	protein	can	potentially	
have	 an	 effect	 on	 the	 remaining	 activity	 of	 the	 protein,	 engineering	 of	 protein	 to	 have	 one	
binding	site	is	a	helpful	strategy	to	achieve	the	required	specificity.219,220	However,	in	the	case	of	
already	commercially	available	PEGylated	proteins,	non-specific	binding	nevertheless	improved	
the	pharmaceutical	properties	of	the	conjugate.7		
The	 architecture,	 size,	 coupling	 strategy,	 and	 distribution	 of	 the	 polymer	 can	 also	 affect	 the	
performance	 of	 the	 conjugate.	 High	 molar	 mass	 linear	 polymers	 and	 dendrimers	 generally	
exhibit	steric	hindrance.	It	 is	important,	therefore,	to	adjust	the	size	of	the	polymer,	as	well	as	
the	 number	 of	 incorporated	 chains,	 to	 ensure	 that	 the	 performance	 of	 the	 conjugate	 is	
improved.76	 An	 alternative	 strategy	 to	 avoid	 steric	 hindrance	 is	 the	 use	 of	 linkers,	 commonly	
polypeptides,	between	the	polymer	and	the	protein.221				
A	 variety	 of	 strategies	 to	 form	 polymer-conjugate	 systems	 is	 available.	 The	 first	 approach	
(grafting	 onto)	 is	 the	 design	 of	 polymers	 with	 reactive	 groups	 towards	 either	 the	 C-	 or	 N-	
terminus	or	the	amino	acids	along	the	protein	chain.	Alternatively,	proteins	can	be	modified	to	
add	initiators	to	the	amino	acid	chain,	becoming	macro	initiators	for	controlled	polymerization	
techniques.	In	this	approach	(grafting	from),	the	polymer	grows	from	the	protein	(Scheme	12).		
	 Protein	conjugation	 2.5	
47	
	
	
Scheme	 12.	 General	 approaches	 used	 to	 synthesize	 protein-polymer	 conjugates	 (Adapted	 from	
reference	222	with	permission	from	Elsevier).	
	
Considering	the	first	approach,	where	polymer	chains	are	grafted	to	the	protein,	lysine	residues	
are	a	highly	popular	target	for	the	conjugation,	due	to	the	high	reactivity	of	the	amine	side	chain	
towards	a	number	of	functional	groups	including	activated	esters,	thioimido	esters,	isocyanates,	
dichlorotriazines,	ketones,	and	aldehydes.6		
N-hydroxysuccinimide	(NHS)	ester	activation	on	polymers	is	a	widely	used	approach	for	further	
conjugation.	 NHS	 ester-activated	 compounds	 react	 with	 primary	 amines,	 in	 this	 case	 lysine	
residues,	in	physiological	to	slightly	alkaline	conditions	(pH	7.2	to	9)	to	yield	stable	amide	bonds,	
with	simultaneous	release	of	NHS	(Figure	21).	One	disadvantage	of	this	approach	is	the	lack	of	
site-specificity	during	conjugation,	since	most	proteins	contain	more	than	one	accessible	lysine	
in	their	structure.		
To	 obtain	 NHS-functionalized	 polymers,	 a	 strategy	 for	 polymers	 possessing	 hydroxyl	 groups,	
such	as	PEG,	is	to	turn	them	into	an	acid	functionality	with	succinic	anhydride,	with	subsequent	
activation	with	N-hydroxysuccinimide.6	Controlled	polymerization	 techniques	can	also	be	used	
to	 obtained	NHS	 functionalities	 on	 the	 end	 chain.	 For	 example,	with	 an	NHS	 ester-containing	
chain-transfer	agent	for	RAFT	polymerization,	PVP	was	conjugated	to	 lysozyme.223	Using	ATRP,	
NHS	 ester-terminated	 glycopolymers	 (glucofuranose	 and	 galactopyranose)	 were	 synthesized	
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and	conjugated	to	small	polypeptides.224	The	polymerization	of	N,N-dimethylacrylamide	using	a	
carboxylic	acid-functionalized	 initiator	 for	NMP	that	was	then	modified	post	polymerization	to	
an	NHS	ester,	and	conjugated	to	lysozyme.225		
	
Figure	21.	NHS	ester	reaction	scheme	for	protein	conjugation	to	a	primary	amine.	
	
Other	examples	of	conjugation	to	the	lysine	residues	include	the	introduction	of	a	thiazolidine-
2-thione	group	using	a	functional	chain-transfer	agent	for	RAFT	polymerization	of	HPMA,226	and	
an	aldehyde-containing	POEGMA	synthesized	by	ATRP.227	
Cysteine	 residues	 are	 another	 attractive	 targets	 for	 the	 conjugation	 of	 polymers	 to	 proteins.	
The	 advantage	 over	 lysine	 residues	 is	 the	 rareness	 of	 free	 cysteine	 residues	 on	 the	 protein	
surface,	which	 leads	to	a	more	site-specific	conjugation.	Alternatively,	 if	 the	protein	does	not	
naturally	contain	 free	cysteine	residues	 in	 its	structure,	a	site-specific	cysteine	residue	can	be	
added	 using	 protein	 engineering	 without	 modifying	 the	 3D	 structure	 of	 the	 protein	 or	 its	
activity.228	Activated	disulfides,	haloacyl	compounds,	and	maleimides,	among	others	can	react	
with	 cysteine	 for	 conjugation	 (Figure	 22).229	 The	 common	 conjugation	 reaction	 is	 a	Michael	
addition,	or	alternatively,	reactions	that	create	a	disulfide	bond	can	be	used.230		
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Figure	 22.	 Coupling	methods	 for	 cysteine	 residues	 (adapted	 from	 reference	 229	with	 permission	
from	John	Wiley	and	Sons).		
	
PEG	 derivatives	 for	 cysteine	 conjugation	 have	 been	 developed,	 including	 PEG-maleimide,	
vinylsulfone,	 iodoacetamide,	 and	 orthopyridyl	 disulfide,	 and	 are	 widely	 used	 with	 high	
conjugation	efficiencies.6,7	Among	the	possible	reactive	groups,	maleimide	 is	preferred	due	to	
its	high	 reactivity	 towards	 cysteine.	Protected	maleimide	 functionalized	 chain-transfer	 agents	
for	 RAFT	 polymerization	 have	 been	 developed.	 For	 example,	 to	 furan-protected	 maleimido-
poly(ethylene	glycol	acrylate)	(PEGA)	was	synthesized,	and	after	deprotection,	conjugated	to	a	
model	protein.231	Protected	maleimides	can	also	be	 introduced	 to	 the	end	chain	of	polymers	
using	 functional	 ATRP	 initiators.232	 Other	 groups	 such	 as	 pyridyl	 disulfide	 and	 vinyl	 sulfones	
have	also	been	used	to	functionalize	either	RAFT	chain-transfer	agents	or	ATRP	initiators.233–235	
Other	 possible	 target	 amino	 acids	 that	 can	 be	 used	 for	 conjugation	 are	 tyrosine,	 glutamine,	
tryptophan,	 aspartic	 acid,	 glutamic	 acid,	 arginine,	 and	 phenylalanine.230	 However,	 the	 low	
reactivity	 shown	 by	 some	 of	 these	 compared	 to	 lysine	 or	 cysteine,	 along	 with	 reaction	
conditions,	 that	 in	some	cases	 require	enzymatic	or	organometallic	catalysts,	make	them	 less	
convenient	for	conjugation.		
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The	second	strategy,	that	consists	on	modifying	the	protein	so	that	the	polymer	grows	from	the	
protein,	 has	 the	 advantage	 that	 no	 excess	 of	 polymer	 chains	 is	 required.	 In	 this	 case,	 the	
selected	 amino	 acid	 is	modified	 to	become	either	 a	macromolecular	 chain-transfer	 agent	 for	
RAFT	 polymerization	 or	 a	macroinitiator	 for	 ATRP.	 For	 instance,	 a	 biotinylated	ATRP	 initiator	
was	developed	for	conjugation	to	streptavidin	for	the	polymerization	of	N-isopropylacrylamide	
(NIPAAm).23	Similarly,	maleimide	or	pyridyl	disulfide	ATRP	initiators	have	been	synthesized	for	
conjugation	 to	cysteine,	 forming	an	ATRP	macroinitiator.236	Via	RAFT	polymerization	 it	 is	also	
possible	to	produce	a	protein-polymer	conjugate	in	situ.	In	this	case,	the	protein	is	attached	to	
a	 pyridyl	 disulfide	 trithiocarbonate	 CTA	 for	 subsequent	 polymerization.237	 In	 all	 cases,	 it	was	
proved	that	the	proteins	used	for	conjugation	retained	the	activity	after	polymerization.	
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3	
	Maleimide-	and	Thiol-
Functionalized	Initiators	for	the	
Polymerization	of	2-Oxazolines		
 
3.1. Introduction1	
As	 stated	 in	 section	 2.2,	 the	 synthesis	 of	 PAOx	 can	 proceed	 via	 living	 CROP,	 a	method	 that	
allows	 full	 control	 over	 molar	 mass,	 narrow	 distributions,	 and	 the	 possibility	 of	 tuning	 the	
properties	 of	 the	 polymer.36,37,238	 Taking	 advantage	 of	 the	 CROP	 mechanism,	 a	 number	 of	
functionalization	strategies	are	available,	depending	on	the	choice	of	2-oxazoline	monomer	or	
the	 use	 of	 functional	 initiators	 and	 terminating	 agents	 to	 obtain	 end-functionalized	 PAOx	
(Scheme	13).35,92	
																																								 																				
1 Part	 of	 this	 chapter	was	 done	 in	 collaboration	with	 the	 group	 of	 Prof.	 Richard	 Hoogenboom	 at	 Gent	 University,	 in	
Belgium,	 and	 was	 adapted	 from	 reference	 267.	 XPS	 analyses	 were	 performed	 by	 Vanessa	 Trouillet	 in	 KIT.	 Surface	
patterning	was	carried	out	by	Dr.	Sylwia	Sekula-Neuner,	at	INT,	in	KIT.  
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In	principle,	 the	use	of	 functional	 initiators	provides	 an	advantage	 in	 terms	of	 stoichiometry,	
since	 one	 chain	 should	 grow	 per	 initiating	 molecule	 available.	 In	 contrast,	 the	 use	 of	
terminating	 agents	 requires	 an	 excess	 of	 the	 terminating	 molecule.	 Furthermore,	 using	 a	
functional	 initiator	 to	 introduce	 the	 functionality	 at	 the	 α	 chain	 end	 offers	 an	 interesting	
alternative,	 since	 it	 opens	 the	 possibility	 to	 create	 bifunctional	 (hetero)telechelic	 PAOx	 by	
terminating	the	reaction	with	a	functional	nucleophile.		
	
Scheme	13.		General	strategies	for	the	functionalization	of	PAOx.	
 
Generally	 used	 initiators	 for	 CROP	 include	 alkyl	 halides,239-94	 or	 alkyl	 sulfonates,	 such	 as	
tosylates,240	nosylates,241	and	triflates.240	The	most	commonly	used	initiator	is	methyl	tosylate,	
however,	 available	 initiators	 that	 add	 specific	 functionalities	 to	 the	 polymeric	 chain	 or	 allow	
further	 functionalization	 include	 allyl,120	 amine,123	 hydroxyl,124	 or	 carboxylic	 acid,125	 in	 some	
cases	requiring	the	protection	of	the	functional	group.125		
In	this	chapter,	 the	aim	 is	 to	develop	a	strategy	for	the	 introduction	of	 functional	moieties	at	
the	α	chain	end	of	PAOx.	Thiol	and	maleimide	were	chosen	functionalities	for	this	project	since	
these	can	undergo	a	variety	of	reactions	with	multiple	applications.	For	instance,	the	maleimide	
moiety	 can	 engage	 in	 a	 number	 of	 coupling	 reactions,	 such	 as	 Diels–Alder	 reactions,242–245	
dipolar	 cycloadditions,246	 and	 Michael-type	 additions,246	 and	 may	 react	 via	 radical	
copolymerization.247	 This	 versatility	 makes	 maleimides	 a	 convenient	 group	 for	 post-
polymerization	 modification,	 protein	 conjugation,	 synthesis	 of	 block	 copolymers,	 surface	
functionalization,	or	network	 formation.	On	the	other	hand,	 thiol-based	chemistry	 is	versatile	
and	powerful	because	the	thiol	group	can	be	used	as	a	nucleophilic	agent,248	a	chain	transfer	
agent	 in	 radical	processes	 (radical	addition249	or	 radical	polymerization250),	or	an	electrophilic	
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reagent.251	 In	 addition,	 thiol-based	 reactions	 are	usually	 very	 efficient	 and	 can	be	performed	
under	 a	 wide	 variety	 of	 conditions,	 usually	 without	 side	 reactions.252	 Post-polymerization	
modifications	to	introduce	thiol	groups	at	the	chain	end	have	been	increasingly	used	to	create	
functional	polymers	and	architectures	for	biological	and	nanotechnology	applications.253	
Some	examples	of	maleimide	or	 thiol	end-functionalized	PAOx	have	been	reported,254–258	but	
mainly	by	adding	the	functionality	on	the	ω	end	chain	by	termination,	or	post-polymerization	
modification.	In	the	case	of	maleimide,	the	group	of	Schacher	reported	the	introduction	of	the	
end	group	on	the	ω	end	chain	by	first	capping	with	sodium	azide	and	then	performing	an	azide–
alkyne	 cycloaddition	with	an	alkyne-functionalized	protected	maleimide.	The	 synthesis	of	 the	
alkyne-protected	maleimide	compound	used	was	developed	using	a	 three-step	reaction,	with	
an	overall	 yield	of	9%,	 that	 included	a	 column	chromatography	purification	 step.254	A	 second	
approach	 to	add	a	maleimide	 functionality	on	 the	ω	chain	end	was	 reported	by	 the	group	of	
Luxenhofer,257	where	 furan-protected	maleimide	was	directly	used	as	a	 terminating	agent	 for	
the	CROP	of	2-oxazolines.	The	capping	agent	was	obtained	in	a	single	step	without	a	complex	
purification	 with	 a	 yield	 of	 45%.	 Yet,	 the	 termination	 efficiency	 was	 55%,	 followed	 by	 a	
deprotection	step,	with	an	85%	efficiency,	to	yield	the	maleimide-bearing	PAOx.	
PAOx	presenting	a	thiol	at	the	ω	end	chain	have	been	synthesized	by	direct	termination	with	a	
thiol,259	a	thioacetate,260	or	after	the	modification	of	functional	terminating	agents	that	include	
xanthate,261,262	dithiocarbonates,259	diallyl	amine,263	and	maleimide.264	A	strategy	to	add	thiols	
on	the	α end	chain	was	developed	by	Ruehe	and	coworkers,	who	synthesized	tosylates	of	ω,ω-
dihydroxy	 alkyl	 disulfide	 initiators	 for	 the	 CROP	 of	 2-oxazolines,	with	 the	 aim	 of	 grafting	 the	
polymer	on	gold	surfaces.265	However,	no	extensive	characterization	of	the	polymers	obtained	
was	done.		
Throughout	this	chapter,	the	synthesis	of	novel	maleimide-	and	thiol-containing	CROP	initiators	
and	 their	 application	 to	 the	 synthesis	 of	 α-functional-PAOx	 is	 presented.	 In	 addition,	 the	
reactivity	 of	 both	 maleimide-	 and	 thiol-functional	 PAOx	 by	 coupling	 with	 small	 molecules	 is	
described,	 as	well	 as	 in	 the	 formation	of	 either	 protein-PAOx	 conjugates,	 for	 the	maleimide-
PAOx,	or	surface	patterning,	in	the	case	of	thiol-PAOx.	
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3.2. Synthesis	of	functional	initiators	for	the	CROP	of	2-oxazolines	
When	 designing	 a	 functional	 initiator	 for	 the	 polymerization	 of	 2-oxazolines,	 an	 important	
parameter	 to	 consider	 is	 the	 compatibility	 of	 the	 chosen	 functional	 group	 with	 the	 CROP	
reaction.	 Functionalities	 that	 are	 incompatible	 with	 the	 CROP	 of	 2-oxazolines	 can	 also	 be	
introduced	during	initiation,	but	in	these	cases,	an	appropriate	protecting	group	strategy	has	to	
be	utilized.		
The	protection	of	 the	maleimide	by	cycloaddition	with	 furan	 is	necessary	during	 the	CROP	to	
avoid	 nucleophilic	 attacks	 and	 other	 potential	 side	 reactions.	 In	 the	 case	 of	 thiols,	 the	
protection	in	the	form	of	thioacetates	is	required	since	thiols	exhibit	a	high	reactivity	toward	a	
large	 variety	 of	 substrates,	 and	 are	 sensitive	 to	 oxidation,	 which	 leads	 to	 the	 formation	 of	
disulfides.266	
It	 was	 decided	 to	 use	 alkyl	 sulfonate	 initiators	 because	 these	 typically	 lead	 to	 faster	
polymerizations	 via	exclusive	 cationic	propagation,240	 and	are	easily	 synthesized	 from	alcohol	
derivatives,	 typically	 with	 simple	 purification	 procedures.128	 While	 tosylate	 derivatives	 are	
significantly	more	popular,	the	utility	of	nosylate	initiators	was	recently	demonstrated.93	In	this	
project,	 both	 types	 of	 sulfonates	 for	 each	 functional	 group	 chosen	 were	 synthesized	 and	
characterized	for	the	CROP	of	EtOx.	
3.2.1. Synthesis	of	maleimide-functional	initiators	
The	 synthetic	 strategy	 followed	 to	 obtain	 the	 maleimide-functional	 initiators	 is	 depicted	 in	
Scheme	14.	Maleic	 anhydride	was	 used	 as	 the	 starting	material	 to	 incorporate	 the	 activated	
ene	group.	Prior	to	further	functionalization,	the	 latter	was	protected	through	a	classic	Diels–
Alder	 cycloaddition	 with	 furan.	 The	 cycloadduct	 1	 was	 ring-opened	 with	 ethanolamine	 and	
dehydrated,	 to	 produce	 the	 hydroxylated	N-substituted	 protected	maleimide	 2.	 Nucleophilic	
substitution	 of	 2	 with	 tosyl	 and	 nosyl	 chloride	 generated	 the	 corresponding	 tosylate	 3	 and	
nosylate	4,	respectively.	The	overall	yield	for	these	(non-optimized)	3-step	syntheses	were	17.5	
and	8.1%,	for	3	and	4,	respectively.		
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Scheme	14.  Synthetic	route	for	maleimide-functionalized	tosylate	and	nosylate	initiators	for	the	CROP	
of	2-oxazolines	(Adapted	from	267).	
 
It	 is	worth	highlighting	 that	 the	 starting	materials	 for	 these	 syntheses	are	very	 cheap	and	no	
chromatographic	 step	 was	 required,	 in	 contrast	 to	 the	 previously	 mentioned	 synthetic	
strategies	 for	maleimide	 end-functional	 PEtOx.254,257	 Analysis	 of	 both	 initiators	 by	 1H	 and	 13C	
NMR	spectroscopy	(Figure	23,	Figure	24,	Figure	26,	and	Figure	27),	as	well	as	ESI-MS	(Figure	25	
and	 Figure	 28)	 confirmed	 that	 the	 targeted	 structures	 were	 obtained	 with	 high	 purity.	 The	
nosylate	 initiator	 (FurMalNos	4)	unfortunately	showed	a	 limited	solubility	 in	MeCN,	 the	most	
commonly	employed	solvent	for	the	CROP	of	2-oxazolines.	
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Figure	23. 1H	NMR	spectrum	of	FurMalTos	3	in	CDCl3	(Adapted	from	267).	
 
 
Figure	24. 13C	NMR	spectrum	of	FurMalTos	3	in	CDCl3	(Adapted	from	267).	
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Figure	25. 	ESI	mass	spectrum	of	FurMalTos	3	(Adapted	from	267).	
 
 
Figure	26. 	1H	NMR	spectrum	of	FurMalNos	4	in	DMSO-d6	(Adapted	from	267).	
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Figure	27. 	13C	NMR	spectrum	of	FurMalNos	4	in	DMSO-d6	(Adapted	from	267).	
 
 
Figure	28. ESI	mass	spectrum	of	FurMalNos	4	(Adapted	from	267).	
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3.2.2. Synthesis	of	thiol-functional	initiator	
Two	different	synthetic	strategies	were	developed	to	obtain	the	tosylate	and	nosylate	versions	
of	the	thiol	initiators,	as	depicted	in	Scheme	15.	In	the	case	of	the	tosylated	initiator,	ThioAcTos	
6,	 the	 synthetic	 route	 started	 with	 the	 nucleophilic	 substitution	 of	 allyl	 alcohol	 with	 tosyl	
chloride	to	yield	allyl	tosylate	5.	The	corresponding	initiator	ThioAcTos	6	was	obtained	by	photo	
thiol-ene	addition	of	5	with	thioacetic	acid	with	a	55%	overall	yield.	An	alternative	route	for	the	
synthesis	of	the	nosylate	 initiator	was	used,	since	purification	of	the	products	when	following	
the	previous	strategy	proved	to	be	a	more	challenging	task.	ThioAcNos	8	was	obtained	after	the	
nosylation	of	 the	product	of	 the	photo	 thiol-ene	addition	of	 thioacetic	 acid	 and	allyl	 alcohol.	
The	 product,	ThioAcNos	 8,	was	 purified	 by	 recrystallization,	 avoiding	 chromatographic	 steps,	
with	an	overall	yield	of	60%.	
 
 
Scheme	 15.	 Synthetic	 routes	 designed	 for	 thiol-functionalized	 tosylate	 and	 nosylate	 initiators	 for	 the	
CROP	of	2-oxazolines.	
 
Similar	 to	 the	 maleimide	 initiators	 described	 earlier,	 the	 low	 cost	 of	 the	 starting	 materials	
selected	and	 the	 reasonable	yields,	 combined	with	an	uncomplicated	synthesis,	make	 this	an	
advantageous	methodology	to	obtain	thiol-functionalized	PEtOx.	Analysis	of	both	 initiators	by	
1H	and	13C	NMR	spectroscopy,	as	well	as	ESI-MS	confirmed	that	 the	targeted	structures	were	
obtained	with	high	purity	(Figure	29,	Figure	30,	Figure	31,	Figure	32,	Figure	33,	and	Figure	34).	
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Figure	29. 	1H	NMR	spectrum	of	ThioAcTos	6	in	CDCl3.	
 
 
Figure	30. 	13C	NMR	spectrum	of	ThioAcTos	6	in	CDCl3.	
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Figure	31. ESI	mass	spectrum	of	ThioAcTos	6.	
 
 
Figure	32. 	1H	NMR	spectrum	of	ThioAcNos	8	in	CDCl3.	
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Figure	33. 13C	NMR	spectrum	of	ThioAcNos	8	in	CDCl3.	
 
 
Figure	34. ESI	mass	spectrum	of	ThioAcNos	8.	 	
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3.3. 	Cationic	ring-opening	polymerization	
For	this	project,	the	chosen	monomer	to	polymerize	using	the	new	functional	initiators	was	2-
ethyl-2-oxazoline.	Compared	to	2-methyl-2-oxazoline,	PEtOx	has	a	lower	water-solubility	due	to	
the	existence	of	an	LCST	at	approximately	60	°C.	In	spite	of	this,	it	is	still	more	convenient	that	
PMeOx,	that	has	a	lower	solubility	in	other	solvents,	including	in	the	monomer	itself.258		
Reported	optimized	conditions	for	a	very	fast	CROP	of	various	2-oxazolines,	among	them	EtOx,	
are	microwave-assisted	polymerization	 in	acetonitrile	at	140	°C.97	However,	depending	on	the	
compatibility	of	the	chosen	initiator	with	these	conditions,	some	modifications	are	necessary	to	
achieve	the	living	character	of	the	polymerization.		
In	 this	 section,	 the	 optimized	 conditions	 used,	 as	 well	 as	 analyses	 of	 the	 kinetic	 studies	
performed	and	the	characterization	of	the	resulting	polymers	using	each	functional	initiator	will	
be	addressed.		
3.3.1. Maleimide	initiator	
In	 the	 case	 of	 these	 new	 protected	 maleimide	 initiators,	 the	 high	 temperature	 used	 in	 the	
optimal	 polymerization	 conditions	 reported	 is	 not	 compatible,	 as	 it	 would	 lead	 to	 the	
deprotection	 of	 the	maleimide	 group	by	 cycloelimination.	 Consequently,	 lower	 temperatures	
were	 directly	 employed	 for	 preliminary	 experiments.	 Unfortunately,	 the	 microwave-assisted	
polymerization	at	80	 °C	 in	acetonitrile	 already	 triggered	 the	 loss	of	 the	maleimide	protecting	
group,	as	shown	by	1H	NMR	in	Figure	35.	Further	polymerization	tests	performed	at	80	°C	with	
conventional	heating	displayed	broad	molar	mass	distributions	 in	 SEC	 (Ð	 =	 1.32–1.41),	which	
indicates	the	loss	of	control	over	the	polymerization	(Figure	36).	Therefore,	the	polymerization	
temperature	was	 lowered	to	50	°C	using	conventional	heating	to	prevent	the	deprotection	of	
the	maleimide	group	and	favor	a	controlled	polymerization	(Scheme	16).	
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Figure	35.	1H	NMR	spectrum	of	the	crude	polymer	mixture	after	microwave-assisted	polymerization	of	
2-ethyl-2-oxazoline	using	[EtOx]/[FurMalTos	3]	=	40	at	80	°C	for	50	minutes	in	acetonitrile.	No	end	group	
signals	remain	(Adapted	from	267).	
 
 
Figure	 36. 	SEC	 traces	 of	 PEtOx	obtained	with	 either	FurMalNos	 4	 or	FurMalTos	 3	 as	 initiator	 and	 at	
either	50	°C	for	75	h	or	80°C	for	3	hours.	Polymers	made	at	80	°C	show	a	broader	distribution,	indicating	
the	loss	of	control	over	the	polymerization	at	such	temperature	(Adapted	from	267).	
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A	first	set	of	kinetic	experiments	to	polymerize	EtOx	was	performed	in	MeCN	with	[EtOx]	=	4	M,	
in	the	case	of	FurMalTos	3,	and	[EtOx]	=	1.5	M	for	FurMalNos	4.	The	monomer	concentration	
for	 the	 polymerization	 using	 FurMalNos	 4	 is	 significantly	 lower	 than	 what	 is	 typically	
encountered	in	the	literature	(the	optimal	monomer	concentration	is	established	as	4	M),95	due	
to	the	previously	mentioned	solubility	limits	of	FurMalNos	4	in	MeCN.		
 
 
Scheme	 16. Synthetic	 route	 for	 the	 synthesis	 of	 α-maleimido-PEtOx	 by	 polymerization	 of	 EtOx	 using	
functional	initiators	3	and	4	and	retro-Diels–Alder	cycloelimination,	followed	by	Michael	addition	with	a	
model	small	molecule	(Adapted	from	267).	
 
A	preliminary	assessment	of	the	ability	of	the	two	protected	maleimide-functionalized	sulfonic	
esters	 to	 initiate	 the	 polymerization	 was	 performed	 at	 50	 °C,	 targeting	 a	 degree	 of	
polymerization	 (DP)	 of	 50	 at	 full	 conversion	 ([EtOx]/[initiator]	 =	 50).	 After	 74	 hours,	 72%	
conversion	 was	 achieved	 with	 the	 FurMalNos	 4,	 whereas	 less	 than	 10%	 was	 obtained	 for	
FurMalTos	 3,	 as	 can	 been	 seen	 in	 Figure	 37.	 Importantly,	 for	 the	 FurMalNos	 4	 initiated	
polymerization,	it	was	possible	to	observe	the	survival	of	the	furan-maleimide	at	the	end	of	the	
polymerization	using	1H	NMR	spectroscopy	(Figure	43).	
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Recent	studies	on	 the	CROP	of	2-oxazolines	 in	MeCN	at	80	 °C,	 report	 that,	except	 for	methyl	
tosylate,	initiation	with	alkyl	tosylates	generally	leads	to	slow	initiation	and	propagation	rates,	
as	a	 consequence	of	 low	electrophilicity	and	 relatively	 low	 leaving	group	ability.93	 It	was	also	
reported	that	the	reactivity	of	ethyl	nosylate	is	high	enough	to	quantitatively	initiate	in	the	first	
instants	 of	 the	 polymerization.	 Considering	 the	 above	 mentioned	 facts,	 along	 with	 the	
experimental	 findings	 of	 the	 preliminary	 experiments,	 subsequent	 investigations	 were	
exclusively	conducted	with	FurMalNos	4	as	initiator.		
 
Figure	37.	Monomer	 conversion	as	 a	 function	of	 time	 for	 the	CROP	of	 2-ethyl-2-oxazoline	 at	 50	 °C	 in	
acetonitrile	 using	 FurMalTos	 3	 and	 FurMalNos	 4	 as	 initiators.	 [EtOx]	 =	 1.5	M;	 [EtOx]/[Initiator]	 =	 50	
(Adapted	from	267).	
 
In	order	to	evaluate	the	possibility	of	producing	α-maleimido-PEtOx	of	various	molar	masses,	a	
number	of	polymerizations	varying	monomer-to-initiator	ratios	were	carried	out	(Figure	39).	It	
was	observed	that	when	keeping	all	other	parameters	constant,	faster	polymerization	rates	are	
obtained	when	using	a	 lower	monomer-to-initiator	 ratio	 (Figure	39A).240	Long	polymerization	
times	of	up	to	76	hours	to	reach	94%	conversion	in	the	case	of	DP	20	were	required	(Figure	38).	
The	change	in	monomer	concentration	and	the	dramatic	decrease	of	the	reaction	temperature	
had	a	significant	effect	on	the	polymerization	rate.	Despite	these	long	polymerization	times,	all	
	 Maleimide	initiator	 3.3.1	
67	
	
kinetics	 showed	 a	 similar	 trend,	 i.e.,	 a	 rather	 slow	 polymerization	with	 two	 distinct	 regimes:	
first,	 a	 slow	 non-linear	 increase	 of	 ln(1/(1-conversion))	 with	 time	 at	 the	 beginning	 of	 the	
polymerization,	 followed	 by	 a	 linear	 behavior	 indicating	 a	 constant	 concentration	 of	
propagating	species	(Figure	39,	top).		
	
 
Figure	38.	Monomer	 conversion	as	 a	 function	of	 time	 for	 the	CROP	of	 2-ethyl-2-oxazoline	 at	 50	 °C	 in	
acetonitrile	 using	FurMalNos	 4	 as	 initiator	 at	 three	 distinct	 targeted	 degrees	 of	 polymerization	 (DP	 =	
[EtOx]/[FurMalNos].	[EtOx]	=	1.5	M	(Adapted	from	267).	
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Figure	 39. 	 (A)	 First-order	 kinetic	 plots	 and	 (B)	 evolution	 of	 the	 number-average	 molar	 mass	 and	
dispersity	vs	conversion	for	the	CROP	of	EtOx	 initiated	by	FurMalNos	4	at	various	targeted	degrees	of	
polymerization	(DP	=	[EtOx]/[FurMalNos])	in	MeCN	at	50	°C.	[EtOx]	=	1.5	M	(Adapted	from	267).	
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The	apparent	propagation	 rate	constant	values,	kp,	were	calculated	 for	each	kinetic	 run	 from	
Figure	39	using	the	following	equation:	
− d Mdt = k! ∙ [P∗] ∙ [M] 
where	 [M]	 and	 [P*]	 are	 the	monomer	 and	 propagating	 species	 concentrations,	 respectively.	
Assuming	 that	 all	 initiators	 react	 simultaneously	 upon	 heating,	 and	 therefore	 that	 [P*]	 =	 [I]0	
(initial	initiator	concentration),	the	integration	of	the	previous	equation	leads	to:	
ln M ![M] = k! ∙ [I]! ∙ t 
The	 kp	 values	 obtained	 are	 shown	 in	 Table	 2	 and	 appear	 to	 be	 independent	 of	 the	 initial	
monomer-to-initiator	ratio,	as	observed	in	previous	studies.240	The	observed	two	stages	of	the	
polymerization	 can	be	explained	by	 a	 relatively	 slow	 initiation	 reaction	 that	 results	 in	 a	 slow	
build-up	of	 the	 concentration	of	 propagating	 species.	 This	 phenomenon	 can	be	 attributed	 to	
the	 different	 polymerization	 conditions	 that	 include	 lower	 temperature	 and	 lower	monomer	
concentration,	in	comparison	to	classic	EtOx	polymerization	conditions.	
Table	 2.	 Estimated	polymerization	 rate	 constant	kp	 of	 the	 polymerization	of	 PEtOx	with	FurMalNos	 4	
using	three	different	monomer-to-initiator	ratios	(Adapted	from	267).	
[EtOx]/[FurMalNos]	 kp	(10
–6	L	mol–1	s–1)	
20:1	 158	
40:1	 166	
60:1	 160	
	
As	conversion	increased,	all	SEC	traces	shifted	towards	lower	retention	times	(Figure	40,	Figure	
41	 and	 Figure	 42).	 In	 addition,	 number-average	molar	masses	 (Mn)	 increased	 linearly,	 while	
dispersity	 values	 remained	 confined	 between	 1.1	 and	 1.2	 (Figure	 39B),	 evidence	 of	 a	
polymerization	with	 living	 character.	 It	 is	 important	 to	mention	 that	 to	 obtain	 the	Mn	 and	Ð	
values	 from	 the	 chromatogram,	 the	 integration	 of	 the	 polymer	 peak	was	 selected	 from	 low	
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elution	 times	 to	 approximately	 33	minutes	 because	 of	 an	 overlap	with	 an	 SEC	 system	 peak.	
Therefore,	Mn	and	Ð	can	be	considered	estimates.	Nevertheless,	at	high	conversions	the	values	
obtained	can	be	considered	quite	accurate	since	minimal	overlap	is	observed.	
	
 
Figure	 40. Overlay	 of	 SEC	 traces	 for	 the	 CROP	 of	 2-ethyl-2-oxazoline	 at	 50	 °C	 in	 acetonitrile	 using	
FurMalNos	4	as	initiator.	[EtOx]	=	1.5	M.	[EtOx]/[FurMalNos]	=	20	(Adapted	from	267).	
 
 
	 Maleimide	initiator	 3.3.1	
71	
	
 
Figure	 41. Overlay	 of	 SEC	 traces	 for	 the	 CROP	 of	 2-ethyl-2-oxazoline	 at	 50	 °C	 in	 acetonitrile	 using	
FurMalNos	4	as	initiator.	[EtOx]	=	1.5	M.	[EtOx]/[FurMalNos]	=	40	(Adapted	from	267).		
 
Figure	 42.	 Overlay	 of	 SEC	 traces	 for	 the	 CROP	 of	 2-ethyl-2-oxazoline	 at	 50	 °C	 in	 acetonitrile	 using	
FurMalNos	4	as	initiator.	[EtOx]	=	1.5	M.	[EtOx]/[FurMalNos]	=	60	(Adapted	from	267).	
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The	 linear	 increase	 of	 Mn	 values	 with	 conversion,	 along	 with	 low	 Ð,	 demonstrates	 that	
FurMalNos	 4	 enables	 the	 synthesis	 of	 well-defined	 polymers,	 despite	 the	 signs	 of	 slow	
initiation.	 The	 Mn	 values	 obtained	 from	 SEC	 are	 significantly	 higher	 than	 the	 expected	
theoretical	ones,	another	evidence	suggesting	the	slow	initiating	nature	of	reaction.	However,	
the	 difference	 in	 the	 values	 is	 also	 partly	 caused	 by	Mn	 values	 calculated	 with	 a	 calibration	
based	 on	 poly(methyl	 methacrylate)	 standards,	 which	 results	 in	 an	 overestimation.268	 To	
calculate	molar	masses	for	final	samples	after	purification,	1H	NMR	spectroscopy	was	used.	The	
end	group	signals	from	the	protected	maleimide,	found	at	5.2	and	6.5,	were	compared	to	the	
signals	corresponding	to	the	side	chain	and	backbone	of	the	polymer	(Figure	43A).	A	summary	
of	the	obtained	Mn	values,	and	the	relevant	characteristics	of	the	polymers	obtained	is	provided	
in	 Table	 3.	 The	Mn,NMR	 values	 obtained	 were	 significantly	 closer	 to	 the	 theoretical	 ones,	 in	
contrast	 to	 the	 SEC	 results.	 For	 instance,	 for	 the	 α-furan-maleimide-PEtOx	 sample	 prepared	
with	 DP	 40	 ([EtOx]/[FurMalNos]	 =	 40),	 after	 78%	 conversion,	 the	Mn,SEC	 value	 obtained	 was	
10600	g	mol–1,	whereas	Mn,NMR	was		6100	g	mol–1.	Although	the	value	obtained	with	1H	NMR	is	
significantly	 closer,	 it	 is	 still	 higher	 than	 the	 theoretical	 one.	 This	 corroborates	 the	 slow	
initiation	 that	 would	 result	 in	 a	 higher	 effective	 monomer-to-initiator	 ratio	 throughout	 a	
signiﬁcant	 part	 of	 the	 polymerization.	 Another	 possible	 explanation	 for	 the	 discrepancy	
between	experimental	and	theoretical	values,	can	also	involve	a	low	initiator	efficiency.	In	this	
case,	 the	difference	between	 the	expected	and	NMR-calculated	degrees	of	polymerization	of	
the	resulting	polymer	would	lead	to	a	53%	initiator	efficiency.	However,	even	when	there	may	
be	a	low	initiator	efficiency,	it	does	not	have	implications	on	the	actual	functionalization	of	the	
α	end	chain	of	the	polymer.		
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Figure	43.	1H	NMR	spectra	of	a	poly(2-ethyl-2-oxazoline)	FurMal-PEtOx	obtained	through	FurMalNos	4	
initiation	 ([EtOx]/[FurMalNos]	=	20;	Mn,SEC	=	6500	g	mol–1,	Ð	=	1.20;	Mn,NMR	=	4400	g	mol–1)	before	 (A)	
and	after	(B)	deprotection	of	the	maleimide	group	by	retro-Diels–Alder	cycloelimination	(Adapted	from	
267).	
 
Table	3.	Summary	of	 the	 characterization	of	 the	 final	purified	products	of	 the	polymerization	of	 EtOx	
with	FurMalNos	4	as	the	initiator	(Adapted	from	267).	
[EtOx]/	
[FurMalNos]	
Conversion	
(%)	
Mn,theo	
(g	mol–	1)	
Mn,	NMR	
(g	mol–	1)	
Mn,	SEC*	
(g	mol–	1)	 Ð	
20	 94	 2190	 4400	 6500	 1.20	
40	 78	 4172	 6100	 10600	 1.13	
60	 62	 6153	 6700	 11900	 1.16	
*Relative	to	PMMA	standards	
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3.3.1.1. Bifunctional	heterotelechelic	PEtOx	
The	functionalization	of	PAOx	using	the	initiation	approach	provides	the	possibility	to	produce	a	
bifunctional	polymer	by	addition	of	a	moiety	on	the	ω	end	chain	by	termination.	The	successful	
polymerization	with	FurMalNos	4	led	to	preliminary	tests	to	form	a	PEtOx-based	macro-CTA	by	
termination	with	 the	 deprotonated	 version	 of	 a	 pentanoic	 acid-bearing	 dithiobenzoate	 RAFT	
agent	(Figure	44).	PEtOx-based	macro	CTAs	can	be	used	for	the	synthesis	of	block	copolymers	
and	 the	 formation	 of	maleimide-functionalized	 nanoparticles	 by	 polymerization	 induced	 self-
assembly	(PISA).		
	
 
Figure	44.	RAFT	agent	used	in	the	present	study	4-cyano-4-(phenylcarbonothioylthio)pentanoic	acid.	
 
The	CROP	initiated	by	FurMalNos	4	was	performed	using	similar	reaction	conditions	described	
in	previous	experiments,	except	 the	 termination	was	carried	out	using	1.5	equivalents	of	 the	
selected	RAFT	agent	(DTB)	deprotonated	in	situ	with	TEA.	The	produced	polymers,	with	DPs	20	
and	40,	were	 characterized	by	 1H	NMR,	SEC,	 and	ESI-MS	 to	 confirm	 the	 introduction	of	both	
functional	 groups	 at	 the	 end	 chain	 (Figure	45,	Figure	46,	 and	Figure	47).	 1H	NMR	 shows	 the	
characteristic	signals	of	the	protected	maleimide	at	5.2	and	6.5	and	the	successful	introduction	
of	the	CTA	observed	by	the	signals	of	the	dithiobeozoate	group	between	7.3	and	8	ppm	(Figure	
45).	A	comparison	between	the	integral	values	of	the	end	groups	shows	a	lower	proportion	of	
CTA	protons	than	expected,	indicating	the	termination	was	not	quantitative.	Calculated	Mn,NMR	
values	 obtained	 by	 comparing	 the	 integrals	 of	 the	 protected	 maleimide	 signals	 to	 polymer	
backbone	 are	 in	 close	 agreement	 to	 those	 calculated	 for	 FurMalPEtOx	 from	 previous	
experiments.	 ESI-MS	 spectra	 of	 both	 synthesized	 polymers	 (Figure	 46)	 show	 that	 the	 most	
prominent	 population	 can	 be	 assigned	 to	 the	 FurMalPEtOx-DTB	 structure.	 Although	 the	
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presence	 of	 other	 signals	with	 lower	 intensity	 is	 observed,	 these	 could	 not	 be	 assigned.	 SEC	
traces,	 in	 Figure	 47,	 show	 a	 broader	 distribution	 compared	 to	 FurMalPEtOx.	 This	 can	 be	 an	
indication	of	possible	 side	 reaction	during	 termination,	 since	 it	 has	been	proved	 that	narrow	
distributions	 can	 be	 achieved	 with	 initiator	 FurMalNos	 4.	 Optimization	 of	 this	 synthesis	 to	
achieve	 well-defined	 polymers	 can	 lead	 to	 a	 number	 of	 applications	 depending	 on	 the	 co-
monomer	of	choice.		
 
Figure	45. 1H	NMR	spectrum	of	FurMal-PEtOx-DTB	obtained	after	CROP	of	EtOx	initiated	by	FurMalNos	
4	and	terminated	by	DTB	RAFT	agent	using	[EtOx]/[FurMalNos]	=	20.	
3.	 Maleimide-	and	Thiol-Functionalized	Initiators	for	the	Polymerization	of	2-Oxazolines	
76	
	
 
Figure	46. ESI-MS	spectra	of	FurMal-PEtOx-DTB	obtained	after	CROP	of	EtOx	initiated	by	FurMalNos	4	
terminated	by	DTB	RAFT	agent	using	[EtOx]/[FurMalNos]	=	20	(A)	and	40	(B).	
 
 
Figure	 47.	 SEC	 traces	 of	 FurMal-PEtOx-DTB	 obtained	 after	 CROP	 of	 EtOx	 initiated	 by	 FurMalNos	 4	
terminated	 by	 DTB	 RAFT	 agent	 using	 [EtOx]/[FurMalNos]	 20	 and	 40.	 The	 polymers	 show	 a	 broader	
distribution	indicating	a	certain	loss	of	control	of	the	polymerization.	
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A	 summary	 of	 the	 obtained	 Mn	 values,	 and	 the	 relevant	 characteristics	 of	 the	 polymers	
obtained	is	provided	in	Table	4.	
	
Table	 4.	 Summary	 of	 the	 characterization	 of	 the	 products	 of	 the	 polymerization	 of	 EtOx	 initiated	 by	
FurMalNos	4	and	terminated	by	DTB	RAFT	agent		
[EtOx]/	
[FurMalNos]	
Mn,theo	
(g	mol–	1)	
Mn,	NMR	
(g	mol–	1)	
Mn,	SEC*	
(g	mol–	1)	 Ð	
20	 2450	 4400	 6600	 1.25	
40	 4430	 6100	 8700	 1.26	
*Relative	to	PMMA	standards	
	
3.3.2. Thiol	initiator	
Contrary	to	the	polymerization	initiated	with	the	protected	maleimide	initiators,	the	CROP	of	2-
ethyl-2-oxazoline	 using	 the	 synthesized	 thiol-functional	 initiators	 was	 performed	 using	
optimized	microwave	conditions,97	at	140	°C	and	with	acetonitrile	as	reaction	solvent,	since	in	
principle,	no	thermal	incompatibility	is	expected	(Scheme	17).	
To	 assess	 the	 ability	 of	 both	 alkyl	 sulfonate	 esters	 to	 start	 the	 polymerization,	 a	 first	 set	 of	
experiments	was	carried	out	with	[EtOx]	=	4	M	and	a	degree	of	polymerization	of	50.	After	7.5	
minutes	 under	 microwave	 irradiation,	 the	 SEC	 traces	 of	 the	 polymers	 obtained	 revealed	
dispersities	 of	 1.20	 and	 1.10	 for	 ThioAcTos	 6	 and	 ThioAcNos	 8,	 respectively	 (Figure	 48).	
Although	both	dispersity	values	are	good	indication	of	a	controlled	polymerization,	the	broader	
molar	mass	distribution,	and	the	shape	of	the	signal	that	shows	some	tailing	on	the	SEC	traces	
obtained	when	initiating	the	polymerization	with	ThioAcTos	6,	indicate	a	lack	of	control	on	the	
polymerization,	 compared	 to	 the	 very	 low	 Ð	 value	 (1.1)	 of	 the	 polymers	 initiated	 with	
ThioAcNos	8.	For	this	reason,	only	the	latter	was	used	for	subsequent	experiments.	
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Scheme	 17.	 Synthetic	 route	 for	 the	 synthesis	 of	 α-Thiol-PEtOx	 by	 polymerization	 of	 EtOx	 using	
functional	 initiators	 6	 and	 8,	 followed	 by	 deprotection,	 and	 subsequent	Michael	 addition	 with	 three	
model	molecules.	
 
Figure	48.	SEC	traces	of	PEtOx	obtained	with	either	ThioAcTos	6	or	ThioAcNos	8	as	initiator.	Microwave	
assisted	polymerization	at	140	°C	in	acetonitrile	for	7.5	minutes.	Polymers	made	with	ThioAcTos	6	show	
a	broader	distribution	and	tailing,	indicating	the	loss	of	control	over	the	polymerization.	
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Kinetic	studies	of	a	set	of	polymers	with	three	different	monomer	to	initiator	ratios	(20,	40,	and	
60)	were	carried	out	(Figure	50).	As	expected,	the	polymerization	proceeds	faster	when	a	lower	
monomer-to-initiator	ratio	is	used	(Figure	50A).240	It	is	worth	highlighting	the	advantages	of	the	
compatibility	of	 this	 initiator	with	 the	use	of	 a	 single-mode	microwave	 reactor.	Compared	 to	
the	previously	described	FurMalNos	4	 initiated	reaction,	where	polymerization	reactions	took	
over	70	hours	to	get	to	a	high	conversion,	with	the	ThioAcNos	8	initiator	the	reaction	rate	was	
enhanced	so	that	in	less	than	150	seconds,	high	conversions	were	already	achieved	in	all	cases	
(Figure	49).			
	
 
Figure	49.	Monomer	conversion	as	a	 function	of	time	for	the	CROP	of	2-ethyl-2-oxazoline	at	140	°C	 in	
acetonitrile	 using	 ThioAcNos	 8	 as	 initiator	 at	 three	 distinct	 targeted	 degrees	 of	 polymerization	 DP	 =	
[EtOx]/[ThioAcNos].	
 
All	 kinetic	 experiments	 performed	 show	a	 linear	 increase	of	 ln(1/1-conversion)	 as	 conversion	
progressed,	which	indicates	a	constant	concentration	of	the	propagating	species,	a	requirement	
to	obtain	the	living	character	of	a	polymerization	(Figure	50).	The	propagation	constants	were	
calculated	 for	 the	 three	 different	 DPs	 used,	 according	 to	 the	 same	 procedure	 described	 for	
FurMalNos	8	in	section	0.	The	obtained	values,	shown	in	Table	5,	are	quite	similar,	which	shows	
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the	 kp	 obtained	 is	 independent	 of	 the	 DP	 used.	 Compared	 to	 the	 kp	 calculated	 for	 the	
polymerization	 using	 FurMalNos	 4,	 the	 kp	 values	 of	 the	 polymerization	 performed	 with	
ThioAcNos	8	are	three	orders	of	magnitude	larger,	further	highlighting	the	advantages	of	higher	
temperatures	enabled	by	microwave	irradiation	at	enhancing	the	polymerization	rate.		
	
Table	5.	Estimated	polymerization	rate	kp	of	the	polymerization	of	PEtOx	with	ThioAcNos	8	using	three	
different	monomer	to	initiator	ratios.	
[EtOx]/[ThioAcNos]	 kp	(10
–3	L	mol–1	s–1)	
20:1	 200	
40:1	 190	
60:1	 225	
	
Additionally,	the	SEC	traces	of	the	samples	taken	at	time	intervals	show	a	linear	increase	of	the	
number-average	molar	masses	(Mn),	dispersity	values	below	1.11	(Figure	50B),	and	a	uniform	
shift	to	higher	retention	times	as	conversion	increases	(Figure	51	and	Figure	52).	All	of	this	is	in	
agreement	 with	 living	 polymerization	 conditions.	 The	 difference	 between	 theoretical	 and	
experimental	Mn	 values	 in	 this	 case,	 again	 comes	 from	 the	 calculation	 of	 the	 experimental	
values	relative	to	 	poly(methyl	methacrylate)	standards	which	results	 in	an	overestimation.268	
Similar	 to	 the	 chromatograms	 obtained	 from	 the	maleimide-functionalized	 polymers,	 the	Mn	
and	Ð	values	can	be	considered	estimates,	since	the	integration	was	done	in	the	same	way	for	
all	 samples	 (from	 low	elution	 times	 to	approximately	33	minutes	due	 to	overlap	with	an	SEC	
system	peak).		
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Figure	 50.	 	 (A)	 First-order	 kinetic	 plots	 and	 (B)	 evolution	 of	 the	 number-average	 molar	 mass	 and	
dispersity	vs	conversion	 for	 the	CROP	of	EtOx	 initiated	by	ThioAcNos	4	at	various	 targeted	degrees	of	
microwave-assisted	polymerization	(DP	=	[EtOx]/[ThioAcNos])	in	MeCN	at	140	°C.	[EtOx]	=	4	M.	
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The	 calculation	 of	 the	 molar	 masses	 of	 the	 purified	 samples	 obtained	 at	 the	 end	 of	 the	
polymerization	 was	 done	 using	 1H	 NMR	 spectroscopy.	 The	 visible	 end	 group	 signals	 of	 the	
initiator,	 found	 at	 1.8,	 2.8,	 and	 4.4,	 were	 compared	 to	 the	 side	 chain	 and	 backbone	 of	 the	
polymer	(Figure	53).	A	summary	of	the	calculated	results,	along	with	other	relevant	features	of	
the	 synthesized	polymers,	 is	 shown	 in	Table	6.	 The	Mn,NMR	values	obtained	were	 significantly	
closer	 to	 the	 theoretical	 values,	 compared	 to	 the	 Mn,SEC	 results.	 For	 instance,	 for	 the	 α-
thioacetate-PEtOx	 sample	 prepared	 with	 DP	 40	 ([EtOx]/[ThioAcNos]	 =	 40),	 after	 91%	
conversion,	the	Mn,SEC	value	obtained	was	5800	g	mol–1,	whereas	Mn,NMR	was		4100	g	mol–1.	The	
value	obtained	with	1H	NMR	is	very	close	to	the	expected	theoretical	value,	which	indicates	a	
high	efficiency	of	the	initiator.	Even	when	the	obtained	Mn,NMR	values	are	in	the	case	of	DP	20	
and	40	slightly	above	what	 is	expected,	 it	 is	probably	caused	by	a	negligible	amount	of	chain	
transfer	 reactions	 occurring	 during	 the	 polymerization,	 with	 proton-initiated	 chains	 as	 by-
product.	 Nevertheless,	 the	 living	 polymerization	 requirements	 of	 linear	 increase	 in	 polymer	
chain	size	as	conversion	progresses,	and	low	molar	mass	dispersities	are	still	satisfied.		
	
	
Figure	 51.	 Overlay	 of	 SEC	 traces	 for	 the	 CROP	 of	 2-ethyl-2-oxazoline	 at	 140	 °C	 in	 acetonitrile	 using	
ThioAcNos	8	as	initiator.	[EtOx]	=	4	M.	[EtOx]/[ThioAcNos]	=	40.	
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Figure	 52.	 Overlay	 of	 SEC	 traces	 for	 the	 CROP	 of	 2-ethyl-2-oxazoline	 at	 140	 °C	 in	 acetonitrile	 using	
ThioAcNos	8	as	initiator.	[EtOx]	=	4	M.	[EtOx]/[ThioAclNos]	=	60.	
 
Table	6.	 Summary	of	 the	 characterization	of	 the	 final	purified	products	of	 the	polymerization	of	 EtOx	
with	ThioAcNos	8	as	the	initiator. 
[EtOx]/	
[ThioAcNos]	
Conversion	
(%)	 Yield	(%)	
Mn,theo	
(g	mol–1)	
Mn,	NMR	
(g	mol–1)	
Mn,	SEC*	
(g	mol–1)	 Ð	
20	 97	 89	 2246	 2700	 3800	 1.08	
40	 91	 83	 3909	 4100	 5800	 1.09	
60	 100	 87	 6277	 5500	 9500	 1.09	
*Relative	to	PMMA	standards	
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Figure	53.	1H	NMR	spectra	of	a	poly(2-ethyl-2-oxazoline)	ThioAc-PEtOx	obtained	through	ThioAcNos	8	
initiation	([EtOx]/[ThioAcNos]	=	40;	Mn,SEC	=	5800	g	mol–1,	Ð	=	1.09;	Mn,NMR	=	4100	g	mol–1).	
	
The	compatibility	of	the	new	initiator	ThioAcNos	8	with	the	polymerization	conditions	using	a	
single-mode	microwave	 reactor	 gave	 the	 reaction	 the	 advantages	 such	 as	 enhanced	 reaction	
rates	 and	 reduction	 of	 side	 reactions,	 while	maintaining	 first-order	 kinetics	 of	 the	monomer	
consumption	and	the	livingness	of	the	polymerization.97		
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3.4. 	Deprotection	and	reactivity	assessment	
3.4.1. Maleimide-PEtOx	
A	polymer	FurMal-PEtOx	obtained	at	94%	conversion	(Mn,SEC	=	6500	g	mol–1,	Ð	=	1.20;	Mn,NMR	=	
4400	 g	mol–1)	was	 purified	 to	 confirm	 the	 nature	 of	 the	 end	 groups,	 and	was	 later	 used	 for	
coupling	reactions.	To	evaluate	the	stability	of	the	furan-protected	maleimide	throughout	the	
polymerization	and	 to	monitor	 further	modifications,	 1H	NMR	spectroscopy	and	ESI-MS	were	
used	 (Figure	43	and	Figure	54).	 The	 1H	NMR	 spectrum	of	FurMal-PEtOx	 shows	 the	expected	
signals	for	the	6	methine	protons	(e–g)	of	the	furan-maleimide	Diels–Alder	cycloadduct	(Figure	
43A).	In	addition,	no	signal	corresponding	to	vinyl	protons	of	deprotected	maleimide	was	found	
(expected	δ	at	approx.	6.7	ppm).	The	stability	of	the	protecting	group	was	corroborated	by	ESI-
MS	with	the	presence	of	a	major	population	corresponding	to	chains	having	the	initiating	group	
and	 a	 hydroxyl	moiety	 as	 the	 end	 groups	 (Figure	 54A).	 The	major	 side-product	 is	 a	 proton-
initiated	 PEtOx,	 which	 is	 seen	 in	 most	 PAOx	 reports	 and	 originates	 from	 a	 chain	 transfer	
reaction	via β-elimination	described	in	section	2.2.1.101	
Thermal	 treatment	 in	 toluene	 at	 110	 °C	 for	 4	 h	 yielded	 the	 deprotected	 α-functional	Mal-
PEtOx.	 As	 shown	 in	 the	 1H	 NMR	 spectrum,	 the	 characteristic	 oxanorbornene	 signals	 of	 the	
cycloadduct	quantitatively	disappeared	(Figure	43B),	 leaving	new	signals	(e’)	corresponding	to	
vinylic	protons	of	an	electron-deficient	structure.	When	integrating	the	corresponding	signals,	
the	similar	integration	values	obtained	evidence	the	quantitative	survival	of	the	maleimide.	To	
assess	 chain-end	 transformation,	 mass	 spectrometry	 was	 used.	 While	 the	 original	 signals	
assigned	to	FurMal-PEtOx	vanished,	a	new	set	of	peaks	with	a	shift	of	about	34	amu	(doubly	
charged	 species)	 corresponding	 to	 the	 loss	 of	 a	 furan	molecule	 was	 observed	 after	 thermal	
treatment	(Figure	54B).	
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Figure	54. ESI-MS	spectra	of	(A)	FurMal-PEtOx	as	obtained	after	CROP	of	EtOx	initiated	by	FurMalNos,	
(B)	Mal-PEtOx	obtained	after	thermal	treatment	of	FurMal-PEtOx,	and	(C)	the	Michael	addition	product	
of	Mal-PEtOx	with	benzyl	mercaptans	(BzSMal-PEtOx)	(Adapted	from	267).	
 
The	reactivity	of	the	maleimide	group	of	Mal-PEtOx	was	evaluated	by	trimethylamine-catalyzed	
Michael	addition	with	a	model	thiol.	In	this	case	benzyl	mercaptan	was	chosen.	Again,	the	peak	
corresponding	 to	 the	 precursor	 polymer	 disappeared	 and	 a	 new	 main	 population	 appeared	
with	a	shift	of	approximately	62	amu	considering	double	charges,	which	perfectly	matches	the	
addition	of	a	benzyl	mercaptan	molecule,	proving	the	reactivity	of	the	maleimide	at	the	α	end	
of	the	polymeric	chain	(Figure	54C).	Two	by-products	on	the	ESI	MS	spectrum	are	observed	but	
it	 was	 not	 possible	 to	 identify	 them.	 The	 integrity	 of	 the	 polymer	 backbone	 during	 the	
successive	 transformations	could	be	confirmed	by	SEC,	where	no	significant	difference	 in	 the	
molar	mass	distributions	of	FurMal-PEtOx,	Mal-PEtOx,	and	BzSMal-PEtOx	was	observed	(Figure	
55;	Mn	=	6500–7000	g	mol–1,	Ð	=	1.20–1.27).	
	 Thiol-PEtOx	 3.4.2	
87	
	
 
Figure	55.	Overlay	of	SEC	traces	of	FurMal-PEtOx	(Mn,SEC	=	6500	g	mol–1,	Ð	=	1.20),	its	deprotection	Mal-
PEtOx	(Mn,SEC	=	6900	g	mol–1,	Ð	=	1.24),	and	BzSMal-PEtOx	(Mn,SEC	=	7000	g	mol–1,	Ð	=	1.27)	obtained	by	
Michael	addition	with	benzyl	mercaptan	(Adapted	from	267).	
	
3.4.2. Thiol-PEtOx	
The	purified	polymer	ThioAc-PEtOx	(DP	=	40,	Mn,SEC	=	5800	g	mol–1,	Ð	=	1.09	;	Mn,NMR	=	4100	g	
mol–1)	 was	 used	 to	 confirm	 the	 nature	 of	 the	 end	 groups,	 and	 then	 for	 deprotection	 and	
modification	 with	 model	 molecules.	 The	 deprotection	 procedure	 was	 achieved	 using	
triazabicyclodecene	(TBD),	a	mild	base,	and	characterized	via	SEC	(Figure	57)	and	ESI-MS	(Figure	
56).	 	As	 shown	 in	 the	ESI-MS	 spectra	of	 the	ThioAcPEtOx	 and	 its	deprotected	version,	Thiol-
PEtOx,	 the	 shift	 in	 the	 signals	of	21	amu	considering	double	charges	matches	 the	 theoretical	
expected	 value.	 The	 presence	 of	 another	 polymer	 family	 is	 visible,	 since	 there	 are	 smaller	
signals	from	another	distribution	in	the	spectra.	It	corresponds	to	the	product	of	chain-transfer	
reactions	 during	 the	 polymerization:	 proton-initiated	 chains,	with	 a	 hydroxyl	 group	on	 the	ω	
end	chain.	Although	ESI-MS	is	not	a	quantitative	method,	it	can	be	assumed	that	the	size	of	this	
secondary	 population	 is	much	 smaller	 than	 the	main	 and	 targeted	 polymer	 structure.	 These	
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proton-initiated	 chains,	 however,	 increase	 the	 calculated	 value	Mn,NMR,	 and	 can	 explain	 the	
slightly	higher	Mn,NMR	value,	compared	to	the	theoretical	Mn.		
	
 
Figure	56. ESI-MS	spectra	of	ThioAc-PEtOx	as	obtained	after	CROP	of	EtOx	initiated	by	ThioAcNos,	Thiol-
PEtOx	obtained	after	treatment	of	ThioAc-PEtOx	with	TBD,	and	the	Michael	addition	products	of	Thiol-
PEtOx	with	butylacrylate	(BA-thiol-PEtOx),	acrylic	acid	NHS	(NHS-thiol-PEtOx),	and	furfuryl	methacrylate	
(FurfurylMA-thiol-PEtOx).	
 
As	previously	mentioned,	the	versatility	of	the	thiol	group	allows	a	wide	range	of	reactions.	In	
this	study,	three	different	model	molecules	were	attached	to	the	polymer	via	Michael	addition:	
n-butyl	acrylate,	acrylic	acid	NHS	ester,	and	furfuryl	methacrylate.	 In	each	case,	 in	ESI-MS,	the	
major	population	is	shifted	from	the	deprotected	thiol	signal	to	a	value	that	corresponds	to	the	
change	in	molar	mass	expected	from	the	addition	of	the	chosen	molecule	(Figure	56).	There	is	a	
number	 of	 smaller	 signals	 appearing	 after	 the	Michael	 addition	 of	 the	model	molecules	 that	
have	not	been	 identified.	 It	 is	assumed	these	correspond	to	the	occurrence	of	side	reactions.	
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Nevertheless,	the	SEC	traces	show	the	backbone	structure	of	the	polymer	is	conserved	(Figure	
57).		
 
 
Figure	57.	Overlay	of	SEC	traces	of	ThioAc-PEtOx	(Mn,SEC	=	5800	g	mol–1,	Ð	=	1.09;	Mn,NMR	=	4100	g	mol–1),	
its	deprotection	product	Thio-PEtOx	with	and	without	a	reducing	agent	(DTT),	and	the	products	of	the	
Michael	addition	of	furfuryl	methacrylate	FurfurylMA-Thiol-PEtOx,	and	butyl	acrylate	BA-Thiol-PEtOx.		
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3.5. 	Bioconjugation	
As	 described	 in	 section	2.1.2.2,	 PAOx	 have	 been	 discussed	 as	 a	 promising	 option	 for	 stealth	
polymers88	 and,	 as	 such,	 can	 be	 used	 for	 “PAOxylation”	 of	 proteins.	 Examples	 include	 the	
conjugation	 of	 PEtOx	 and	 PMeOx	 to	 model	 proteins	 such	 as	 catalase,269	 horseradish	
peroxidase,270	bovine	serum	albumin,43	uricase,43	 insulin,43	and	granulocyte	colony	stimulating	
factor.119		
Considering	 the	 relatively	 low	 abundance	 of	 free	 cysteine	 residues	 in	 natural	 proteins,	 the	
maleimide-mediated	 functionalization	with	polymers	 can	provide	 specificity	 to	 the	conjugate,	
compared	 with	 other	 coupling	 strategies	 using	 lysine	 residues.	 The	 thiol	 addition	 to	 the	
activated	double	bond	 in	 aqueous	 conditions	works	best	 at	 neutral	 or	mild	 alkaline	pH	 (7.5–
8.5).51	
An	 experiment	 to	 conjugate	 a	 functional	 Mal-PEtOx	 (Mn,NMR	 =	 6100	 g	 mol–1)	 to	 BSA	 was	
performed.	BSA	was	chosen	as	a	model	protein	 since	 it	has	one	 free	cysteine	exposed	on	 its	
surface	 (Cys-34	 residue)	 and	 available	 for	 conjugation.271	 The	 conjugation	 reaction	 ran	
overnight	 with	 three	 different	 polymer-to-protein	 molar	 ratios	 f	 (5,	 10,	 and	 15)	 in	 100	mM	
phosphate	buffer	at	pH	7.6.	Under	these	pH	conditions,	it	is	ensured	that	no	conjugation	via	the	
amino	group	of	lysine	residues	happens,	ensuring	only	attachment	of	the	free	cysteine	present	
in	BSA.230		
The	characterization	of	the	resulting	conjugate	was	performed	using	SDS-PAGE	electrophoresis	
and	MALDI	spectrometry	(Figure	58).	For	SDS-PAGE,	in	all	lanes	corresponding	to	the	incubation	
of	 BSA	 with	Mal-PEtOx	 a	 shift	 in	 the	 protein	 signal	 towards	 higher	 molar	 masses	 can	 be	
observed,	 indicating	successful	conjugation.	The	BSA	signal	broadened	because	only	about	55	
to	70	percents	of	 commercial	 BSA	actually	 contain	 the	 free	 cysteine	 residue,258	which	means	
this	signal	 is	a	mixture	of	native	and	conjugated	BSA.	In	addition,	there	was	no	shift	observed	
when	 non-deprotected	 FurMal-PEtOx	 was	 incubated	 with	 BSA	 in	 identical	 conditions.	 To	
further	characterize	the	conjugate,	a	preparative	chromatographic	separation	was	done	and	a	
sample	 collected	 at	 lower	 retention	 time	 than	 the	 BSA	 eluting	 time	 (highest	 intensity	
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considered)	was	analyzed	by	MALDI-ToF	mass	 spectrometry.	The	spectrum	of	 the	conjugated	
sample	 (Figure	58C,	bottom)	shows	a	mixture	of	 two	species.	First,	a	 signal	 corresponding	 to	
the	mass	 of	 pure	 BSA,	 which	 was	 expected	 since	 not	 all	 BSA	molecules	 contain	 a	 free	 thiol	
available	 for	 conjugation,	 and	 a	 second	 population	 at	 higher	m/z	 with	 a	 shift	 corresponding	
approximately	 to	 the	 mass	 of	Mal-PEtOx.	 The	 second	 signal	 exhibits	 a	 significantly	 broader	
distribution	than	the	protein,	as	expected	from	a	synthetic	polymer-protein	conjugate.		
 
Figure	58.	Protein	conjugation	experiment	in	100	mM	phosphate	buffer	at	pH	7.6	for	18	hours	at	room	
temperature	 using	 three	 different	 [Mal-PEtOx]/[BSA]	 ratios.	 A)	 SDS-PAGE	 gel	 stained	with	 Coomassie	
blue.	B)	Intensity	of	the	signals	from	each	lane	as	a	function	of	electrophoretic	mobility.	C)	MALDI-ToF	
spectra	 of	 (top)	 BSA	 and	 (bottom)	 the	 fraction	 collected	 after	 preparative	 FPLC	 of	 the	 PEtOx-BSA	
conjugate	(Adapted	from	267).		
 
These	results	are	an	early	proof	that	show	the	possibility	of	conjugation	of	the	synthesized	Mal-
PEtOx	 to	model	 proteins.	 Further	 investigations	 should	 be	 conducted	 to	 assess	 the	 ability	 of	
PEtOx	to	provide	a	stealth	character	similar	to	PEG.	 	
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3.6. 	Surface	functionalization	
Several	 strategies	 to	 graft	 PAOx	on	 surfaces	 have	 been	 reported.272,273	 A	 simple	 and	popular	
method	 uses	 α-	 or	 ω-functional	 PAOxs	 prepared	 with	 either	 a	 functional	 initiator,	 or	 a	
terminating	 agent,	 to	 add	 (directly	 or	 after	 modification)	 a	 coupling	 agent	 at	 the	 end	
chain.273,272	Functionalities	introduced	by	direct	end-capping	of	the	living	polymer	species	to	be	
used	as	anchors	for	the	modification	of	substrates	include	silanes,153,274	alkene,153	xanthane,261	
and	 alkyne275	 groups.	 For	 similar	 surface	 immobilization	 purposes,	 allyl-,153	 disulfide-,265	 and	
alkyne-functional	 initiators276	 were	 used	 to	 produce	 α-functionalized	 PAOxs. Alternative	
strategies	 to	 graft	 PAOx	 on	 substrates	 include	 surface-initiated	 or	 -terminated	
polymerization,265,277,278	 photo-immobilization	 of	 the	 polymer	 at	 the	 backbone	 or	 the	 side	
chain,273,272	and	the	use	of	graft	copolymers	bearing	a	coupling	moiety.273,272	
For	this	project,	the	synthesized	α-Thiol-PEtOx	using	the	initiator	strategy	were	immobilized	on	
acrylate-modified	 silicon	 substrates	 by	 Michael	 addition	 using	 micro-contact	 patterning	
(Scheme	 18).	 The	 wafer	 functionalization	 with	 acrylate	 silane	 was	 carried	 out	 following	
reported	protocols.	The	 ink	mixtures	were	prepared	combining	1	µl	Thiol-PEtOx	 solution	 (2.5	
mg	 mL–1	 in	 DMSO)	 with	 0.2	 µl	 of	 dimethylphenylphosphine	 (DMPP)	 as	 catalyst	 and	 1	 µl	 of	
glycerol	to	prevent	the	premature	drying	of	the	ink.	A	neat	silicon	wafer	with	a	layer	of	silicon	
dioxide	was	patterned	as	control.	Dots	with	a	diameter	of	approximately	15	µm	were	patterned	
on	the	surfaces	using	a	30	µm	spacing	between	each	other.	Unreacted	material	was	removed	
from	the	surfaces	by	extensive	washing	with	water	and	ethanol,	and	subsequently,	the	wafers	
were	dried	in	a	N2	stream	and	analyzed	by	X-ray	photoelectron	spectroscopy	(XPS).	The	surface	
with	immobilized	Thiol-PEtOx	was	compared	to	the	patterned	silicon	wafer	used	as	control,	an	
acrylate-functionalized	silicon	wafer,	and	a	piranha	solution-activated	silicon	wafer	 (Figure	59	
and	Table	7).		
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Scheme	18.	General	strategy	for	the	immobilization	of	Thiol-PEtOx	on	acrylate-modified	silicon	wafers	
by	micro-contact	patterning.	
	
XPS	analysis	of	 the	activated	wafer	 showed	a	 total	 carbon	content	of	4.3	at%	at	 the	 surface,	
attributed	to	contaminants	(Figure	59A).	After	functionalization	with	acrylate,	the	total	carbon	
content	 increased	 significantly	 to	19.7	at%	and	 the	appearance	of	 a	peak	at	289.2	eV	 can	be	
observed	 (Figure	59B),	proving	 the	presence	of	 the	O–C=O	species	with	a	contribution	of	3.5	
at%.	Subsequently,	an	 intensity	decrease	of	this	 latter	signal	after	Thiol-PEtOx	patterning	(1.1	
at%),	indicated	successful	surface	modification	(Figure	59C).	Furthermore	the	appearance	of	an	
additional	peak	at	288.4	eV,	attributed	to	amide	carbons,	was	observed	with	a	concentration	of	
0.5	at%	(Figure	59C),	proving	functionalization	with	PEtOx.	Additionally,	the	signal	at	400.1	eV	
(0.5	 at%)	 indicates	 the	presence	of	 nitrogen	 atoms	on	 the	 surface	with	 a	 1	 to	 1	 ratio	 to	 the	
amide	carbon	 (Table	7).	 Signals	at	288.0	eV	and	400.1	eV	were	also	detected	 for	 the	control	
sample	(0.3	%at	in	each	case),	attributed	to	potential	adsorption	of	PEtOx	to	the	silicon	wafer	
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(Figure	 59D)	 or	 other	 contaminants.	 Nevertheless,	 since	 the	 total	 carbon	 content	 on	 this	
control	surface	reaches	only	a	concentration	of	5.2	at%,	this	value	is	comparable	to	the	carbon	
content	of	the	activated	surface	and	potential	PEtOx	adsorption	is	neglegible.		
	
	
Figure	 59.	 C	 1s	 XP	 spectra	 of	 piranha	 solution-activated	 wafer	 (A),	 acrylate-functionalized	 wafer	 (B),	
Thiol-PEtOx	 functionalized	Si	wafer	 (C),	 and	patterned	Si	wafer	with	a	 layer	of	 SiO2	 as	 control	 (D).	All	
intensities	are	normalized	to	the	maximum	of	intensity.		
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Table	7.	Atomic	concentrations	of	carbon	and	nitrogen	species	calculated	from	XPS	quantitative	analysis	
of	piranha	solution-activated	wafer	(A),	acrylate-functionalized	wafer	(B),	Thiol-PEtOx	functionalized	Si	
wafer	(C),	and	neat	Si	wafer	with	a	layer	of	SiO2	as	control	(D).			
Binding	
energy	(eV)	
Attribution	
Atomic	%	
A	 B	 C	 D	
285.0	 C-C,	C-H	 3.1	 13.3	 14.5	 3.5	
286.6	 C-O	 0.9	 2.9	 2.8	 1.2	
288.0	 C=O	 -	 -	 -	 0.3	
288.4	 N–C=O	 -	 -	 0.5	 -	
289.2	 O–C=O	 0.3	 3.5	 1.1	 0.2	
	 Total	C	 4.3	 19.7	 18.8	 5.2	
400.1	 N	 0.2	 -	 0.5	 0.3	
	
Further	studies	to	evaluate	the	anti-fouling	behavior	of	immobilized	PEtOx	on	surfaces,	as	well	
and	 cytotoxicity	 studies,	 should	 be	 carried	 out	 to	 corroborate	 its	 potential	 for	 biomedical	
applications.	 In	 addition,	 functionalization	 of	 the	ω-	 chain	 end	 of	 PEtOx	with	 an	 appropriate	
moiety	 to	 link	 biomolecules	 can	 provide	 specific	 attachment	 to	 the	 surface	 of	 molecules	 of	
interest.		
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3.7. Conclusion	
A	novel,	efficient	route	 for	 the	synthesis	of	maleimide	and	thiol	end-functionalized	PAOx	was	
established	using	nosylate	initiators	bearing	either	a	maleimide	moiety	protected	in	the	form	of	
a	furan-based	Diels–Alder	adduct,	or	a	thiol	group	in	the	form	of	tihoacetate	for	protection.	In	
the	 case	 of	 FurMalNos	 4,	 the	 limited	 solubility	 and	 thermal	 lability	 of	 the	 initiator	 required	
polymerization	 at	 a	 lower	 monomer	 concentration,	 and	 temperature.	 For	 ThioAcNos	 8,	 the	
simple	synthetic	strategy,	great	solubility,	along	with	the	advantages	of	being	compatible	with	
microwave-assisted	 polymerization	 provided	 the	 possibility	 to	 synthesize	 well-defined	
polymers,	available	for	post-polymerization	modification,	or	direct	surface	functionalization.	In	
both	 cases,	 molar	 masses	 relevant	 for	 bioconjugation	 or	 surface	 functionalization	 could	 be	
obtained.	Although	the	 functionalized	 initiator	 route	 (mainly	 in	 the	case	of	FurMalNos	4)	can	
lead	to	the	presence	of	non-functionalized	chains,	via	H	transfer,	or	molar	mass	discrepancies	
caused	 by	 lower	 initiator	 efficiency,	 the	 combination	 of	 a	 straightforward	 synthesis	with	 the	
availability	 of	 the	 ω	 chain	 end	 for	 further	 functionalization	 makes	 this	 route	 particularly	
attractive	 for	 advanced	 application	 in	 life	 sciences.	 We	 envision	 that	 this	 route	 would	 be	
practical	 for	 the	 development	 of	 bifunctional	 linkers	 for	 surface	 biofunctionalization,	 or	
antifouling	surfaces,	or	for	the	construction	of	artificial	protein	dimers.	
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4	
Poly(2-ethyl-2-oxazoline)	
macromonomers	for	the	
synthesis	of	functional	
bottlebrush	polymers	
4.1. Introduction2	
PAOx	 is	 a	 polymer	 class	 with	 potential	 applications	 in	 the	 biomedical	 field	 thanks	 to	 its	
properties	 such	 as	 biocompatibility	 and	 stealth	 behavior.84,279	 Specifically,	 the	 water-soluble	
PEtOx	and	PMeOx	are	nontoxic	 and	have	high	 stability	 and	 low	viscosity,	which	makes	 them	
potential	alternatives	to	the	gold	standard	polymer	used	for	biomedical	applications,	PEG.13,47	
PAOxs	are	synthesized	by	living	CROP,	which	provides	synthetic	versatility	from	the	wide	range	
of	2-oxazoline	monomers	available	and	the	possibility	to	add	functionalities	at	the	chain	ends	
depending	on	the	 initiator	or	terminating	agent	of	choice.36,92	Using	the	capping	agent	option	
for	 functionalization	allows	the	 facile	 introduction	of	ω	end	groups	to	the	polymer	chain	that	
are	 incompatible	 with	 the	 polymerization	 reaction.	 For	 instance,	 termination	 of	 PAOx	 with	
																																								 																				
2	 The	 project	 described	 in	 this	 chapter	 was	 done	 in	 collaboration	 with	 the	 group	 of	 Prof.	 Jeremiah	 Johnson,	 at	 the	
Department	of	Chemistry	of	the	Massachusetts	Institute	of	Technology.	EPR	and	relaxivity	studies	were	experimentally	
carried	out	by	Hung	VanThanh	Nguyen.	
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polymerizable	 units	 such	 as	 styrenics,155,259,280,281	 acrylates,104,118,156,282,283	 and	
methacrylates,104,117,283,284	allows	the	formation	of	macromonomers	(MM)	to	develop	graft	and	
comb	copolymers	by	(controlled)	radical	polymerization.	RAFT	graft-through	polymerization	of	
methacrylate	 end-functionalized	 PEtOx	 MMs	 was	 used	 to	 obtain	 pH	 and	 temperature	
responsive	 comb	 or	 graft	 copolymers	 by	 incorporation	 of	 methyl	 methacrylate	 as	
comonomer.117	 In	 another	 contribution,	 PEtOx	MMs	obtained	by	direct	 end	 functionalization	
with	in	situ	deprotonated	acrylic	acid,	were	polymerized	by	FRP,	NMP,	and	RAFT	graft-through	
polymerization.	 Kinetic	 studies	 of	 brush	 formation	 revealed	 an	 unusual	 behavior	 on	 the	 SEC	
traces	with	proceeding	monomer	consumption	but	with	a	 limit	 to	the	reached	molar	mass	of	
the	comb	polymer	with	narrow	molar	mass	distributions.	 It	was	proposed	 	 that	due	 to	 steric	
crowding	effects	the	backbone	DP	did	not	exceed	25.282	
Other	 than	 radical-based	 polymerization	 techniques,	 the	 graft-through	 ROMP	 approach	 has	
been	recently	applied	 for	 the	synthesis	of	bottlebrush,	bivalent	bottlebrush,	and	dendronized	
polymers	 by	 direct	 polymerization	 of	 norbornene-functionalized	macromonomers.3,199	 ROMP	
using	 ruthenium	 catalysts	 is	 particularly	 suited	 for	 the	 synthesis	 of	 side-chain	 functional	
polymers	 with	 controllable	 molar	 masses	 and	 low	 dispersities.	 For	 instance,	 graft-through	
ROMP	 of	 a	macromonomer,	 followed	 by	 in	 situ	 crosslinking	 is	 a	 useful	methodology	 for	 the	
synthesis	 of	 BASPs.	 These	 nanoparticles	 feature	 a	 unimolecular	 micelle-like	 structure	 with	
readily	tunable	core	and	shell	functionalities	that	may	contain	a	variety	of	polymer	arms,	drug	
molecules,	and	imaging	agents.	The	brush-first	ROMP	method	to	form	BASPs	has	been	reported	
for	the	preparation	of	drug-loaded	PEG-based	BASPs,285	two-	and	three-miktoarm	BASPs,198	and	
nitroxide-loaded	PEG	BASPs197,286	that	serve	as	metal-free	MRI	probes.		
Organic-based	MRI	agents	are	an	alternative	to	already	existing	metal-based	MRI	probes	that	
may	present	 toxicity	concerns	 in	 some	patients.	Nitroxide	 radicals	are	organic	molecules	 that	
have	 a	 single	 unpaired	 electron	 and	 have	 been	 extensively	 studied	 as	 potential	 contrast	
enhancing	 agents	 for	MRI	 applications.287–289	 Paramagnetic	 nitroxides	 present	 low	 toxicity	 in	
vivo,289	 which	 makes	 them	 potential	 alternatives	 to	 metal-based	 MRI	 probes	 that	 may	
accumulate	in	biological	tissue.290	Commonly	used	nitroxides	have	the	disadvantage	of	 low	1H	
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water	 relaxivities	compared	to	contrast	agents	based	on	Gd3+	or	Mn2+,	due	to	 the	number	of	
unpaired	 electrons	 available	 (1	 versus	 7	 or	 5,	 respectively).	 Another	 challenge	 is	 the	 fast	
reduction	 in	vivo	 (in	 the	order	of	minutes)	of	commonly	used	nitroxides	 to	 form	diamagnetic	
hydroxylamines.291	 Strategies	 to	 address	 these	 challenges	 include	 the	use	of	 poly(nitroxides),	
where	relaxivity	 is	multiplied	by	the	number	of	available	nitroxides,	or	the	conjugation	of	the	
nitroxide	 radicals	 to	 a	 rigid	 scaffold	 to	 increase	 resistance	 to	 reduction.197,201,292	 Recently	
developed	macromolecular	nitroxide	organic	 radical	contrast	agents	 (ORCAs)	 feature	polymer	
chains	conjugated	 to	nitroxide	 radicals	 to	 form	 	dendrimer	scaffolds,292	branched	bottlebrush	
polymers,201	 or	 brush-arm	 star	 polymers	 (BASPs)	 from	 branched	 macromonomers.197	 For	
instance,	a	nitroxide-based	MRI	probe	using	a	BASP	nanostructure	consisting	of	a	dense	layer	of	
the	paramagnetic	nitroxide	chex	at	 the	 interface	of	a	poly(acetal)	core	and	a	hydrophilic	PEG	
shell,	was	reported	to	enhance	relaxivity	up	to	44-fold	when	compared	to	common	nitroxides,	
while	maintaining	stability	in	vivo	for	up	to	20	hours	after	injection	in	mice.197	
In	 this	 chapter,	 the	 first	 PEtOx	 macromonomers	 for	 ROMP	 were	 synthesized	 by	 ω	
functionalization	 via	 termination	using	 a	norbornene	derivative	of	 hexanoic	 acid.	 Bottlebrush	
copolymers	of	different	MM-to-catalyst	ratios	were	synthesized	by	graft-through	ROMP,	as	well	
as	 BASPs	 by	 graft-through	 ROMP	 followed	 by	in	 situ	crosslinking	 with	 a	 bis-norbornene	
derivative.	 This	 MM	 approach	 was	 then	 combined	 with	 the	 previously	 reported	 strategy	 to	
form	branched	MMs,	where	an	alkyne	group	from	a	bivalent	norbornene	MM	is	available	 for	
functionalization	 with	 a	 molecule	 of	 interest.	 The	 capability	 of	 the	 alkyne	 group	 to	
react	by	CuAAC	click	reaction	allows	the	introduction	of	a	number	of	azide-functionalized	drugs	
or	imaging	agents	to	the	macromonomer.	For	this	project,	the	paramagnetic	nitroxide	chex	was	
attached	to	the	macromonomer	to	produce	a	new	type	of	organic-radical	based	MRI	contrast	
agent	(Figure	60).	In	this	project,	the	first	PAOx	MMs,	and	chex-branched	MMs	for	ROMP	were	
synthesized	and	characterized.	The	latter	were	used	to	produce	an	MRI	probe	that	serves	as	an	
alternative	to	the	previously	reported	structures.	
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Figure	 60.	 General	 procedure	 for	 the	 formation	 PEtOx-based	 BASP-ORCA.	 Graft-through	 ROMP	 of	
branched	 MMs	 functionalized	 with	 chex	 nitroxide	 exposed	 to	 Grubbs	 III	 catalyst	 produced	 living	
brushes,	 and	 subsequent	 addition	 of	 acetal-XL	 yielded	 BASP-ORCA	 (Adapted	 from	 reference	 293	
Copyright	2018	American	Chemical	Society).	
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4.2. Synthesis	of	norbornene-terminated	PEtOx	macromonomers	
For	 this	 project,	 2-ethyl-2-oxazoline	 was	 used	 as	 monomer	 since	 PEtOx	 is	 a	 biocompatible,	
water-soluble,	 non-toxic	 polymer	 with	 high	 stability	 and	 a	 suitable	 choice	 for	 potential	
applications	 in	 biomedical	 fields	 as	 an	 alternative	 to	 PEG.	 As	 initiator,	 methyl	 tosylate	 was	
chosen	 for	 its	 demonstrated	 efficient	 initiation	 for	 the	 polymerization	 of	many	 2-oxazolines,	
among	them,	2-ethyl-2-oxazoline.	Norbornene	(as	opposed	to	cyclobutene	or	cyclooctene)	was	
selected	as	the	polymerizable	group	due	to	its	high	ring	strain,	commercial	availability,	and	the	
lack	 of	 chain	 transfer	 in	 ROMP.294	 Particularly,	 exo-norbornenes	 were	 utilized	 since	 these	
exhibit	 higher	 reactivity	 than	 their	 endo-norbornene	 analogues,	 due	 to	 reduced	 steric	
hindrance	at	 the	olefin	 site.	The	norbornene	 functionality	was	 introduced	 to	 the	PEtOx	chain	
during	 the	 termination	 step	 in	an	effort	 to	 simplify	 the	 synthetic	 setup	since	neither	 initiator	
synthesis	 nor	 post-polymerization	 modification	 is	 required.	 Termination	 was	 carried	 out	 by	
addition	 of	 a	 carboxylic	 acid-functionalized	 norbornene	 molecule,	 mixed	 with	 TEA	 to	
deprotonate	 the	 carboxylic	 acid	 group,	 facilitating	 the	nucleophilic	 attack.	A	 five-carbon	alkyl	
spacer	between	the	norbornene	moiety	and	the	carboxylic	acid	group	was	selected	to	reduce	
the	steric	congestion	during	ROMP.	 It	was	also	observed	 in	the	group	of	Jeremiah	Johnson	at	
MIT	 (collaborator	 in	 the	 present	 project)	 that	 the	 presence	 of	 polar	 moieties	 close	 to	 the	
polymerization	site	was	detrimental	for	ROMP.	The	already	optimized	conditions	for	the	CROP	
of	EtOx	reported	in	the	literature	(microwave-assisted	polymerization	at	140	°C	in	acetonitrile	
with	monomer	 concentration	 4	M)	were	 used	 to	 produce	 polymers	 of	 various	molar	masses	
(Scheme	19).	
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Scheme	19.	Synthesis	of	PEtOx	MM.	
Polymers	from	three	different	monomer-to-initiator	ratios	were	synthesized	and	characterized	
by	 1H	NMR	 spectroscopy,	 SEC,	 and	MALDI-ToF,	 to	 ensure	 end-group	 fidelity	 and	 confirm	 the	
production	 of	 polymers	 with	 well-defined	 molar	 masses	 and	 narrow	 distributions.	 SEC	 was	
performed	in	two	sets	with	DMAc	or	THF	as	solvents	(Figure	61).	In	all	cases,	the	Mn,SEC	values	
obtained	proportionally	increased	for	each	polymer	depending	on	the	target	DP	with	Ð	<	1.16.	
However,	 the	Mn,DMAc-SEC	values	obtained	are	close	to	the	theoretical	values,	which	 is	unusual	
considering	there	generally	exists	an	overestimation	of	values	for	PAOx	when	using	PMMA	as	
standard.	 In	 addition,	 the	 shape	 of	 the	 signal	 of	 PEtOx	 MM	 1.6kDa	 shows	 a	 bimodal	
distribution,	 different	 from	 the	 monomodal	 distribution	 obtained	 from	 THF	 SEC.	 Mn,THF-SEC	
values	are	significantly	lower	than	Mn,theo.	Polystyrene	standards	were	used	for	the	calculation	
of	Mn	and	cannot	be	directly	correlated	to	PEtOx.		Nevertheless,	narrowly	dispersed	polymers	
were	obtained	in	all	cases	(Ð	<	1.15),	sign	of	a	controlled	polymerization	(Figure	61).		
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Figure	61.	SEC	traces	of	the	PEtOx	MMs	obtained	using	DMAC	SEC	(solid)	and	THF	SEC	(dashed).	
	
The	end-group	fidelity	and	success	of	the	termination	reaction	were	proved	by	1H	NMR	(Figure	
62),	 where	 polymer	 backbone	 and	 side-chain	 signals	 were	 assigned,	 as	 well	 as	 end-chain	
signals.	The	1H	NMR	spectrum	obtained	from	PEtOx	MM	3kDa	shows	integration	values	of	both	
end-group	 signals	 (found	 at	 2.9	 ppm	 for	 the	 α	 methyl	 group	 and	 at	 6.2	 ppm	 for	 the	 ω	
norbornene	olefin	moiety)	of	2.4	and	2.	The	discrepancy	displayed	with	respect	to	the	expected	
3	 to	 2	 ratio	 of	 protons	 on	 each	 end	 group	 is	 potentially	 caused	 by	 proton	 initiated	 chains,	
product	 of	 transfer	 reactions.	 For	 all	 samples,	 the	Mn,NMR	 values	 were	 calculated	 using	 the	
norbornene	 olefin	 signal	 at	 6.2	 ppm	 and	 comparing	 it	with	 the	 polymer	 backbone	 and	 side-
chain	 signals	at	3.4,	2.3,	 and	1.0	ppm,	 respectively.	 The	calculated	Mn,NMR	values	are	 in	 close	
agreement	with	the	theoretical	value	expected	from	the	monomer-to-initiator	ratio	targeted	on	
each	case,	indicating	high	degree	of	end	group	functionalization.		
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Figure	62.	1H	NMR	spectrum	of	PetOx	MM	3kDa.	
MALDI-ToF	analysis	further	confirmed	the	introduction	of	norbornene	as	end	group	during	the	
termination	 reaction.	 The	 spectrum	shows	one	main	 family	of	polymers,	 that	 corresponds	 to	
the	polymer	ionized	with	a	proton,	and	the	m/z	values	match	the	theoretical	value	calculated	
for	 the	 target	 structure	 (Figure	 63).	 A	 second	 population	 with	 lower	 intensity	 is	 visible	 and	
corresponds	to	a	lower	molar	mass	polymer	family.	It	was	assigned	to	a	proton-initiated	PEtOx	
terminated	with	 the	 norbornenyl	molecule.	 Although	 this	 population	 is	 the	 product	 of	 chain	
transfer	reactions,	 it	carries	the	desired	norbornene	group	and	can	be	polymerized	by	ROMP.	
Additionally,	the	MALDI	signals	with	highest	intensity	are	in	m/z	range	values	that	closely	agree	
with	the	Mn	value	calculated	by	1H	NMR	and	show	a	narrow	distribution.		
A	summary	of	the	characterization	of	the	synthesized	polymers	is	presented	on	Table	8.	
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Figure	63.	MALDI	spectrum	of	PEtOx	MM	3kDa.	
	
	
Table	8.	Summary	of	the	characterization	of	PEtOx	MMs.	
Name	
[EtOx]/ 
[MeOTs] 
Mn,theo	
(g	mol–1)	
Mn,NMR	
(g	mol–1) 
Mn,DMAc-SEC	
(g	mol–1)	
Ð(DMAc)	
Mn,THF-SEC	
(g	mol–1) 
Ð(THF) 
PEtOx	MM	
1.6kDa	
15 1780	 1600 1400	 1.15	 1000 1.09 
PEtOx	MM	
3kDa	
30 3260	 3000 3200	 1.08	 1600 1.11 
PEtOx	MM	
4.3kDa	
45 4750	 4300 5100	 1.14	 2400 1.12 
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4.3. Synthesis	of	polymer	bottlebrushes	
The	 viability	 of	 the	 synthesized	MMs,	PEtOx	MM	3kDa	 and	PEtOx	MM	1.6kDa,	 to	 carry	 out	
ROMP	using	Grubbs	III	(G3)	bis-pyridin	as	catalyst	was	tested.	This	catalyst	has	been	applied	to	
the	synthesis	of	bottlebrush,	bivalent	bottlebrush,	and	dendronized	polymers	by	graft-through	
polymerization	 of	 functional	 norbornene	 macromomoners.	 Here,	 each	 PEtOx	 MM	 was	
dissolved	in	THF	to	a	concentration	of	0.05	M,	and	mixed	with	catalyst	G3	bis-pyridin	(from	a	
stock	solution)	at	different	PEtOx	MM-to-G3	ratios	at	room	temperature	(Scheme	20).		
	
	
Scheme	20.	Synthesis	of	brush	copolymers	from	PEtOx	MM.	
	
The	 solutions	 were	 stirred	 overnight	 and	 quenched	 with	 excess	 ethyl	 vinyl	 ether	 (EVE).	 SEC	
traces	 in	 DMAc	 of	 the	 bottlebrush	 polymers	 produced	 from	 PEtOx	MM	 3kDa,	 in	 Figure	 64,	
show	 a	 nearly	 quantitative	 conversion	 from	MM	 to	 bottlebrush	 polymer	 in	 all	 cases,	 with	 a	
proportional	increase	in	Mn,DMAc-SEC	and	Ð	<	1.17.	The	remaining	signal	at	higher	retention	time	
can	be	attributed	to	non-functionalized	or	unreactive	MM.	The	SEC	traces	of	PEtOx	MM	1.6kDa	
bottlebrush	polymers	in	DMAc	show	for	all	screened	DPs	a	bimodal	distribution	(Figure	65).	At	
lower	retention	times,	a	signal	with	increasing	Mn	that	corresponds	to	conversion	from	MM	to	
bottlebrush	is	observed.	However,	the	signal	at	higher	retention	time	remains	constant	for	all	
experiments.	 The	 proximity	 of	 the	 MM	 to	 the	 lower	 limit	 of	 the	 calibration	 curve	 may	 be	
causing	 this	 signal,	 since	 no	 other	 distributions	 or	 contaminants	 were	 observed	 during	 the	
characterization	 of	 the	 polymer	 using	 THF	 SEC,	 1H	 NMR	 spectroscopy,	 or	 MALDI-ToF	 mass	
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spectrometry.	 These	 same	 samples	 were	 analyzed	 by	 THF-SEC	 (Figure	 66)	 where	 high	
conversion	was	observed	(>	85%)	for	DPs	50	and	below.	The	 lowest	conversion	was	achieved	
with	DP	100,	where	a	larger	amount	of	MM	remained	unreactive.	
	
	
Figure	64.	DMAc	SEC	traces	of	the	polymers	obtained	after	graft-through	ROMP	of	PEtOx	MM	3kDa	with	
THF	as	solvent	and	[MM]	0.05	M,	at	various	[MM]/[G3]	ratios	(=	DP).	
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Figure	65.	DMAc	SEC	traces	of	the	products	of	the	graft-through	ROMP	of	PEtOx	MM	1.6kDa	at	various	
targeted	DPs	with	THF	as	solvent	and	[MM]	0.05	M.	
	
	
Figure	66.	THF	SEC	traces	of	 the	products	of	 the	graft-through	ROMP	of	PEtOx	MM	1.6kDa	at	various	
targeted	DPs	with	THF	as	solvent	and	[MM]	0.05	M.	
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Kinetic	 experiments	 of	 PEtOx	 MM	 3kDa	 ROMP	 at	 DP	 10	 were	 performed	 using	 similar	
conditions	 as	 previous	 experiments.	 Samples	 were	 taken	 after	 10,	 15,	 and	 20	 minutes	 and	
quenched	with	EVE.	SEC	analysis	in	DMAc	of	the	produced	samples,	in	Figure	67,	show	that	full	
conversion	was	achieved	from	the	first	sample	taken	at	10	minutes,	indicating	fast	ROMP	rates	
at	 low	DP.	These	results	 indicate	the	potential	of	the	produced	bottlebrush	polymers	to	form	
BASPs	 using	 the	 brush-first	 approach,	 where	 a	 bifunctional	 crosslinker	 is	 added	 to	 living	
polymer	brushes	of	low	DP	to	produce	the	micelle-like	structure	of	BASPs.	
	
	
Figure	67.	DMAc	SEC	traces	of	kinetic	experiments	of	PEtOx	MM	3kDa	ROMP	with	targeted	DP	10,	using	
THF	as	solvent	and	[MM]	0.05	M.		
	
To	evaluate	the	potential	incorporation	of	molecules	of	interest	(e.g.,	drugs,	imaging	agents)	to	
the	 polymer	 brush	 as	 random	 copolymers,	 PEtOx	 MM	 3kDa	 was	 copolymerized	 with	
norbornene-functionalized	hexanoic	acid.	The	copolymerization	experiments	were	carried	out	
using	similar	conditions	as	previous	experiments	with	MM-to-norbornene-carboxylic	acid	ratios	
of	1:4,	1:1,	and	3:1.	The	 resulting	SEC	 traces	 show	nearly	quantitative	conversion	 in	all	 cases	
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with	 some	 remaining	 unreactive	 MM	 (Figure	 68).	 The	 produced	 bottlebrushes	 reached	Mn	
values	in	the	range	of	45700-49400	g	mol–1	with	Ð	<	1.16.	These	results	are	promising	for	the	
incorporation	 or	 functional	molecules	 on	 the	 backbone	 of	 the	 polymer	 brush.	 However,	 this	
approach	has	the	disadvantage	of	random	addition	to	the	bottlebrush	without	the	possibility	to	
control	the	amount	of	loaded	molecule.		
	
	
Figure	 68.	 	 DMAc	 SEC	 traces	 of	 graft	 through	 copolymerization	 of	 PEtOx	 MM	 3kDa	 :	 norbornene-
hexanoic	acid	on	1:4,	1:1,	and	3:1	ratios	with	targeted	DP	25	and	THF	as	solvent.	 	
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4.4. Synthesis	of	brush-arm	star	polymers	(BASPs)	
BASP	synthesis	provides	a	broadly	useful	methodology	 for	nanoparticle	synthesis	with	readily	
tunable	core	and	shell	functionality.	For	this	project,	the	viability	of	BASP	formation	from	PEtOx	
MMs	was	first	tested.	The	BASPs	were	synthesized	by	graft-through	ROMP	of	PEtOx	MM	3kDa	
using	G3	bis-pyridine	initiator	with	a	MM-to-G3	ratio	of	7	(m	=	7)	for	20	min.	Subsequently,	the	
living	bottlebrush	polymers	were	crosslinked	by	addition	of	20	equivalents	of	bis-norbornene	
acetal	 crosslinker	 (acetal-XL)	 (N	 =	 20)	 to	 the	 reaction	 mixture.	 The	 size	 of	 the	 BASP	 is	
determined	by	both	m	and	N	values.	Samples	of	 the	 resulting	bottlebrush	polymer	and	BASP	
were	analyzed	by	SEC	and	DLS.	
SEC	revealed	nearly	quantitative	MM-to-bottlebrush	conversion,	as	well	as	high	conversion	to	
BASP	from	bottlebrush	polymer	(Figure	69).	The	unreactive	species	can	potentially	be	assigned	
to	either	unfunctionalized	or	unreactive	macromonomers.	
	
	
Figure	69.	SEC	traces	in	DMF	of	Norbornene-PEtOx	3kDa,	the	bottlebrush	polymer,	and	BASPs	obtained.			
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The	diameters	of	bottlebrush	polymer	and	BASP	were	determined	by	DLS	in	water	at	25	°C,	and	
are	5	nm	and	17	nm,	respectively	(Figure	70).	However,	in	the	case	of	the	bottlebrush	polymer	
sample,	the	presence	of	particles	with	diameter	of	144.5	nm	was	observed,	which	potentially	
correspond	to	the	formation	of	aggregates.	Nevertheless,	a	3-fold	size	increase	observed	from	
the	 bottlebrush	 of	 DP	 7,	 to	 the	 BASP	 formed	with	 20	 equivalents	 of	acetal-XL,	 indicates	 the	
successful	formation	of	the	BASPs.	
	
	
Figure	70.	DLS	analysis	in	water	at	25	°C	of	living	brush	polymer	and	produced	BASP.	
	
The	 successful	 synthesis	 of	 bottlebrush	polymers	 and	BASPs	 from	PEtOx	MMs	 is	 a	 promising	
foundation	to	explore	other	functional	PEtOx	MM	to	form	this	architecture.	
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4.5. Synthesis	of	norbornene-branched-alkyne	PEtOx	macromonomers	
The	already	described	strategy	to	obtain	bottlebrush	copolymers	and	BASPs	from	PEtOx	MM,	
was	combined	with	a	previously	reported	approach	to	synthesize	branched	MM	with	a	pendant	
alkyne	group,	which	allows	the	introduction	of	a	functional	molecule	by	CuAAC	click	reaction.194	
Using	a	branched	MM	provides	 the	advantage	 that	one	molecule	of	 interest	 is	quantitatively	
integrated	in	one	polymer	chain.	Consequently,	the	amount	of	 loaded	molecule	 is	known	and	
can	be	controlled.		
The	 branched	MMs	 (alkyne-PEtOx	MM)	 were	 synthesized	 using	 similar	 conditions	 as	 PEtOx	
MM,	 except	 the	 termination	 step	 was	 carried	 out	 using	 1.5	 equivalents	 of	 norbornene-
branched-alkyne	hexanoic	acid	dissolved	in	DCM	(Scheme	21).	The	synthesized	polymers	were	
analyzed	by	1H	NMR	spectroscopy,	SEC,	and	MALDI-ToF	mass	spectrometry.	
	
	
Scheme	21.	Synthesis	of	alkyne-PEtOx	MM.	
	
SEC	 analyses	 show	 a	 proportional	 increase	 in	Mn,SEC	 to	 the	 target	 DP	 for	 each	 polymer.	 In	
general,	the	Mn,SEC	values	are	similar	to	Mn,theo,	which	is	unusual	considering	that	for	PEtOx	an	
over	estimation	in	values	is	normally	encountered	when	using	PMMA	standards.	Nevertheless,	
the	 dispersity	 values	 obtained	 reflect	 a	 controlled	 polymerization,	 with	Ð	 values	 below	 1.15	
(Figure	75).	
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1H	 NMR	 spectra	 of	 the	 synthesized	 polymers	 confirmed	 the	 quantitative	 presence	 of	 the	
terminating	 norbornene-branched-alkyne	 molecule.	 Figure	 71	 shows	 the	 1H	 NMR	 obtained	
from	 alkyne-PEtOx	MM	 3kDa,	 where	 polymer	 backbone	 and	 side-chain	 signals	 are	 assigned	
and	integrated,	as	well	as	end	groups.	The	integration	of	both	the	α−methyl and	ω−norbornene	
end	group	signals	(d,	at	2.9	ppm,	and	f	at	6.2	ppm,	respectively)	corresponds	to	the	expected	
proton	 ratio	 (3	 to	 2),	 indicating	 that	 both	 efficient	 initiation	 and	 termination	 occurred.	
Furthermore,	 the	 Mn,NMR	 values	 were	 calculated	 similar	 to	 the	 PEtOx	 MM	 (using	 the	
norbornene	signal	at	6.2	ppm	and	comparing	it	to	backbone	and	side	chain	signals	at	4.0,	3.5,	
and	2.0	ppm,	 respectively).	The	values	obtained	are	 in	agreement	with	 the	 target	DP	 in	each	
case,	a	good	indication	of	both	efficient	initiation	and	termination.		
	
	
Figure	71.	1H	NMR	spectrum	of	alkyne-PEtOx	3kDa.	
	
MALDI-ToF	analysis	was	also	used	to	confirm	the	introduction	of	the	branched	norbornene	as	
an	 end	 group	during	 termination.	 The	 spectrum	of	alkyne-PEtOx	MM	3kDa	 shows	one	main	
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family	of	polymers,	 that	corresponds	 to	 the	polymer	structure	 ionized	with	a	proton	and	has	
m/z	 values	 that	match	 the	 theoretical	m/z	 (Figure	 72).	 Additionally,	 the	 signals	with	 highest	
intensity	are	 in	close	agreement	with	the	Mn	value	calculated	by	1H	NMR	and	show	a	narrow	
distribution.		
	
	
Figure	72.	MALDI	spectrum	of	alkyne-PEtOx	MM	3kDa.	
	
The	values	obtained	after	characterization	of	each	polymer	are	summarized	on	Table	9.		
		
Table	9.	Summary	of	the	characterization	of	alkyne-PEtOx	MMs		
Name	
[EtOx]/ 
[MeOTs] 
Mn,theo 
(g	mol–	1)	
Mn,NMR 
(g	mol–	1) 
Mn,DMAc-SEC 
(g	mol–	1) 
Ð 
Alkyne-PEtOx	1.6kDa	 15 1890	 1600 1400 1.12 
Alkyne-PEtOx	3kDa	 30 3360	 3100 2900 1.13	
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4.6. Synthesis	of	chex-PEtOx	MM	
Among	 the	 most	 widely	 used	 nitroxides	 as	 MRI	 contrast	 agents	 is	 3-carboxy-2,2,5,5-
tetramethyl-L-pyrrolidinyloxy	(3-CP)	and	its	derivatives	(Figure	73).	The	half-life	in	vivo	of	these	
nitroxides	is	approximately	2	minutes	in	MRI	mouse	studies.291,295	A	reported	alternative,	chex,	
is	 a	 five-member	 ring	 (pyrrolidinyl)	 nitroxide	 that	 is	 sterically	 hindered	 by	 spirocyclohexyl	
groups	(Figure	73).	The	shielding	effect	decreases	the	reduction	rate	of	the	nitroxide	radical	in	
vivo,	 and	 it	 was	 found	 that	 when	 conjugated	 to	 a	 dendrimer	 the	 longitudinal	 relaxitivy	 (r1)	
increases	to	0.44	mM−1	s−1,	when	compared	to	r1	=	0.15	mM−1	s−1	from	the	conjugate	using	the	
model	 nitroxide	 3-CP.292,296	 The	 higher	 relaxivity	 values	 obtained	 by	 conjugation	 of	 chex	 to	
different	 polymer	 architectures	 make	 it	 a	 suitable	 choice	 for	 the	 development	 of	 nitroxide-
PEtOx	MM	conjugates.			
	
Figure	73.	Structures	of	nitroxides	chex	and	3-CP.	
	
The	 introduction	 of	 nitroxide	 chex	 was	 carried	 out	 using	 azide-functionalized	 chex,	 for	
attachment	to	alkyne-PEtOx	MM	3kDa	by	CuAAC	click	reaction	(Scheme	22).	The	reaction	was	
performed	 in	a	glove	box	using	DCM	as	solvent.	The	resulting	polymer,	chex-PEtOx	MM,	was	
analyzed	using	MALDI-ToF	mass	spectrometry	and	SEC.		
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Scheme	22.		Synthesis	of	chex-PetOx	MM.	
	
The	successful	introduction	of	the	nitroxide	radical	to	the	branched	PEtOx	MM	was	confirmed	
by	 MALDI,	 where	 one	 main	 population	 is	 observed	 and	 the	 theoretical	 m/z	 value	 of	 the	
repeating	units	matches	the	m/z	found	experimentally	(Figure	74).	
	
	
Figure	74.		MALDI	spectrum	of	chex-PEtOx	3kDa.	
	
The	SEC	traces	obtained	from	DMAc	SEC	confirm	that	the	structure	of	 the	polymer	backbone	
before	and	after	CuAAC	remains	unchanged	(Mn,SEC	=	2900	and	3300	g	mol−1,	respectively),	and	
with	low	dispersity	values	(Ð	=	1.13)	(Figure	75).		
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Figure	75.	SEC	traces	of	alkyne-PEtOx	MM	3kDa	and	the	product	of	the	click	reaction	of	 it	with	azide-
chex	to	yield	chex-PEtOx	MM	3kDa.			 	
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4.7. Synthesis	of	functional	polymer	brushes	and	BASP-ORCAs	
The	 BASP	 structure	 provides	 the	 possibility	 to	 incorporate	 molecules	 at	 a	 rigid	 core	 shell	
interface,	 providing	potential	 benefits	 such	 as	more	 stability	 or	 activity	 enhancement.	 In	 this	
case,	 bottlebrush	 and	 BASPs	 were	 synthesized	 from	 the	 newly	 developed	 chex-PEtOx	 MM	
3kDa.	To	evaluate	the	properties	of	the	BASPs,	a	screening	of	MM-to-G3	(m)	and	crosslinker-to-
G3	 (N)	 ratios	was	 carried	 out	 (Table	 10).	 Similar	 to	 the	 previous	 BASP	 synthesis	 experiment,	
chex-PEtOx	MM	3kDa	underwent	graft-through	ROMP	using	G3	bis-pyridine	initiator.	After	20	
minutes,	 the	 living	 bottlebrush	 polymers	 were	 crosslinked	 by	 addition	 of	 N	 equivalents	 of	
crosslinker	 (acetal-XL)	to	the	reaction	mixture.	The	reactions	were	quenched	with	excess	EVE	
and	samples	 taken	of	 the	 resulting	bottlebrush	polymer	and	BASP	were	analyzed	by	SEC	and	
DLS.	
Nearly	quantitative	 conversion	was	obtained	 for	 the	 formation	of	bottlebrush	polymers	 from	
MM	and	BASPs	from	bottlebrush	polymers,	as	observed	from	the	SEC	traces	in	DMF	(Figure	76).	
The	remaining	signals	can	be	attributed	to	unreactive	MMs	and	bottlebrush	polymers,	similar	
to	 traces	 obtained	 from	previous	 experiments.	 These	 results	 are	 in	 agreement	with	 previous	
reports	of	related	nitroxide-labeled	ROMP	polymer	systems,	proving	the	high	efficiency	of	the	
graft-through	ROMP	process.201	The	Mn	values	of	BASPs	obtained	with	a	similar	crosslinker-to-
catalyst	 ratio	 (N	 =	 20)	 but	 varying	 the	 size	 of	 the	 bottlebrush	 polymer	 (m	 =	 7	 or	 10)	 are	
relatively	similar	(5	or	5.9	x105	g	mol−1).	Conversely,	by	keeping	bottlebrush	size	constant	(m	=	
10)	but	 increasing	N	 from	20	 to	30,	 the	Mn	 exhibits	 an	 approximately	 2-fold	 increase	 (5.9	 to	
10.8	x105	g	mol−1),	evidence	of	the	influence	of	N	on	the	size	of	the	resulting	BASPs	(Table	10).	
A	 similar	 behavior	 was	 observed	 from	 the	 BASP-ORCA	 diameters	 determined	 by	 DLS.	 The	
largest	BASP	diameter	(27	nm)	was	observed	from	N	=	30,	compared	to	diameters	from	BASPs	
with	N	=	20	from	similar	bottlebrush	size	(21	nm)	(Table	10).	Compared	to	the	PEG-based	BASPs	
analogues	 with	 similar	 N	 and	 m	 values,	 PEtOx-based	 BASPs	 are	 approximately	 10	 nm	more	
compact	in	diameter.197		
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Figure	76.	SEC	traces	in	DMF	of	chex-PEtOx	3kDa,	the	chex-bottlebrush	polymer	with	DP	10,	and	BASP-
ORCAs	obtained	varying	MM-to-G3	ratio	(m)	and	crosslinker-to-G3	ratio	(N).			
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4.8. Characterization	of	PEtOx-based	BASP-ORCA	magnetic	properties	
4.8.1. Electron	paramagnetic	resonance	spectroscopy	
Electron	paramagnetic	resonance	spectroscopy	(EPR)	was	used	to	confirm	the	presence	of	chex	
and	 to	 characterize	 the	 spin	 concentration	 in	 the	 produced	 bottlebrush	 polymer	 and	 BASP-
ORCAs.	The	EPR	spectra	of	chex-MM,	bottlebrush,	and	BASP-ORCAs	were	normalized	and	are	
shown	 in	 Figure	 77.	 The	 spectra	 of	 bottlebrush	 polymer	 and	 BASP-ORCAs	 are	 significantly	
broader	 than	 chex-MM,	 which	 is	 attributed	 to	 the	 high	 nitroxide	 density	 near	 the	
poly(norbornene)	 backbone.	 Additionally,	 for	 BASP-ORCAs,	 the	 signal	 broadening	 is	 more	
intense	due	to	the	 larger	and	more	rigid	BASP	structure	where	chex	 is	at	 the	dense	 interface	
between	 the	 crosslinked	 core	 and	 the	 PEtOx	 shell.	 In	 all	 cases,	 the	 spin	 concentrations	
measured	 were	 >	 85%,	 similar	 to	 the	 observed	 values	 for	 the	 PEG-based	 BASP-ORCAs	
reported.197,201		
	
	
Figure	77.	Electron	paramagnetic	resonance	(EPR)	spectra	of	chex-PEtOx	MM	3kDa,	chex-PEtOx	brush	
DP	10,	and	BASP-ORCAs	obtained	varying	MM-to-G3	ratio	(m)	and	crosslinker-to-G3	ratio	(N).	
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4.8.2. Relaxivity	studies	
The	longitudinal	(r1)	and	transverse	(r2)	relaxivities	of	the	resulting	BASP-ORCAs	were	measured	
using	a	Bruker	7	T	MRI	scanner.	The	r1	values	obtained	as	a	function	of	m	and	N	ranged	from	
0.17	to	0.19	mM−1s−1,	showing	no	variation	when	modifying	the	polymer	architecture	from	MM	
to	bottlebrush.	Furthermore,	these	values	are	similar	to	the	r1	values	obtained	from	nitroxide	
CP-3,	 but	 below	what	 is	 reported	 for	 chex-PEG	macromonomer	 (r1	 values	 of	 0.15	 and	 0.21,	
respectively).	Nevertheless,	the	r2	values	for	BASPs	ranged	from	1.83	to	2.28	mM−1s−1,	which	is	
in	 average	∼2.5-fold	 greater	 than	 the	 reported	 r2	 of	 chex-PEG	 bottlebrush	 polymers201	 and	∼11-	 to	∼13.5-fold	 greater	 than	 nitroxide	 3-CP.	 However,	 the	 r2	 values	 obtained	 are	 below	
those	 reported	 for	 the	 analogue	 PEG-based	 BASP-ORCAs	 which	 range	 from	 4.67	 to	 7.40	
mM−1s−1.197	Further	screening	of	synthetic	parameters	such	as	MM-to-catalyst	and	bottlebrush	
polymer-to-catalyst	ratios	could	potentially	modify	the	resulting	relaxivity	to	values	comparable	
to	 the	 already	 reported	 PEG-based	 BASP-ORCAs.	 Besides	 relaxivity	 enhancement,	 it	 is	
fundamental	to	reduce	the	rapid	reduction	of	the	nitroxide	in	biologically	relevant	conditions.	
Therefore,	 the	 stability	 in	 vivo	 of	 the	 PEtOx-based	 BASP-ORCAs	 should	 be	 evaluated	 and	
compared	 to	 the	 available	 PEG-based	 MRI	 probes.	 Additionally,	 cytotoxicity	 studies	 are	
necessary	to	ensure	the	viability	of	PEtOx-based	nanoparticles	in	biological	systems.	
	
Table	10.	Characterization	data	for	BASP-ORCAs	
	 m	 N	
r1	
(mM−1s−1)	
r2	
(mM−1s−1)	
Dh	(nm)	
Mn	(×	105	
g	mol−1)	
Mw	(×	105	
g	mol−1)	
Đ	
MM	 1	 0	 0.14	 0.17	 n.d.	 0.0527	 0.0544	 1.03	
Brush	 10	 0	 0.16	 0.58	 10	±	4	 0.373	 0.374	 1.01	
BASP	
10	 20	 0.19	 1.83	 18	±	4	 5.04	 6.00	 1.19	
7	 20	 0.17	 1.96	 21	±	6	 5.89	 8.25	 1.40	
7	 30	 0.19	 2.28	 27	±	9	 10.8	 15.9	 1.47	
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4.9. Conclusion	
The	 successful	 synthesis	 of	 the	 first	 PEtOx-based	 macromonomers	 for	 ROMP	 was	 achieved	
using	the	termination	step	of	the	CROP	of	2-oxazolines	to	introduce	a	norbornene	moiety.	The	
obtained	polymers	were	fully	characterized	by	SEC,	MALDI-ToF	mass	spectrometry,	and	1H	NMR	
spectroscopy,	 to	 confirm	 end	 group	 fidelity	 with	 the	 targeted	 molar	 masses	 and	 narrow	
dispersities	(Ð	<	1.15).	The	viability	of	the	new	PEtOx	MM	to	form	bottlebrush	copolymers	and	
BASPs	by	graft-through	ROMP	was	 tested.	Quantitative	 conversions	 from	MM	to	bottlebrush	
were	obtained	for	all	MMs,	as	observed	from	an	increase	in	Mn	on	the	SEC	traces.	In	addition,	a	
preliminary	test	to	form	BASPs	from	PEtOx	MM	3kDa	 resulted	 in	 increased	Mn	and	diameter,	
indicating	 the	 successful	 formation	 of	 the	 desired	 architecture.	 We	 combined	 the	 newly	
synthesized	PEtOx	MMs	with	a	previously	reported	strategy	to	form	bivalent	macromonomers	
where	one	domain	 contains	 a	 linear	 polymer	 and	 the	 second	 a	 functional	moiety	 of	 interest	
(e.g.,	anti-cancer	drugs	or	imaging	agents).194	To	achieve	this,	the	termination	step	of	the	CROP	
of	 EtOx	 was	 carried	 out	 with	 an	 alkyne-branched-norbornene	 moiety,	 followed	 by	 the	
attachment	of	the	paramagnetic	nitroxide	chex	by	CuAAC	click	reaction.	Characterization	of	the	
polymers	by	SEC,	MALDI-ToF	spectrometry,	and	1H	NMR	spectroscopy	revealed	defined	narrow	
molar	 mass	 distributions	 and	 the	 integrity	 of	 the	 end	 group	 and	 polymer	 backbone	 after	
functionalization.	The	successful	 synthesis	of	bottlebrush	polymers	and	BASPs	 from	the	chex-
functionalized	PEtOx	MMs	by	graft-through	ROMP	was	carried	out	with	the	screening	of	various	
MM-to-catalyst	and	crosslinker-to-catalyst	ratios.	Characterization	of	the	resulting	polymers	by	
SEC	 revealed	 nearly	 quantitative	 conversion	 from	 monomer	 to	 bottlebrush,	 and	 from	
bottlebrush	 to	 BASP,	 as	 observed	 from	 the	 Mn	 increase.	 Furthermore,	 DLS	 measurements	
evidenced	 an	 increase	 in	 diameter	 after	 crosslinking	 indicating	 the	 successful	 formation	 of	
BASPs.	Additionally,	the	size	range	of	the	measured	BASPs	is	suitable	for	in	vivo	administration,	
since	 polymer-conjugated	 particles	 of	 similar	 sizes	 show	 enhanced	 circulation	 times	 in	 blood	
and	 selective	 tumor	 uptake.	 The	 magnetic	 properties	 of	 the	 produced	 BASP-ORCAs	 were	
measured	 and	 showed	 improved	 transverse	 relaxivity	 values	 (r2)	 of	 up	 to	∼13.5-fold	 when	
compared	to	the	conventional	nitroxide	CP-3,	and	up	to	∼2.5-fold	compared	to	the	analogue	
chex-PEG	bottlebrush	previously	 reported.201	However,	 the	 relaxivity	 values	obtained	are	 still	
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below	what	 is	 reported	 for	PEG-based	BASP-ORCA	analogues,	which	can	 increase	 r2	up	 to	44	
times	 compared	 to	 CP-3.	 Optimization	 of	 synthetic	 parameters,	 as	 well	 as	 stability	 and	
cytotoxicity	 assessments	 should	 be	 conducted	 to	 demonstrate	 the	 viability	 of	 PEtOx-based	
BASP-ORCAs	in	biologically	relevant	environments.	Nevertheless,	the	newly	synthesized	metal-
free	PEtOx-based	MRI	probes	have	potential	 for	further	development	as	an	alternative	to	the	
previously	reported	PEG-based	MRI	probes.		
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5	
PNAM	and	POEGMA	
conjugates	as	alternatives	to	
protein	PEGylation	
5.   
5.1. Introduction3	
The	use	of	 recombinant	enzymes	 in	 the	biotechnological	 field	 is	 rapidly	 increasing	due	to	 the	
wide	 range	 of	 applications	 available,	 from	 biocatalysis	 to	 textile,	 food,	 and	 pharmaceutical	
industries.	 Particularly,	 the	 use	 of	 protein-	 or	 peptide-based	 drugs	 has	 benefited	 the	
pharmaceutical	market,	 since	 these	 bring	 specificity	 for	molecular	 targets	 in	 the	 body,	while	
exhibiting	 reduced	 side	 effects.297	 The	 complex	molecular	 structure	 of	 proteins	 provides	 the	
specificity	required	from	a	drug,	however,	it	also	brings	a	series	of	challenges	such	as	instability,	
often	poor	solubility,	and	an	 immune	response	from	the	body	that	results	 in	short	circulation	
times.298–300		
																																								 																				
3 The	 project	 described	 in	 this	 chapter	was	 done	 in	 collaboration	with	 the	 group	of	 Prof.	 Juergen	Hubbuch	 from	 the	
Institute	of	Engineering	 in	Life	Sciences,	KIT.	The	conjugation,	 separation,	activity,	and	phase	diagram	experiments,	as	
well	 as	 characterization	 by	 capillary	 gel	 electrophoresis	 and	 size	 exclusion	 chromatography	 of	 proteins	were	 done	 by	
Josefine	Morgenstern	and	Nicolai	Bluthardt. 
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A	strategy	to	improve	the	properties	of	the	pharmaceutical	active	is	the	generation	of	polymer-
protein	conjugates	by	covalent	attachment	of	a	polymer	to	the	protein	of	interest.299,301,302	The	
potential	polymer	should	 fulfill	 requirements	such	as	high	solubility	 in	aqueous	environments	
and	 biocompatibility,	 and	 should	 bear	 a	 functional	 group	 available	 for	 conjugation	 to	 the	
protein.303		
As	 previously	 mentioned	 in	 other	 sections	 (2.1.1),	 PEG	 is	 the	 gold	 standard,	 FDA-approved,	
most	 commonly	 used	 hydrophilic	 polymer	 in	 biomedical	 applications.	 Among	 the	 many	
advantages,	 PEGylated	 proteins	 possess	 increased	 stability,304	 solubility,305	 and	 circulation	
time.306	However,	the	huge	amount	of	exposure	of	humans	to	PEG	for	the	last	decades	has	also	
lead	to	the	formation	of	antibodies	against	PEG,10,12,307–310	which	as	a	consequence,	decreases	
the	circulation	time	of	PEGylated	actives,311	defeating	the	purpose	of	conjugation.	In	addition,	
depending	 on	 the	 PEG	 size,	 larger	 conjugates	 cannot	 be	 excreted	 from	 the	 body,	 and	 these	
accumulate	as	vacuoles	in	the	liver,	kidneys,	or	spleen.13,312	As	a	result	of	these	findings,	there	is	
an	increasing	interest	 in	the	development	of	alternative	polymers	for	biomedical	applications.	
Among	the	many	polymer	systems	available,	synthetic	polymers	are	an	attractive	possibility.313–
315	 The	 recently	 developed	 RDRP	 techniques,	 allow	 the	 development	 of	 a	 wide	 range	 of	
architectures,	 with	 defined	 polymer	 sizes,	 narrow	 distributions,	 and	 the	 possibility	 to	 add	
desired	functional	groups	on	the	end	chains.302	In	addition,	by	varying	the	monomer	choice,	the	
resulting	properties	of	the	resulting	polymer	system	can	be	tuned.316		
The	 optimization	 of	 the	 biological	 and	 physicochemical	 properties	 of	 conjugates	 depends	 on	
the	careful	selection	of	the	type	of	polymer	bound,	its	size,	and	the	number	of	chains	attached	
to	 the	 protein.302	 However,	 so	 far	 there	 is	 no	 available	 tool	 to	 quantify	 the	 influence	 of	 the	
mentioned	 parameters	 on	 the	 properties	 of	 the	 polymer-protein	 conjugates.	 In	 this	 chapter,	
poly(N-acryloylmorpholine)	(PNAM)	and	poly(oligo(ethylene	glycol)	methyl	ether	methacrylate)	
(POEGMA)	of	varied	sizes	were	synthesized	by	RAFT	polymerization	and	conjugated	to	different	
degrees	to	a	model	protein.	The	influence	of	the	polymer	used,	its	size,	and	conjugation	degree,	
on	 the	 physicochemical	 properties	 of	 the	 resulting	 conjugates	 was	 investigated	 using	 high-
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throughput	 screening.	 The	 properties	 investigated	 are	 aggregation	 behavior,	 solubility,	 and	
remaining	activity	of	a	model	protein	(Figure	78).		
	
	
Figure	 78.	 Strategy	 for	 the	 formation	 of	 polymer-protein	 conjugates	 and	 its	 separation	 for	 high-
throughput	screening	of	physicochemical	properties.	
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5.2. Synthesis	of	PNAM	and	POEGMA	by	RAFT	polymerization	
The	search	for	alternatives	to	PEG	for	therapeutic	purposes	makes	synthetic	polymers	such	as	
PNAM	and	POEGMA	an	interesting	choice	to	explore	(Figure	79).	PNAM	is	a	water-soluble	bi-
substituted	acrylamide	derivative.	It	has	been	synthesized	by	RAFT	polymerization	and	modified	
for	selective	attachment	to	surfaces,	as	well	as	enzymes,	showing	a	reduced	immunogenicity.78	
For	 instance,	 drug-PNAM	 conjugates	 have	 been	 reported	 for	 doxorubicin	 and	 amoxicillin,	
although	without	 further	evaluation.79	 In	addition,	PNAM	conjugation	to	 the	enzyme	Candida	
lipase	 resulted	 in	 hybrids	 with	 a	 higher	 solubility	 in	 organic	 solvents	 and	 higher	 remaining	
activity	 when	 compared	 to	 its	 reported	 PEG	 analogue.79	 POEGMA,	 on	 the	 other	 hand,	 is	 a	
hydrophilic,	 PEG-based	 comb-like	 polymer,	 that	 has	 been	 extensively	 studied	 for	 potential	
biomedical	applications.	POEGMA	can	be	synthesized	by	RDRP	techniques	such	as	ATRP	or	RAFT	
polymerization,	and	can	be	modified	to	add	special	functionalities	to	the	polymeric	chain	ends	
depending	on	the	initiator	or	transfer	agent	used.22–24	POEGMA	has	been	grafted	from	model	
proteins	 using	 modified	 ATRP	 initiators	 in	 aqueous	 medium,23,68,69	 with	 the	 advantage	 of	
specificity	on	the	conjugation	site	(either	N	or	C	terminus).	In	addition,	 in	vivo	studies	showed	
an	 increased	 circulation	 time	of	 15-50	 times,	 as	well	 as	 increased	 tumor	 accumulation	when	
compared	to	the	native	protein,	lysozyme.13	Both	polymer	systems	share	characteristics	such	as	
high	solubility	in	water	and	other	polar	solvents,	as	well	as	low	toxicity.	In	addition,	both	can	be	
synthesized	with	relative	ease	by	RAFT	polymerization,	which	brings	all	the	advantages	of	RDRP	
techniques,	with	the	possibility	to	add	a	linking	functionality	for	conjugation	on	the	end	chain	
by	careful	selection	of	the	RAFT	agent.		
	
Figure	 79.	 Structures	 of	 poly(oligo(ethylene	 glycol)	 methyl	 ether	 methacrylate)	 (POEGMA)	 (left)	 and	
poly(N-acryloylmorpholine)	(PNAM)	(right).	
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For	 this	 project	 it	 was	 decided	 to	 form	 the	 conjugates	 with	 the	 activated	 ester	 –	 lysine	
methodology,	by	direct	incorporation	to	the	polymer	chain	of	an	activated	NHS	ester	present	in	
a	 functionalized	 CTA	 (Figure	 80)	 during	 the	 RAFT	 polymerization.	 A	 description	 of	 the	 NHS-
lysine	 binding	 for	 conjugation	 was	 given	 in	 section	 2.5.	 For	 each	 monomer	 selected,	 two	
different	sizes	were	targeted	so	that	the	influence	of	polymer	size	could	be	analyzed.		
	
	
Figure	80.	RAFT	agent	used	in	the	present	study	4-cyano-4-(phenylcarbonothioylthio)pentanoic	acid	N-
succinimidyl	ester.	
	
The	 polymers	were	 synthesized	 using	 conditions	 adapted	 from	 the	 literature,317,318	 and	 after	
purification	 were	 analyzed	 by	 1H	 NMR	 and	 SEC.	 The	 1H	 NMR	 spectra	 obtained	 show	 the	
polymer	backbone	signals	expected,	as	well	as	the	side	chain	(Figure	81,	Figure	82,	Figure	83,	
and	 Figure	 84).	 Importantly,	 signals	 corresponding	 to	 the	 aromatic	 (at	 approximately	 7.3-8.0	
ppm)	 and	 NHS	 groups	 (at	 approximately	 2.8	 ppm)	 of	 the	 RAFT	 agent	 can	 also	 be	 observed,	
which	 gives	 an	 indication	 of	 the	 quantitative	 survival	 of	 the	 CTA.	 The	 aromatic	 signals	 were	
used	 to	 calculate	Mn,NMR	 by	 comparing	 the	 integration	 values	 to	 those	 of	 the	 signals	 that	
correspond	 to	 the	 repeating	 unit	 of	 the	 polymer	 (approximately	 at	 3.2-3.9	 ppm	 for	 the	
morpholine	 repeating	unit	of	PNAM,	and	3.9-4.2	ppm	 for	 the	methylene	protons	adjacent	 to	
ester	bond	of	POEGMA).	 In	each	case,	the	target	was	to	have	two	different	molar	masses	for	
each	 polymer	 that	 could	 then	 be	 compared	 after	 conjugation.	 PNAM	 and	 POEGMA	 of	
approximately	3.5	kDa	and	7	kDa	were	obtained	according	to	the	values	calculated	by	1H	NMR,	
through	integration	of	chain	end	and	backbone	peaks.	
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Table	11.	Summary	of	the	characterization	of	the	four	polymers	synthesized	for	this	study.	
Polymer	 Mn,NMR	(g	mol–	1)	
Mn,SEC	
(g	mol–	1)	 Ð	
PNAM3.5kDa	 3500	 1900	 1.08	
PNAM7kDa	 7100	 3800	 1.09	
POEGMA3.5kDa	 3600	 3400	 1.10	
POEGMA7.5kDa	 7600	 6700	 1.10	
	
	
Figure	81.		1H	NMR	spectrum	of	the	purified	PNAM3.5kDa.	
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Figure	82.	1H	NMR	spectrum	of	the	purified	PNAM7kDa.	
	
	
Figure	83.	1H	NMR	spectrum	of	the	purified	POEGMA3.5kDa.	
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Figure	84.	1H	NMR	spectrum	of	the	purified	POEGMA7.5kDa.	
	
The	SEC	traces	of	all	polymers	 in	THF	gave	dispersity	values	Ð	below	1.1,	which,	as	expected,	
indicates	 a	 narrow	 distribution	 typical	 of	 a	 controlled	 polymerization	 (Figure	 85).	 The	Mn,SEC	
values	 were	 calculated	 based	 on	 PMMA	 standards	 and	 therefore	 do	 provide	 accurate	
estimates.	The	obtained	Mn,SEC	values	increased	proportionally	with	target	polymer	size.	MALDI-
ToF	analyses,	shown	in	Figure	87	(a	and	c)	and	Figure	88	(a	and	c)	confirmed	the	defined	size	
with	narrow	dispersities	of	the	obtained	polymers.	Table	11	summarizes	the	characterization	of	
the	polymers	used	for	conjugation.		
	 Synthesis	of	PNAM	and	POEGMA	by	RAFT	polymerization	 5.2		
133	
	
 
Figure	85.	Size-exclusion	chromatograms	in	THF	of	the	synthesized	polymers.	
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5.3. Protein	conjugation	and	purification		
The	conjugation	reaction	was	carried	out	 for	each	of	 the	polymers	using	 lysozyme	of	chicken	
egg	white	as	model	protein.	The	extensive	research	on	conjugates	from	this	protein,	due	to	the	
availability	 of	 lysine	 residues,	 make	 it	 a	 suitable	 prospect	 for	 the	 study.	 The	 conjugation	
reaction	was	performed	using	 a	2-fold	excess	polymer	 at	pH	7.2	 in	 a	phosphate	buffer	 for	 1	
hour	at	room	temperature.		
The	 species	 present	 in	 the	 mixture	 were	 separated	 by	 preparative	 cation	 exchange	
chromatography	(CEX)	for	subsequent	analysis	of	each	fraction.	The	chromatograms	presented	
in	Figure	86	were	obtained	 from	diluted	batches	 (1:12)	 of	 the	original	 reaction	mixture.	 The	
first	50	ml	correspond	to	the	loading	phase	carried	out	with	a	50	mL	loop	and	are,	therefore,	
not	 displayed	 on	 the	 chromatograms.	 The	 separation	 was	 monitored	 using	 two	 different	
wavelengths:	280	nm	for	the	detection	of	both	polymer	and	protein,	and	320	nm	for	polymer	
detection	exclusively,	thanks	to	the	characteristic	absorption	of	the	dithiobenzoate	group	in	the	
CTA	 (see	 experimental	 section	 for	 UV	 spectra).	 The	 difference	 in	 absorption	 of	 polymer	 and	
protein	 at	 the	 designated	 wavelengths	 facilitated	 a	 first	 assumption	 on	 the	 nature	 of	 each	
species	on	the	chromatogram.	A	high	absorption	at	280	nm,	with	little	to	none	at	320	nm,	can	
be	 expected	 from	 native	 lysozyme,	 and	 as	 the	 320	 nm:280	 nm	 absorption	 ratio	 increases,	
higher	 conjugation	 degrees	 are	 expected.	 This	 would	 mean	 that	 native	 lysozyme	 has	 the	
highest	binding	affinity	to	the	column	and	is	the	last	species	to	be	eluted,	while	the	addition	of	
polymer	 chains	 to	 the	 protein	 decreases	 the	 binding	 affinity,	 resulting	 in	 faster	 elution.	 The	
attachment	of	the	polymer	on	the	surface	of	the	protein	weakens	the	electrostatic	interaction	
between	 the	protein	 surface	and	 the	charged	column	material.319–321	This	assumption	can	be	
corroborated	by	comparison	of	the	results	obtained	with	the	reported	chromatograms	of	the	
purification	of	PEGylated	lysozyme,305	where	a	similar	pattern	was	obtained.			
	 Protein	conjugation	and	purification	 5.3		
135	
	
	
Figure	86.	CEX	chromatograms	of	1:12	diluted	conjugation	batches	(2-fold	polymer	excess,	pH	7.2,	1	h)	
for	(A)	PNAM3.5kDa,	(B)	PNAM7kDa,	(C)	POEGMA3.5kDa,	and	(D)	POEGMA7.5kDa.	
	
The	collected	fractions,	as	well	as	a	sample	of	the	raw	mixture,	were	analyzed	using	MALDI-ToF	
to	confirm	the	nature	of	each	peak	on	the	chromatogram.	The	obtained	spectra	are	shown	in	
Figure	87	(b	and	d)	and	Figure	88	(b	and	d).	Three	main	distributions	are	visible	on	the	MALDI	
spectra	of	all	raw	reaction	mixtures,	before	purification	by	CEX.	The	very	narrow	distribution	at	
m/z	=	14.3	kDa	corresponds	to	remaining	unreactive	lysozyme,	while	higher	m/z	values	can	be	
associated	to	the	conjugated	species	obtained.		
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Figure	87.	MALDI-ToF	spectra	of	the	synthesized	PNAM	with	two	different	chain	lengths	(A	and	C),	and	
the	conjugated	fractions	separated	using	CEX	chromatography	(B	and	D).		
	
MALDI-ToF	analysis	confirmed	the	purification	of	the	PNAM	conjugates.	Fractions	collected	by		
CEX	give	one	 (almost	pure)	distribution	 in	mass	 spectrometry,	 that	 corresponds	 to	either	 the	
native	 protein	 or	 the	 protein	 with	 one	 or	 two	 polymer	 chains,	 respectively	 (Figure	 87).	
However,	in	the	case	of	POEGMA,	despite	the	good	separation	obtained	on	CEX,	surprisingly,	all	
MALDI	spectra	of	the	collected	fractions	from	CEX	show	the	characteristic	signal	of	the	native	
protein,	besides	the	expected	population	of	conjugates	(Figure	88).	Further	characterization	of	
the	 conjugated	 species	 carried	 out	 by	 capillary	 gel	 electrophoresis	 and	 size-exclusion	
chromatography	 show	 one	 distribution	 on	 each	 case	 (Figure	 89,	 Figure	 90,	 and	 Figure	 91),	
confirming	the	purity	of	the	conjugated	POEGMA	fractions.	The	drastic	difference	in	the	results	
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obtained	from	MALDI	may	come	from	the	high	ionization	capability	of	lysozyme	which,	even	in	
trace	amounts,	would	create	a	much	stronger	signal	than	the	conjugated	protein.		
	
	
Figure	88.	MALDI	spectra	of	the	synthesized	POEGMA	(a	and	c)	and	the	conjugated	fractions	separated	
using	CEX	chromatography	(b	and	d).	
5.	 PNAM	and	POEGMA	conjugates	as	alternatives	to	protein	PEGylation	 	
138	
	
	
Figure	89.	Analysis	of	the	purified	POEGMA7.5kDa-lysozyme	conjugates	using	high-throughput	capillary	gel	
electrophoresis	(HT-CGE),	according	to	reference	322.	
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Figure	 90.	SEC	 chromatograms	of	 (A)	 POEGMA3.5kDa	 conjugation	batch,	 and	 the	purified	 species	 of	 (B)	
native	lysozyme,	(C)	mono-conjugated	lysozyme,	and	(D)	di-conjugated	lysozyme.		
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Figure	 91.	SEC	 chromatograms	of	 (A)	 POEGMA7.5kDa	 conjugation	batch,	 and	 the	purified	 species	 of	 (B)	
native	lysozyme,	(C)	mono-conjugated	lysozyme,	and	(D)	di-conjugated	lysozyme.		
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5.4. Stability	assessment	
5.4.1. Functional	stability		
The	 functional	 stability	 of	 polymer-protein	 conjugates	 refers	 to	 the	 analysis	 of	 the	 residual	
activity	of	a	protein	after	conjugation.	In	this	project,	the	assay	to	calculate	the	residual	activity	
was	based	on	the	lysis	of	M.	lysodeikticus	by	lysozyme.305	The	cell	density	decrease	leads	to	a	
clearer	solution	monitored	by	an	absorbance	measurement	at	450	nm.		
The	results	of	the	assay	for	both	polymer	systems	and	native	lysozyme	are	shown	in	Figure	92.	
The	 residual	 activity	 of	 the	mono	 conjugates	 using	 the	 smaller	 polymer	 chain	 length,	mono-	
PNAM3.5kDaylated	and	mono-POEGMA3.5kDaylated	lysozyme,	was	higher	or	at	least	equal	to	that	
of	 the	native	protein.	For	 the	 rest	of	 the	 tested	conjugates,	 the	 remaining	activity	was	 lower	
compared	to	the	native	protein.		
For	both	polymer	systems,	when	keeping	the	conjugation	degree	constant,	higher	molar	mass	
polymer-conjugates	exhibit	lower	activity.	A	similar	decrease	in	activity	arises	when	increasing	
the	conjugation	degree	and	maintaining	the	molar	mass	constant.	This	drastic	change	in	activity	
may	be	 assigned	 to	 the	hindering	of	 the	 active	 site	of	 the	protein	by	 the	polymer,	 as	 higher	
molar	mass	polymers,	or	an	increased	conjugation	degree	cover	larger	portions	of	the	protein	
surface,	thereby	decreasing	or	even	halting	its	activity.		
When	 directly	 comparing	 PNAM	 conjugates	 to	 POEGMA	 counterparts	 at	 equal	 size	 or	
conjugation	 degree,	 PNAMylated	 conjugates	 show	 a	 higher	 residual	 activity.	 In	 this	 case,	 it	
appears	that	the	nature	of	the	side	chain	plays	an	important	role	on	the	changes	observed	of	
residual	 activity.	 Since	 POEGMA	 is	 a	 comb-like	 polymer,	 the	 conformation	 these	 polymers	
adopt	in	solution	is	different	from	the	linear	chain	of	PNAM.	It	can	be	assumed	in	this	case	that	
the	brush	covers	a	 larger	surface	area	of	the	protein,	probably	close	to	the	catalytic	site,	that	
results	 in	 the	 observed	decrease	 of	 the	 activity.	 The	molecular	 flexibility	 of	 the	 linear	 PNAM	
might	result	in	a	less	hindered	conjugate,	which	causes	a	less	dramatic	decrease	in	activity.		
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Figure	 92.	 Residual	 lysozyme	 activity	 (%)	 of	 protein-polymer	 conjugates	 towards	 the	 substrate	 M.	
lysodeikticus.	The	indicated	activity	values	refer	to	native	lysozyme	as	reference.		
	
For	 further	 analyses,	 the	 di-conjugated	 species	 of	 POEGMA	 and	 PNAM7.5kDa	 were	 not	
considered	due	to	the	very	low	activity	values	obtained	(below	10%).	
5.4.2. Colloidal	stability	
Physicochemical	properties	of	 the	obtained	conjugates	such	as	 solubility	and	phase	behavior,	
were	investigated	as	well.		
For	 colloidal	 stability,	 phase	 diagrams	 were	 created	 for	 monoconjugates	 of	 each	 available	
polymer	 (PNAM3.5kDa,	 PNAM7kDa,	 POEGMA3.5kDa,	 and	 POEGMA7.5kDa)	 and	 di-conjugated	
PNAM3.5kDa.	 Conjugate	 solutions	 of	 different	 concentrations	 at	 pH	 3	 were	 prepared.	 NaCl	 in	
varied	 concentrations	 was	 used	 as	 precipitating	 agent.	 The	 solutions	 were	 mixed	 and	
transferred	 to	 a	 96-well	 plate	 to	 create	 a	 binary	 phase	 diagram	 screening	 conjugate	
concentrations	 ranging	 from	0.17	 to	1.52	M,	and	salt	concentrations	 from	0	 to	2.5	M	(Figure	
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93).	 The	 experiment	was	 transferred	 to	 a	 stable	 25	 °C	 atmosphere	 for	 40	 days	 (17	 days	 for	
mono-POEGMA3.5kDa,	due	to	thesis	submission	deadline)	where	photographs	of	each	well	were	
taken	 by	 an	 automated	 imaging	 system.	 The	 evaluation	 of	 the	 phase	 diagrams	 is	 based	 on	
visual	analysis	where	 the	observed	possibilities	were	precipitation,	crystallization,	or	gelation.	
The	results	were	compared	to	the	previously	reported	native	lysozyme	phase	diagram.323		
For	all	conjugates,	the	soluble	area	was	extended	as	a	result	of	a	reduced	propensity	to	protein	
aggregation.	For	instance,	in	the	case	of	mono-PNAM3.5kDaylated	lysozyme,	the	phase	transition	
was	reached	using	twice	the	salt	concentration	compared	to	native	protein.	The	largest	soluble	
area	 was	 obtained	 with	 the	 mono-POEGMA7.5kDaylated	 lysozyme	 conjugate,	 where	 phase	
transition	 was	 induced	 using	 four	 times	 the	 salt	 concentration	 necessary	 to	 destabilize	 the	
native	 protein.	 This	 effect	 is	 a	 result	 of	 a	 shielding	 phenomenon	 created	 by	 the	 hydrophilic	
polymers	that	decreases	the	interaction	between	the	protein	surface	and	the	surrounding	ions	
of	 the	 medium,	 requiring	 higher	 amounts	 of	 precipitating	 agent	 (NaCl)	 to	 reach	 a	 phase	
transition.		
Although	 the	phase	diagrams	of	both	PNAM3.5kDaylated	 lysozyme	show	similar	characteristics,	
visually,	 the	 aggregates	 formed	 are	 quite	 different	 (see	 Figure	 93	 inserts	 B	 and	 C).	 Mono-
PNAM3.5kDaylated	 lysozyme	 produces	 dark	 precipitates,	 while	 di-PNAM3.5kDaylated	 lysozyme	
forms	 mainly	 gels,	 and	 a	 light	 precipitate.	 At	 higher	 salt	 concentrations,	 the	 protein	 is	 at	 a		
ersaturated	 state	 and	 because	 of	 the	 attachment	 of	 a	 single	 polymer	 chain	 (in	 the	 case	 of	
mono-PNAM3.5kDaylated	 lysozyme)	 lysozyme	 cannot	 have	 ordered	 nucleation	 and	 crystal	
growth,	leading	instead	into	a	direct	transition	to	precipitation.	By	adding	two	polymer	chains,	
not	 only	 precipitation	 is	 favored	 but	 the	 propensity	 of	 the	 PNAM	 to	 create	 physically	
crosslinked	 hydrogels324,325	 is	 showcased,	 observed	 by	 the	 formation	 of	 gels	 and	 a	 light	
precipitate.	By	increasing	the	conjugation	degree	of	the	conjugate,	the	resulting	properties	are	
influenced	by	the	inherent	properties	of	the	polymer	used.		
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Figure	93.		Phase	diagrams	for	(A)	native	lysozyme,	(B)	mono-PNAM3.5kDaylated,	(C)	di-PNAM3.5kDaylated,	
(D)	mono-PNAM7kDaylated,	(E)	mono-POEGMA3.5kDalated,	and	(F)	mono-POEGMA7.5kDalated	lysozyme	with	
sodium	 chloride	 (NaCl)	 as	 precipitant	 at	 pH	 3.	 Phase	 diagrams	 of	 native	 lysozyme	 was	 taken	 from	
reference	323.	Inserts	show	pictures	taken	after	40	days	of	wells	with	conjugate	and	salt	concentrations	
of	1.52	M	and	1.82	M,	respectively,	for	comparison	of	the	aggregates	formed.		
	 Colloidal	stability	 5.4.2		
145	
	
Although	an	excellent	 solubility	 is	achieved	with	 the	mono-POEGMA7.5kDa	 conjugate,	 the	poor	
remaining	 activity	 eclipses	 the	 promising	 results.	 This	 exemplifies	 the	 compromise	 that	must	
exist	 between	molar	mass,	 conjugation	 degree,	 and	 choice	 of	 monomer	 when	 selecting	 the	
conjugate	to	use	for	the	desired	application.	The	mono-POEGMA3.5kDa	conjugate	shows	a	larger	
soluble	 area	 compared	 to	 its	mono-PNAM3.5kDa	 analogue,	 indicating	 the	 influence	 of	 polymer	
structure	on	the	solubility	of	the	conjugates.	Although	its	soluble	area	is	reduced	compared	to	
mono-POEGMA7.5kDa,	 out	 of	 the	 evaluated	 conjugates,	mono-POEGMA3.5kDa	 shows	 the	 largest	
increase	 in	 soluble	 area	 while	 at	 the	 same	 time	 conserving	 activity	 comparable	 to	 native	
lysozyme.	
A	 quantitative	 method	 was	 used	 to	 evaluate	 the	 increase	 in	 solubility	 of	 the	 developed	
conjugates.	 The	 concentration	 of	 remaining	 soluble	 conjugates	 in	 the	 supernatant	 from	 the	
previous	 experiment	 after	 40	 days	 was	 measured.	 The	 solubility	 curves	 obtained	 were	
compared	to	those	previously	reported	for	the	native	 lysozyme326	and	its	PEGylated	analogue	
(Figure	94).305	Unfortunately,	the	solubility	curve	of	mono-POEGMA3.5kDa	could	not	be	included	
since	by	the	time	this	thesis	was	submitted,	the	required	40	days	this	experiment	takes	had	not	
passed	yet.		
All	analyzed	conjugates	display,	in	general,	higher	solubility	compared	to	the	native	protein,	as	
expected.	The	mono-PNAM7kDaylated	conjugate	shows	a	similar	behavior	to	the	PEG	analogue,	
despite	the	lower	Mn	used	for	PEG.	The	different	conformation	in	the	solvent	adopted	by	PEG	
and	PNAM	can	potentially	be	the	reason	why	a	larger	PNAM	chain	is	necessary	to	shield	with	
the	same	magnitude	as	a	shorter	PEG	chain.	Although	solubility	increases	when	conjugating	the	
protein	 to	 PNAM,	 it	 was	 unusual	 to	 find	 that	 at	 lower	 salt	 concentrations	 the	 di-conjugate	
version	of	the	lysozyme	has	a	lower	solubility	than	the	mono-conjugated	analogue,	although	as	
NaCl	concentration	increased	the	difference	became	less	apparent.		
Mono-POEGMA7.5kDa	showed	the	highest	solubility	increase	of	all	analyzed	conjugates,	including	
the	reference	 linear	PEG2kDa	conjugate.	 In	this	case,	 it	 is	the	higher	molar	mass	and	the	brush	
architecture	 that	 provide	 the	 higher	 solubility.	However,	 it	 is	 those	 same	 characteristics	 that	
quantitatively	suppress	the	activity.		
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Figure	 94.	 Solubility	 lines	 of	 unmodified	 lysozyme,326	 mono-PNAM3.5kDaylated	 lysozyme,	 di-
PNAM3.5kDaylated	lysozyme,	mono-PNAM7kDaylated	lysozyme,	mono-POEGMA7.5kDa	 lysozyme,	and	mono-
PEG2kDaylated	 lysozyme305	 at	 pH	 3.	 The	 solubility	 curve	 for	 mono-POEGMA3.5kDa	 lysozyme	 is	 in	
preparation.	 	
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5.5. Conclusion		
PNAM	and	POEGMA	of	different	 chain	 lengths	were	 synthesized	by	RAFT	polymerization	and	
conjugated	 to	 the	 model	 protein	 lysozyme	 from	 chicken	 egg	 white.	 The	 properties	 of	 the	
resulting	conjugates	are	 influenced	by	both	 the	native	protein	and	 the	polymer	properties.	 It	
was	observed	that	for	the	mono-conjugates	with	 lower	molar	mass	polymer	(both	PNAM	and	
POEGMA),	the	activity	of	the	conjugated	protein	was	equal	or	higher	than	native	lysozyme.	For	
the	rest	of	the	conjugates,	the	remaining	activity	decreased,	product	of	possible	shielding	of	the	
polymer	 on	 the	 catalytic	 site.	 In	 all	 cases,	 the	 equilibrium	 solubility	 increased	 under	 the	
influence	of	high	 salt	 concentrations	 (NaCl	up	 to	2	M)	and	acidic	pH,	when	compared	 to	 the	
native	protein.	These	are	promising	results	in	the	case	of	mono-conjugates	with	the	small	molar	
mass,	where	both	 increased	 (or	 equal)	 activity	 and	higher	 solubility	 than	 those	of	 the	native	
enzyme	 were	 achieved.	 However,	 in	 the	 case	 of	 PNAM,	 already	 reported	 PEG-conjugates	
remains	the	better	option	since	it	has	been	proved	these	show	a	higher	solubility	increase.	On	
the	 other	 hand,	 POEGMA7.5kDa	 shows	 a	 better	 solubility	 when	 compared	 to	 PEG-based	
conjugates,	but	at	the	cost	of	a	significant	decrease	in	activity	(less	than	10%).		
From	the	results	obtained,	it	can	be	concluded	that	depending	on	the	desired	application	of	the	
conjugate,	a	compromise	between	enhanced	physicochemical	properties	and	activity	has	to	be	
found.	The	physicochemical	properties	of	the	resulting	conjugate	can	be	shaped	depending	on	
the	choice	of	polymer,	its	size,	and	the	number	of	attached	chains.	The	presented	preparative	
and	 analytical	 methods	 are	 a	 helpful	 tool	 for	 the	 optimization	 of	 these	 parameters.	
Furthermore,	the	robustness	of	the	method	allows	the	potential	extrapolation	of	the	method	to	
assess	 the	 physicochemical	 properties	 of	 conjugates	 using	 other	 biocompatible	 polymers	
alternative	to	PEG.		
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6	
Conclusion	 	
The	 biocompatible	 polymers	 synthesized	 for	 this	 thesis	 show	promising	 results	 on	 each	 case	
study.	 The	 synthetic	 versatility	 of	 PAOx,	 PNAM,	 and	 POEGMA	 was	 showcased	 for	 the	
incorporation	 of	 functional	 groups	 on	 the	 chain	 ends	 of	well-defined	 polymers.	 The	 reactive	
groups	 introduced	 allow	 the	 incorporation	 of	 molecules	 of	 interest	 (including	 proteins	 and	
imaging	agents),	the	attachment	of	the	polymer	to	a	functionalized	surface,	and	the	formation	
of	 complex	 architectures	 such	 as	 bottlebrush	 and	 arm-star	 polymers.	 Nevertheless,	 further	
biological	 studies	 are	 still	 necessary	 to	 ensure	 PAOx,	 PNAM,	 and	 POEGMA	 can	 be	 a	 useful	
alternative	and	a	complementary	polymer	to	PEG.	
In	 Chapter	 3,	 a	 new	 strategy	 to	 obtain	 maleimide	 and	 thiol	 α-functionalized	 PAOx	 was	
established	 using	 nosylate	 initiators.	 The	 novel	 initiators	 bear	 either	 a	 furan-protected	
maleimide	 moiety	 or	 a	 protected	 thiol	 group	 in	 the	 form	 of	 thioacetate.	 For	 FurMalNos	 4,	
thermal	 and	 solubility	 limitations	 required	 polymerization	 conditions	 with	 lower	 monomer	
concentration	and	temperature.	In	the	case	of	ThioAcNos	8,	its	simpler	synthetic	strategy,	good	
solubility,	and	compatibility	with	microwave-assisted	polymerization	provided	a	straightforward	
path	to	well-defined	polymers.	Polymers	with	molar	masses	relevant	for	either	bioconjugation	
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or	 surface	 functionalization	 were	 obtained	 from	 the	 synthesized	 initiators.	 The	 strategy	
described	 provides	 the	 possibility	 to	 functionalize	 the	 ω-chain	 end	 and	 obtain	 bifunctional	
telechelic	polymers	by	appropriate	termination.	However,	this	route	can	potentially	lead	to	the	
presence	of	proton-initiated	chains	(in	the	case	of	FurMalNos	4,	for	instance),	via	H	transfer,	or	
to	discrepancies	on	the	expected	molar	mass	as	a	result	of	lower	efficiency	of	the	initiator.	The	
described	approach	can	potentially	have	applications	in	the	development	of	bifunctional	linkers	
for	surface	biofunctionalization,	stealth	surfaces,	or	the	construction	of	artificial	protein	dimers.	
Chapter	 4	 described	 the	 successful	 synthesis	 of	 the	 first	 PEtOx-based	 macromonomers	 for	
ROMP	 to	 develop	 a	 metal-free	 PEtOx-based	 MRI	 probe.	 New	 branched	 and	 linear	 PEtOx	
macromonomers	were	obtained	taking	advantage	of	the	termination	step	of	the	CROP	of	EtOx	
to	 introduce	 norbornene	 or	 dual	 norbornene-alkyne	 moieties.	 Bivalent	 alkyne-PEtOx	
macromonomers	 were	 functionalized	 with	 the	 paramagnetic	 nitroxide	 chex,	 used	 as	 MRI	
contrast	enhancement	agent,	by	CuAAC	click	 reaction.	The	 synthesis	of	bottlebrush	polymers	
and	BASPs	from	linear	and	chex-functionalized	PEtOx	MMs	by	graft-through	ROMP	was	carried	
out	 screening	 different	MM-to-catalyst,	 and	 crosslinker-to-catalyst	 ratios.	 Nearly	 quantitative	
conversion	 from	monomer	 to	 bottlebrush	 and	 from	bottlebrush	 to	 BASP	was	 observed	 from	
SEC	 characterization.	 The	 magnetic	 properties	 of	 the	 synthesized	 PEtOx-based	 BASP-ORCAs	
showed	an	improved	transverse	relaxivity	(r2)	of	up	to	∼13.5	times	higher	when	compared	to	
nitroxide	CP-3,	and	up	to	∼2.5-fold	compared	to	the	analogue	chex-PEG	bottlebrush	previously	
reported.201	However,	 the	relaxivity	values	observed	are	below	what	 is	 reported	 for	 the	PEG-
based	analogue	BASP,	which	 increases	r2	up	to	44	times	compared	to	CP-3.	Nevertheless,	the	
novel	 metal-free	 PEtOx-based	 MRI	 probes	 have	 potential	 for	 further	 development	 as	 an	
alternative	 to	 the	 previously	 reported	 PEG-based	 MRI	 probes,	 after	 screening	 of	 further	
synthetic	parameters	is	performed.		
In	 Chapter	 5,	 the	 evaluation	 of	 the	 physicochemical	 properties	 of	 PNAM-	 and	 POEGMA-
conjugated	 lysozyme	provided	 information	on	 the	extent	polymer	 type,	 size,	and	conjugation	
degree	 affect	 the	 properties	 of	 the	 conjugates.	 The	 drastic	 effect	 of	 molar	 mass	 and	
conjugation	degree	on	the	activity	of	the	conjugates	was	evident	considering	the	activity	of	the	
6.	 Conclusion	 	
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set	of	3	kDa	mono-conjugates	(both	PNAM	and	POEGMA)	increased	or	was	equal	to	that	of	the	
native	protein,	while	to	higher	molar	mass	and	conjugation	degree	polymer-protein	conjugates	
that	 showed	 lower	activity.	This	 is	 caused	by	a	 shielding	phenomenon	of	 the	polymer	on	 the	
active	 site	 of	 the	 protein.	 The	 equilibrium	 solubility	 increased	 for	 all	 conjugates	 in	 high	 salt	
concentrations	 (NaCl	 up	 to	 2.5	M)	 at	 pH	 3	with	 respect	 to	 the	 native	 protein.	 POEGMA7.5kDa	
showed	 the	 highest	 increase	 in	 solubility	 of	 all	 tested	 conjugates.	 However,	 the	 improved	
solubility	 is	eclipsed	by	 the	minimal	activity	observed	 (less	 than	10%).	The	results	 lead	to	 the	
conclusion	 that	depending	on	 the	desired	application	of	 the	conjugate,	a	compromise	should	
exist	 between	 enhanced	 solubility	 and	 activity.	 The	 high-throughput	 method	 developed	
provides	 a	 systematic	 evaluation	 of	 the	 properties	 of	 polymer-protein	 conjugates.	 Its	
robustness	allows	the	potential	extrapolation	to	assess	other	available	biocompatible	polymers.	
	 	
151	
	
	
7	
Experimental	Section	
	
7.1. Maleimide-	and	thiol-functionalized	initiators	for	the	polymerization	of	2-
oxazolines	
7.1.1. Materials	and	instrumentation	
Materials	
Maleic	 anhydride	 (99%,	 Bernd	 Kraft),	 furan	 (99%,	 Acros),	 allyl	 alcohol	 (99%,	 Sigma),	
ethanolamine	 (99%,	 Acros),	 4-toluenesulfonyl	 chloride	 (99%,	 Acros),	 4-nitrobenzenesulfonyl	
chloride	(97%,	Sigma-Aldrich),	pyridine	(99%,	Roth),	benzene	(99%,	Sigma),	cyclohexane	(VWR),	
benzoin	 (98%,	 Acros),	 4-dimethylaminopyridine	 (DMAP;	 99%,	 Aldrich),	 triazabicyclodecene	
(TBD,	 Sigma),	 dimethylphenylphosphine	 (DMPP;	 99%,	 Sigma),	 sodium	 chloride	 (99.8%,	 Roth),	
thioacetic	acid	(98%,	Acros),	sodium	hydroxide	(99%,	Roth),	tetramethylammonium	hydroxide	
(25	wt%	in	methanol,	Acros),	bovine	serum	albumin	(BSA;	Sigma),	toluene	(Fisher),	petroleum	
ether	 (Acros),	 ethanol	 (99.8%,	 Acros),	 acetone	 (Fisher),	 tetrahydrofuran	 (THF;	 VWR),	 diethyl	
ether	 (99.5%,	 Roth),	 and	 dichloromethane	 (DCM;	 VWR)	 were	 used	 as	 received.	 Acetonitrile	
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(MeCN;	 Sigma-Aldrich)	was	dried	 in	 a	 solvent	 purification	 system	 (JC	Meyer)	 before	use	 as	 a	
polymerization	solvent.	2-ethyl-2-oxazoline	(EtOx;	Aldrich)	was	distilled	over	barium	oxide	and	
stored	under	argon.	
Characterization	techniques	
All	 polymer	 solutions	 and	 samples	were	 prepared	 in	 a	 VIGOR	 Sci-Lab	 SG	 1200/750	Glovebox	
System	with	a	water	concentration	≤	0.1	ppm.	Polymerization	reactions	assisted	by	microwave	
irradiation	were	performed	in	capped	vials	in	a	microwave	reactor	(Biotage)	equipped	with	an	
infrared	(IR)	temperature	sensor.	
Gas	chromatography	(GC)		
Monomer	conversion	was	determined	by	GC.	Samples	were	measured	on	a	7890A	from	Agilent	
Technologies	with	an	Agilent	 J&W	Advanced	Capillary	GC	column	(30	m,	0.320	mm,	and	0.25	
lm).	Injections	were	operated	with	an	Agilent	Technologies	7693	auto	sampler.		
1H	nuclear	magnetic	resonance	(NMR)	spectroscopy		
Measurements	were	performed	on	a	Bruker	AM	500	spectrometer	(500	MHz).	All	compounds	
were	 dissolved	 in	 either	 CDCl3	 or	DMSO-d6	 and	 the	 residual	 solvent	 peak	was	 employed	 for	
shift	correction	(7.26	ppm	for	CDCl3	and	2.50	ppm	for	DMSO-d6).		
Size-exclusion	chromatography	(SEC)		
SEC	was	used	with	N,N-dimethylacetamide	(DMAc)	as	eluent	with	a	sample	concentration	of	2	g	
L−1	on	a	Polymer	Laboratories	PL-GPC	50	Plus	Integrated	system	comprising	an	autosampler,	a	
PLgel	 2,5	 μm	 bead-size	 guard	 column	 (50	 ×	 7.5	mm)	 followed	 by	 three	 PLgel	 5	 μm	MixedC	
columns	(300	×	7.5	mm),	and	a	flow	rate	of	1	mL	min−1.	The	SEC	system	was	calibrated	against	
linear	poly(methyl	methacrylate)	standards	with	molar	masses	ranging	from	700	to	2	×	106	Da.	
The	 samples	 were	 filtered	 through	 PTFE	 membranes	 with	 a	 pore	 size	 of	 0.2	 μm	 prior	 to	
injection.		
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Electrospray	ionization	mass	spectrometry	(ESI-MS)	
Spectra	were	recorded	on	an	LXQ	mass	spectrometer	 (Thermo	Fisher	Scientific,	San	Jose,	CA)	
equipped	with	 an	 atmospheric	 pressure	 ionization	 source	 operating	 in	 the	 nebulizer	 assisted	
electrospray	mode.	The	instrument	was	calibrated	in	the	m/z	range	195−1822	using	a	standard	
containing	 caffeine,	 Met-Arg-Phe-Ala	 acetate	 (MRFA),	 and	 a	 mixture	 of	 fluorinated	
phosphazenes	(Ultramark	1621)	(all	from	Aldrich).	A	constant	spray	voltage	of	4.5	kV	was	used.	
Nitrogen	 at	 a	 dimensionless	 sweep	 gas	 flow	 rate	 of	 2	 (approximately	 3	 L	 min−1)	 and	 a	
dimensionless	sheath	gas	flow	rate	of	5	(approximately	0.5	L	min−1)	was	applied.	The	capillary	
voltage,	the	tube	lens	offset	voltage,	and	the	capillary	temperatures	were	set	to	34	V,	90	V,	and	
275	°C,	respectively.	The	samples	were	dissolved	at	a	concentration	of	0.1	mg	mL−1	in	a	mixture	
of	THF	and	MeOH	(3:2	v/v)	containing	sodium	trifluoroacetate	(0.14	μg	L−1).	
Sodium	dodecyl	sulfate	polyacrylamide	gel	electrophoresis	(SDS-PAGE)		
Protein-polymer	 conjugates	were	analyzed	on	12%	SDS-PAGE	under	non-reducing	 conditions,	
using	standard	molecular	biology	techniques,	followed	by	Coomassie	Brilliant	Blue	staining.	
Fast	protein	liquid	chromatography	(FPLC)		
FPLC	was	performed	for	the	preparative	separation	of	BSA	conjugates.	An	ÄTKA	purifier	system	
equipped	with	 an	 autosampler	 A-905	 and	 a	 Fraction	 Collector	 Frac-950	 (GE	 Healthcare)	was	
used.		The	separation	of	BSA-PEtOx	conjugates	was	performed	on	a	Superdex	200	10/300	GL	
(GE	Healthcare)	SEC	column	using	a	0.05	M	phosphate	buffer	(pH	7.0)	and	0.15	M	NaCl	solution.	
The	column	was	loaded	with	300	μL	of	sample	and	the	system	was	run	at	a	flow	rate	of	0.5	mL	
min–1.	 Fractions	 of	 250	μL	 were	 collected	 into	 a	 96-well	 plate.	A	 UV	 detector	 continuously	
measured	 the	 relative	 absorbance	 of	 the	 mobile	 phase	 at	 280	 nm.	 The	 yields	 were	 not	
optimized.	
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Matrix-assisted	 laser	 desorption	 ionization	 coupled	 to	 time-of-flight	 (MALDI-ToF)	 mass	
spectrometry	
Mass	spectra	were	acquired	with	a	4800	Proteomics	Analyzer	(Applied	Biosystems,	Foster	City,	
CA,	USA)	in	positive	ion	linear	mode	and	a	mass	range	of	60000	to	80000	Da.	The	laser	intensity	
was	 set	 to	 4700.	 The	 spectra	 obtained	 represent	 the	 average	 of	 laser	 shots	 taken	 by	 an	
automatic	scheme	measuring	spectra	over	the	whole	spot.	
X-Ray	Photoelectron	Spectroscopy	(XPS)	
XPS	 investigation	 was	 performed	 in	 a	 K-Alpha+	 spectrometer	 (ThermoFisher	 Scientific,	 East	
Grinstead,	UK)	using	a	microfocused,	monochromated	Al	Kα	X-ray	source	(150	µm	and	400	µm	
spot	 size).	The	kinetic	energy	of	 the	electrons	was	measured	by	a	180°	hemispherical	energy	
analyzer	 operated	 in	 the	 constant	 analyzer	 energy	 mode	 (CAE)	 at	 50	 eV	 pass	 energy	 for	
elemental	 spectra.	The	K-Alpha+	charge	compensation	 system	was	employed	during	analysis,	
using	 electrons	 of	 8	 eV	 energy,	 and	 low-energy	 argon	 ions	 to	 prevent	 any	 localized	 charge	
build-up.	 Data	 acquisition	 and	 processing	 using	 the	 Thermo	 Avantage	 software	 is	 described	
elsewhere.327	The	spectra	were	fitted	with	one	or	more	Voigt	profiles	(BE	uncertainty:	+0.2eV)	
and	Scofield	sensitivity	factors	were	applied	for	quantification.328	All	spectra	were	referenced	to	
the	 C	 1s	 peak	 (C-C,	 C-H)	 at	 285.0	 eV	 binding	 energy	 controlled	 by	means	 of	 the	well-known	
photoelectron	peaks	of	Cu,	Ag,	and	Au	respectively.	
	
7.1.2. Syntheses	
Synthesis	of	maleimide-functionalized	initiators	
3a,4,7,7a-Tetrahydro-4,7-epoxyisobenzofuran-1,3-dione	(1)	
Maleic	anhydride	 (30.0	g,	306	mmol)	was	suspended	 in	 toluene	 (150	mL)	 in	a	250	mL	round-
bottom	flask.	This	mixture	was	heated	to	80	°C.	Furan	(33.4	mL,	459	mmol)	was	added	dropwise	
with	a	syringe.	After	stirring	for	6	h,	the	mixture	was	cooled	to	ambient	temperature	and	then	
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left	in	the	freezer	overnight.	The	resulting	crystals	were	collected	by	filtration	and	washed	with	
petroleum	 ether	 (3	 ×	 30	 mL).	 1	 was	 obtained	 as	 white	 crystals	 after	 drying	 under	 reduced	
pressure	(41.7	g,	82%).	
1H	NMR	(CDCl3,	500	MHz,	δ):	6.58	(s,	2H),	5.47	(s,	2H),	3.18	(s,	2H)	ppm.	
2-(2-Hydroxyethyl)-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione	(2)	
The	anhydride	1	 (10.0	g,	60.2	mmol)	was	dissolved	 in	ethanol	 (15	mL)	 in	a	100	mL	 two-neck	
round-bottom	 flask.	A	 solution	of	 ethanolamine	 (3.75	mL,	 62.1	mmol)	 in	 ethanol	 (5	mL)	was	
added	 dropwise.	 The	 resulting	 solution	 was	 stirred	 and	 heated	 under	 reflux	 for	 4	 h.	
Subsequently,	the	solution	was	kept	at	–20	°C	overnight.	The	obtained	white	solid	was	filtered,	
recrystallized	in	ethanol,	and	dried	under	reduced	pressure	to	yield	2	as	a	white	powder	(4.34	g,	
34%).	
1H	NMR	(CDCl3,	500	MHz,	δ):	6.53	(s,	2H),	5.29	(s,	2H),	3.76-3.79	(m,	2H),	3.70-3.72	(m,	2H),	2.90	
(s,	2H)	ppm.	
2-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-epoxyisoindol-2-yl)ethyl-4-methylbenzene-	
sulfonate	(FurMalTos	3)	
A	solution	of	compound	2	(1.0	g,	4.8	mmol)	and	pyridine	(0.75	g,	9.5	mmol)	in	THF	(7	mL)	was	
prepared	in	a	50	mL	round-bottom	flask	cooled	to	0	°C,	before	a	solution	of	4-toluenesulfonyl	
chloride	(1.82	g,	9.5	mmol)	in	THF	(5	mL)	was	added	dropwise.	The	mixture	was	then	stirred	at	
ambient	 temperature	 overnight.	 The	 remaining	 solution	 was	 filtered	 and	 the	 solvent	 was	
removed	 under	 reduced	 pressure.	 The	 product	 was	 dissolved	 in	 DCM	 and	 the	 mixture	 was	
washed	with	 saturated	NaHCO3	 and	water,	 before	 being	 dried	 over	MgSO4.	 The	 solvent	was	
removed	 under	 vacuum	 and	 the	 residual	 white	 powder	 was	 recrystallized	 in	 an	
ethanol/acetone	mixture	 (2:1	 v/v).	 After	 filtration	 and	drying	 under	 reduced	pressure,	3	was	
obtained	as	white	crystals	(1.10	g,	63%).	
1H	NMR	(CDCl3,	500	MHz,	δ):	7.75-7.73	(d,	2H),	7.31-7.33	(d,	2H),	6.50	(s,	2H),	5.22	(s,	2H),	4.17	
(t,	2H),	3.73	(t,	2H),	2.84	(s,	2H),	2.42	(s,	3H)	ppm.	
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13C	NMR	(CDCl3,	125	MHz,	δ):	21.75,	37.77,	47.63,	65.51,	80.94,	128.05,	129.99,	132.74,	136.61,	
145.15,	175.86	ppm.	
ESI-MS	(m/z):	[M+Na]+	calc.:	386.067,	found:	386.066	amu.	
2-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-epoxyisoindol-2-yl)ethyl-4-nitrobenzene	
sulfonate	(FurMalNos	4)	
A	 solution	 of	 compound	 2	 (1.0	 g,	 4.8	mmol)	 and	 pyridine	 (0.75	 g,	 9.5	mmol)	 in	 THF	 (7	mL)	
prepared	 in	 a	 50	 mL	 round-bottom	 flask	 was	 cooled	 to	 0	 °C.	 To	 this,	 a	 solution	 of	 4-
nitrobenzenesulfonyl	 chloride	 (2.12	 g,	 9.5	 mmol)	 in	 THF	 (5	 mL)	 was	 added	 dropwise.	 The	
mixture	was	then	stirred	at	ambient	temperature	overnight,	after	which	the	produced	solid	was	
filtered.	The	obtained	solid	was	dissolved	in	DCM,	washed	with	saturated	NaHCO3	and	water,	
before	being	dried	over	MgSO4.	After	filtering	off	the	drying	agent,	the	solvent	was	removed.	
The	residual	white	powder	was	recrystallized	 in	an	acetone/methanol	mixture	(3:1	v/v).	After	
filtration	and	drying	under	reduced	pressure,	4	was	recovered	as	a	white	powder	(0.55	g,	29%).	
1H	NMR	(CDCl3,	500	MHz,	δ):	8.38-8.40	(d,	2H),	8.09-8.11	(d,	2H),	6.52	(s,	2H),	5.24	(s,	2H),	4.32	
(t,	2H),	3.80	(t,	2H),	2.88	(s,	2H)	ppm.	
13C	 NMR	 (CDCl3,	 125	 MHz,	 δ):	 37.09,	 47.11,	 67.49,	 80.35,	 125.04,	 129.32,	 136.47,	 140.11,	
150.78,	176.12	ppm.	
ESI-MS	(m/z):	[M-Na+]	calc.:	417.036,	found:	417.035	amu.	
Allyl	tosylate	(5)		
To	 a	mixture	 of	 allyl	 alcohol	 (10.0	 g,	 0.17	mol)	 and	p-toluenesulfonyl	 chloride	 (16.70	 g,	 0.10	
mol)	in	a	250	mL	two-neck	round-bottom	flask	equipped	with	a	dropping	funnel	was	added	5	N	
aqueous	sodium	hydroxide	solution	(50	mL)	below	15	°C.	Additional	tosyl	chloride	(16.70	g,	0.10	
mol)	and	then	5	N	aqueous	NaOH	(50	mL)	were	added	consecutively	to	the	reaction	mixture.	An	
organic	layer	was	extracted	with	toluene,	washed	with	10%	aqueous	NaOH,	and	then	dried	over	
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potassium	carbonate.	Evaporation	of	solvent	produced	liquid	allyl	tosylate	5,	which	was	purified	
by	Kugelrohr	distillation	(110	°C,	0.15	mmHg)	(15.4	g,	43%).		
1H	NMR	(CDCl3,	500	MHz,	δ):	7.76-7.78	(d,	2H),	7.32-7.34	(d,	2H),	5.75-5.88	(m,	1H),	5.28-5.31	
(d,	1H),	5.24-5.22	(d,	1H),	4.50-4.51	(d,	2H),	2.43	(s,	3H)	ppm.	
S-(3-(tosyloxy)propyl)	ethanethioate	(ThioAcTos	6)		
Allyl	 tosylate	 (5)	 from	the	above	reaction	 (5.00	g,	23.6	mmol)	was	mixed	with	 thioacetic	acid	
(5.38	g,	70.7	mmol)	and	benzoin	 (0.100	g,	0.47	mmol).	 The	mixture	was	 flushed	with	N2	and	
then	 irradiated	 for	 1	 h	 using	 a	 36	 W	 compact	 low-pressure	 fluorescent	 lamp	 (Philips	 CLEO	
Compact	PL-L,	λmax	=	355	nm).	The	product	was	dissolved	in	DCM	and	the	mixture	was	washed	
with	 saturated	NaHCO3	 and	water,	 and	 dried	 over	MgSO4.	 After	 removal	 of	 the	 solvent,	 the	
product	was	purified	by	column	chromatography	(silica	gel,	EtOAc	to	cyclohexane).	The	initiator	
(6)	was	obtained	as	a	pale	yellow	oil	(5.3	g,	78%).	
1H	NMR	(CDCl3,	500	MHz,	δ):	7.77-7.79	(d,	2H),	7.34-7.36	(d,	2H),	4.06-4.08	(t,	2H),	2.85-2.88	(t,	
2H),	2.45	(s,	3H),	2.29	(s,	3H),	1.89-1.95	(m,	2H)	ppm.	
13C	 NMR	 (CDCl3,	 125	 MHz,	 δ):	 195.33,	 144.76,	 132.66,	 129.75,	 127.75,	 68.50,	 30.43,	 28.77,	
24.95,	21.51	ppm.	
ESI-MS	(m/z):	[M-Na+]	calc.:	311.0383,	found:	311.0378	amu.	
S-(3-hydroxypropyl)	ethanethioate	(7)		
Allyl	 alcohol	 (5.7	 g,	 98.1	 mmol)	 and	 thioacetic	 acid	 (8.21	 g,	 107.9	 mmol)	 were	 mixed	 with	
benzoin	 (0.417	 g,	 2	 mmol)	 and	 stirred.	 The	 mixture	 was	 flushed	 with	 nitrogen	 and	 then	
irradiated	for	1	h	using	a	36	W	compact	low-pressure	fluorescent	lamp	(Philips	CLEO	Compact	
PL-L,	λmax	=	355	nm).	The	product	(7)	was	dissolved	in	DCM	and	the	mixture	was	washed	with	
saturated	NaHCO3	and	water,	and	dried	over	MgSO4.	The	excess	 solvent	was	 removed	under	
reduced	pressure	to	obtain	10.7	g.	(81%	yield).	
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1H	NMR	(CDCl3,	500	MHz,	δ):	3.61-3.63	(t,	2H),	2.96-2.98	(t,	3H),	2.33	(s,	3H),	1.77-1.82	(m,	2H)	
ppm.	
S-(3-(((4-nitrophenyl)sulfonyl)oxy)propyl)	ethanethioate	(ThioAcNos	8)	
In	 a	 250	mL	 round-bottom	 flask	 compound	 (7)	 (3.62	 g,	 27.0	mmol)	 and	DMAP	 (3.96	 g,	 32.4	
mmol)	 were	 dissolved	 in	 DCM	 (40	 mL).	 Subsequently,	 a	 solution	 of	 4-nitrobenzenesulfonyl	
chloride	(6	g,	27.0	mmol)	in	DCM	(40	mL)	was	added	dropwise	at	0°	C.	After	stirring	for	2	h	the	
reaction	 was	 quenched	 by	 adding	 cold	 water	 (60	 mL)	 and	 DCM	 (60	 mL)	 and	 stirred	 for	 10	
minutes.	The	mixture	was	washed	with	water	 (2x)	and	brine	 (2x).	The	 remaining	 solvent	was	
evaporated	under	reduced	pressure.	The	product	was	precipitated	in	hexane	and	recrystallized	
from	ethanol.	(7.84	g,	74%)	
1H	NMR	(CDCl3,	500	MHz,	δ):	8.41-8.42	(d,	2H),	8.11-8.13	(d,	2H),	4.18-4.21	(t,	2H),	2.88-2.91	(t,	
2H),	2.30	(s,	3H),	1.95-2.00	(m,	2H)	ppm.	
13C	NMR	(CDCl3,	125	MHz,	δ):	194.95,	141.51,	129.09,	124.34,	69.58,	30.42,	28.81,	24.73	ppm.	
ESI-MS	(m/z):	[M-Na+]	calc.:	342.0077,	found:	342.0069	amu.	
	
7.1.3. CROP	of	2-oxazolines	
CROP	of	EtOx	using	furan-protected	maleimide	initiators	
The	 furan-protected	 maleimide	 initiators	 were	 dissolved	 in	 MeCN	 in	 glass	 vials	 at	 different	
monomer-to-initiator	 ratios	 ([M]/[I]	 =	20,	40,	 and	60)	 at	 a	monomer	 concentration	of	1.5	M.	
The	vials	were	capped	under	inert	conditions	in	a	glove	box.	The	capped	vials	were	heated	to	50	
°C	with	constant	stirring	under	inert	atmosphere.	Samples	for	GC	and	SEC	analysis	were	taken	
periodically	using	a	 syringe,	quenched	by	 the	addition	of	water,	 and	 injected	without	 further	
purification	in	order	to	monitor	kinetics	and	molar	mass	distributions.	For	further	experiments,	
the	 polymerization	 was	 terminated	 by	 addition	 of	 tetramethylammonium	 hydroxide.	 After	
	 Maleimide-	and	thiol-functionalized	initiators	for	the	polymerization	of	2-oxazolines	 7.1	
159	
	
evaporation	 of	 the	 solvent	 under	 reduced	 pressure	 and	 dissolving	 the	 residue	 in	 DCM,	 the	
polymer	was	precipitated	in	diethyl	ether,	centrifuged,	separated,	and	dried	under	vacuum.	The	
dry	product	was	analyzed	by	DMAc	SEC,	ESI-MS,	and	1H	NMR	spectroscopy.	
CROP	of	EtOx	using	thioacetate	initiators	
The	 thiol-containing	 initiators	 were	 dissolved	 in	 acetonitrile	 in	 microwave	 vials	 at	 different	
monomer-to-initiator	 ratios	 ([M]/[I]	 =	 20,	 40,	 and	60)	 and	a	monomer	 concentration	of	 4	M.	
The	vials	were	crimped	air-tight	under	inert	conditions	inside	a	glove	box	(Vigor	Gas	Purification	
Technologies).	 The	 capped	 vials	 were	 heated	 to	 140	 °C	 under	 microwave	 irradiation	 with	
constant	 stirring	 under	 inert	 atmosphere.	 For	 kinetic	 investigations	 of	 the	 polymerization,	 a	
stock	 solution	 of	 the	 polymerization	 mixture	 was	 prepared	 in	 a	 glovebox	 and	 divided	 into	
individual	 vials	 before	 transfer	 to	 the	 microwave	 reactor.	 After	 microwave	 irradiation	 the	
polymerization	mixtures	 were	 cooled	 to	 ambient	 temperature	 and	 quenched	 by	 addition	 of	
water.	 Samples	 of	 the	 reaction	 mixture	 were	 taken	 for	 GC	 and	 DMAc	 SEC	 without	 further	
purification.	
For	 further	 experiments,	 the	 polymerization	was	 terminated	 through	 the	 addition	 of	 sodium	
carbonate	and	heated	to	80	°C	in	a	microwave	for	12	h.	After	evaporation	of	the	solvent	under	
reduced	pressure	and	dissolving	 the	 residue	 in	DCM,	 the	polymer	was	precipitated	 in	diethyl	
ether,	centrifuged,	separated,	and	dried	under	vacuum.	The	dry	product	was	analyzed	by	DMAc	
SEC,	ESI-MS,	and	1H	NMR	spectroscopy.	
	
7.1.4. Deprotection	and	modification	of	FurMal-PEtOx	and	ThioAc-PEtOx	
Deprotection	of	the	maleimide	end	group	(Mal-PEtOx)	
In	 a	 25	 mL	 round-bottom	 flask,	 100	 mg	 of	 a	 furan-protected	 maleimide	 end-functionalized	
polymer	FurMal-PEtOx	(Mn,SEC	=	6500	g	mol–1,	Ð	=	1.20,	Mn,NMR	=	4400	g	mol-1)	were	dissolved	in	
toluene	 (10	mL).	 This	 solution	 was	 then	 heated	 to	 110	 °C	 for	 4	 h.	 After	 evaporation	 of	 the	
solvent	 under	 reduced	 pressure	 and	 dissolving	 the	 residue	 in	 DCM,	 the	 product	 was	
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precipitated	in	diethyl	ether,	centrifuged,	separated,	and	dried	under	vacuum.	The	dry	product	
Mal-PEtOx	was	analyzed	by	DMAc	SEC,	ESI-MS,	and	1H	NMR	spectroscopy.	
Deprotection	of	the	thioacetate	end	group	(Thiol-PEtOx)	
In	 a	 25	mL	 round-bottom	 flask,	 200	mg	 of	 a	 thiol	 end-functionalized	 polymer	 ThioAc-PEtOx	
(Mn,SEC	=	5800	g	mol–1,	Ð	=1.09,	Mn,NMR	=	4100	g	mol–1)	was	dissolved	in	methanol	(5	mL).	0.8	mg	
(0.1	 equivalent)	 of	 TBD	was	 added	 and	 the	mixture	was	 then	 heated	 to	 65	 °C	 for	 4	 h.	 After	
evaporation	 of	 the	 solvent	 under	 reduced	 pressure	 and	 dissolving	 the	 residue	 in	 DCM,	 the	
product	was	precipitated	in	diethyl	ether,	centrifuged,	separated,	and	dried	under	vacuum.	The	
dry	product	Thiol-PEtOx	was	analyzed	by	DMAc	SEC,	ESI-MS,	and	1H	NMR	spectroscopy.	
Model	Michael	addition	of	Mal-PEtOx	with	benzyl	mercaptan	
In	a	25	mL	round-bottom	flask,	deprotected	Mal-PEtOx	(30	mg)	was	dissolved	in	DCM	(10	mL),	
then	mixed	with	a	10-fold	excess	of	benzyl	mercaptan	and	0.1	equivalent	of	triethylamine.	The	
mixture	 was	 stirred	 overnight	 at	 room	 temperature.	 After	 evaporation	 of	 the	 solvent	 under	
reduced	pressure	 and	dissolving	 the	 residue	 in	DCM,	 the	product	was	precipitated	 in	 diethyl	
ether,	centrifuged,	separated,	and	dried	under	vacuum.	The	dry	product	was	analyzed	by	ESI-
MS,	SEC,	and	1H	NMR	spectroscopy.	
Model	Michael	addition	of	Thiol-PEtOx	with	butyl	acrylate,	acrylic	acid	N-hydroxysuccinimide	
ester,	and	furfuryl	methacrylate	
In	 a	 25	mL	 round-bottom	 flask,	Thiol-PEtOx	 (30	mg)	was	 dissolved	 in	 acetone	 (10	mL),	 then	
mixed	with	a	3-fold	excess	of	either	butyl	acrylate,	acrylic	acid	N-hydroxysuccinimide	ester,	or	
furfuryl	methacrylate,	 and	 0.3	 equivalent	 of	 DMPP.	 The	mixture	was	 stirred	 for	 3	 h	 at	 room	
temperature.	 After	 evaporation	 of	 the	 solvent	 under	 reduced	 pressure	 and	 dissolving	 the	
residue	in	DCM,	the	product	was	precipitated	in	diethyl	ether,	centrifuged,	separated,	and	dried	
under	vacuum.	The	dry	product	was	analyzed	by	ESI-MS	and	DMAc	SEC.	
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7.1.5. Bioconjugation	of	FurMal-PEtOx	with	BSA	
Three	solutions	at	different	polymer-to-protein	molar	 ratios	were	prepared	 (5,	10,	and	15).	A	
solution	of	100	mM	PBS	was	degassed	by	bubbling	nitrogen	 for	30	min.	3	mL	of	oxygen-free	
water	was	transferred	via	a	degassed	syringe	into	a	sealed	vial	equipped	with	a	rubber	septum,	
containing	40	mg	of	BSA	and	either	18.75,	37.5,	or	56.5	mg	of	MalPEtOx	(Mn,SEC	=	10600	g	mol–1,	
Ð	 =	 1.13,	Mn,NMR	 =	 5500	 g	 mol–1)	 stored	 under	 a	 nitrogen	 atmosphere.	 After	 18	 h,	 several	
aliquots	 were	 taken	 for	 SDS-PAGE.	 For	 the	 sample	 with	 the	 polymer-to-protein	 ratio	 of	 5:1,	
preparative	 FPLC	 was	 carried	 out	 and	 a	 relevant	 fraction	 was	 analyzed	 by	 MALDI-ToF	 mass	
spectrometry.	
7.1.6. Surface	modification	procedures	
Acrylate-modified	surfaces	
Silicon	wafers	(1	×	1	cm2)	were	cleaned	by	3	cycles	of	15	min	sonication	with	dichloromethane,	
acetone,	and	MilliQ	water,	in	this	order.	Surfaces	were	then	activated	by	immersion	into	acidic	
piranha	solution	(H2SO4:H2O2,	3:1)	for	40	min	at	room	temperature.	Caution:	piranha	solution	is	
an	extremely	strong	oxidant	and	should	be	handled	very	carefully!	After	rinsing	the	substrates	
twice	with	MilliQ	water,	they	were	dried	under	a	stream	of	N2	and	used	immediately.	Wafers	
were	 immersed	 in	a	1%	 (v/v)	 solution	of	3-(trimethoxysilyl)propyl	acrylate	 in	dry	 toluene	and	
the	 reaction	was	 carried	 out	 for	 2	 hours	 at	 50	 °C	 and	 then	 overnight	 at	 room	 temperature.	
Finally,	surfaces	were	washed	by	rinsing	sequentially	3	times	with	toluene,	acetone,	and	MilliQ	
water	 solutions,	 and	blow-dried	with	N2.	 All	 these	 steps	were	 followed	 and	 characterized	by	
XPS.	
Spotting	setup	
The	 patterning	 of	 Thiol-PEtOx	 was	 performed	 on	 a	 NLP	 2000	 system	 (NanoInk,	 USA)	 with	
oxygen	plasma	activated	(0.2	mbar	O2,	2	min)	SPT	probes	(SPT-S-C10S,	BioForce	Nanosciences,	
USA).	 The	 ink	 mixture	 was	 prepared	 by	 admixing	 1	 µl	 thiol-PEtOx	 solution	 (2.5	 mg	 mL−1	 in	
DMSO)	with	0.2	µl	of	DMPP	and	1	µl	of	glycerol.	Glycerol	was	added	to	prevent	the	premature	
7.	 Experimental	Section	 	
162	
	
drying	of	the	ink	on	the	SPT.	Probes	were	filled	with	0.4	µL	ink,	mounted	onto	the	probe	holder	
and	used	directly	 for	 spotting	on	acrylate-modified	silicon	wafers.	Spotting	was	performed	at	
50%	relative	humidity.	All	patterning	procedures	were	carried	out	with	the	sample	stage	tilted	
by	 8°	 with	 respect	 to	 the	 SPT	 tip	 to	 minimize	 the	 probability	 of	 a	 contact	 between	 the	 ink	
reservoir	and	the	sample	surface.	The	pattern	was	done	using	a	30	µm	spacing	between	dots.	
Unreactive	material	was	removed	The	wafers	were	washed	3x	with	water	and	ethanol.	Samples	
were	analyzed	by	XPS.	
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7.2. Poly(2-ethyl-2-oxazoline)	macromonomers	for	the	synthesis	of	functional	
bottlebrush	polymers	
7.2.1. Materials	and	characterization	techniques	
Materials	
Tetrahydrofuran	(THF),	ethyl	vinyl	ether,	diethyl	ether,	acetonitrile,	and	trimethylamine,	were	
purchased	 from	 commercial	 suppliers	 and	 used	 without	 further	 purification.	 Grubbs	 III	
bispyridyl	 initiator,329	 norbornene-hexanoic	 acid,286	 norbornene-hexanoic	 acid-alkyne,194	 chex	
nitroxide,201	 and	 cross-linker	Acetal-XL285	were	provided	and	prepared	according	 to	 literature	
procedures.	Methyl	tosylate	and	2-ethyl-2-oxazoline	were	distilled	over	calcium	anhydride.		
Instrumentation	
1H	and	13C	nuclear	magnetic	resonance	(NMR)	spectroscopy	
The	 spectra	were	 recorded	on	Bruker	AVANCE-400	NMR	 spectrometer	 in	 the	Department	 of	
Chemistry	 Instrumentation	 Facility	 at	 the	 Massachusetts	 Institute	 of	 Technology	 (MIT).	 All	
compounds	 were	 dissolved	 in	 CDCl3	 and	 the	 residual	 solvent	 peak	 was	 employed	 for	 shift	
correction	(7.26	ppm).		
Matrix-assisted	laser	desorption	ionization	mass	spectrometry	(MALDI-ToF	MS)		
The	measurements	were	conducted	on	a	Bruker	model	MicroFlex	instrument	using	sinapic	acid	
as	 matrix	 with	 NaTFA	 as	 dopant.	 In	 a	 typical	 experiment,	 2.0	 mg	 of	 polymer	 sample	 were	
dissolved	in	500	µL	of	acetonitrile,	then	mixed	with	the	matrix	solution	(1:2	vol/vol),	and	1	µL	
was	spotted	on	the	MALDI	plate	for	analysis.		
Size	exclusion	chromatography	(SEC)	
Polymer	molar	masses	 and	 dispersity	 values	 were	 determined	 using	 DMAc,	 THF,	 or	 DMF	 as	
solvent.	 SEC	 with	 N,N-dimethylacetamide	 (DMAc)	 as	 eluent	 was	 performed	 with	 a	 sample	
concentration	of	2	g	L−1	on	a	Polymer	Laboratories	PL-GPC	50	Plus	Integrated	system	comprising	
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an	autosampler,	a	PLgel	2,5	μm	bead-size	guard	column	(50	×	7.5	mm)	followed	by	three	PLgel	
5	 μm	MixedC	 columns	 (300	 ×	 7.5	mm),	 and	 a	 flow	 rate	 of	 1	mL	min−1.	 The	 SEC	 system	was	
calibrated	against	linear	poly(methyl	methacrylate)	standards	with	molar	masses	ranging	from	
700	to	2	×	106	Da.	The	samples	were	filtered	through	PTFE	membranes	with	a	pore	size	of	0.2	
μm	 prior	 to	 injection.	 When	 tetrahydrofuran	 (THF)	 was	 the	 eluent,	 an	 HP	 series	 1100	 GPC	
system	was	used.	Polystyrene	standards	were	used	for	calibration	and	at	a	flow	rate	of	1.0	mL	
min	−1.	DMF	Size	exclusion	chromatography	(SEC)	analyses	were	performed	on	an	Agilent	1260	
Infinity	setup	with	 two	Shodex	KD-806M	columns	 in	 tandem	and	a	0.025	M	LiBr	DMF	mobile	
phase	 run	 at	 60	 °C.	 The	 differential	 refractive	 index	 (dRI)	 of	 each	 compound	was	monitored	
using	 a	Wyatt	Optilab	 T-rEX	detector	 and	 the	 light	 scattering	 (LS)	 signal	was	 acquired	with	 a	
Wyatt	Dawn	Heleos-II	detector.	A	differencial	refractive	 index	(dn/dc)	of	0.0600	measured	for	
PEtOx	was	used	for	the	calculation	of	Mn	and	Ð.	
Dynamic	light	scattering	(DLS)		
The	measurements	 were	 performed	 using	 a	Wyatt	 Technology	Mobius	 DLS	 instrument.	 The	
sample	 solution	was	 passed	 through	 a	 0.4	 μm	 Teflon	 syringe	 filter	 directly	 into	 the	 cuvette.	
Measurements	were	made	in	sets	of	10	acquisitions	and	the	average	hydrodynamic	diameters	
were	calculated	using	the	DLS	correlation	function	via	a	regularization	fitting	method	(Dynamics	
7.3.1.15	software	package	from	Wyatt	Technology).	
Preparative	gel-permeation	chromatography	(prep-GPC)		
Prep-GPC	 was	 performed	 on	 a	 JAI	 Preparative	 Recycling	 HPLC	 (LaboACE-LC-5060)	 system	
equipped	with	either	2.5HR	and	2HR	columns	in	series	(20	mm	ID	x	600	mm	length)	using	CHCl3	
as	the	eluent.	
Relaxivity	measurements	by	magnetic	resonance	imaging	(MRI)		
Phantom	MRI	data	were	acquired	in	a	12	cm	outer	diameter	birdcage	transceiver	for	imaging	in	
a	20	cm	bore	Bruker	7	T	Avance	III	MRI	scanner.	Samples	at	varying	concentrations	(0	up	to	5	
mM)	 in	PBS	buffer	were	 loaded	 into	 the	wells	 of	 a	 384-well	 clear	polystyrene	plate	 (Thermo	
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Scientific	Nunc),	which	had	been	pre-cut	in	half	to	optimally	fit	the	coil.	Unused	wells	were	filled	
with	PBS	buffer.	2	mm	slices	were	imaged	through	the	samples	with	the	field	of	view	of	5	x	5	
cm	and	the	data	matrices	were	256	x	256	points.	Longitudinal	(r1)	and	transverse	(r2)	relaxivity	
measurements	 were	 acquired	 using	 multi-spin	 multi-echo	 (MSME)	 sequences	 (flip	 angle	 =	
180°).	 r1;	 TE	=	12	ms,	TR	=	300,	350,	400,	450,	500,	600,	800,	1000,	1200,	1500,	3000,	5000,	
10000	ms.	r2;	TR	=	5000	ms,	TE	=	12,	24,	36,	48,	60,	72,	84,	96,	108,	120,	132,	144,	156,	168,	
280,	 192,	 204,	 216,	 228,	 240,	 252,	 264,	 276,	 288,	 300,	 312,	 324,	 336,	 348,	 360	ms.	 Custom	
routines	written	in	Matlab	(Mathworks,	Natick,	MA)	were	used	to	reconstruct	the	images	and	
compute	relaxation	time	constants	by	fitting	image	intensity	data	to	exponential	decay	curves.	
Electron	Paramagnetic	Resonance	(EPR)		
Spectra	were	acquired	at	 the	University	of	Nebraska	using	a	Bruker	CW	X-band	spectrometer	
equipped	with	a	 frequency	 counter.	 The	 spectra	were	obtained	using	a	dual	mode	cavity;	 all	
spectra	were	 recorded	using	an	oscillating	magnetic	 field	perpendicular	 (TE102)	 to	 the	swept	
magnetic	field.	DPPH	powder	(g	=	2.0037)	was	used	as	a	g-value	reference.	
The	 reference	 for	 spin	 concentration	was	0.50	mM	Proxyl	 in	phosphate-buffered	 saline	 (PBS)	
(pH	 7.2).	 This	 reference	 was	 always	 stored	 in	 dry	 ice,	 except	 during	 measurements,	 and	
occasionally	re-checked	for	spin	concentration	decay.	
	
7.2.2. Synthesis	of	PEtOx	macromonomers		
Synthesis	 of	 norbornene-PEtOx	 macromonomers	 (PEtOx	 MM)	 and	 norbornene-branched-
alkyne	PEtOx	macromonomers	(Alkyne-PEtOx	MM)	
All	polymerizations	were	performed	in	capped	vials	in	a	microwave	reactor	(Biotage)	equipped	
with	 an	 infrared	 (IR)	 temperature	 sensor.	 Methyl	 tosylate	 was	 dissolved	 in	 acetonitrile	 in	
microwave	 vials	 at	 different	 monomer-to-initiator	 ratios	 ([M]/[I]	 =	 15,	 30,	 and	 45)	 and	 a	
monomer	concentration	of	4	M.	The	vials	were	crimped	air-tight	under	inert	conditions	inside	a	
glove	box.	The	capped	vials	were	heated	to	140	°C	under	microwave	irradiation	with	constant	
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stirring	 under	 inert	 atmosphere.	 After	 microwave	 irradiation	 the	 polymerization	 was	
terminated	 through	 the	 addition	 of	 1.5	 equivalents	 of	 norbornene-hexanoic	 acid	 (or	 2	
equivalents	 of	 norbornene-hexanoic	 acid-branch-alkyne	 for	 Alkyne-PEtOx	 MM)	 and	 2	
equivalents	of	TEA.	The	mixture	was	stirred	overnight.	After	evaporation	of	the	solvent	under	
reduced	pressure	and	dissolving	 the	residue	 in	DCM,	 the	polymer	was	precipitated	 in	diethyl	
ether,	centrifuged,	separated,	and	dried	under	vacuum.	The	dry	product	was	analyzed	by	SEC,	
MALDI-ToF	MS,	and	1H	NMR	spectroscopy.	
Synthesis	of	norbornene-branched-chex	PEtOx	macromonomers	(chex-PEtOx	MM)	
Alkyne-PEtOx	 MM	 (114.4	 mg,	 1	 eq)	 was	 added	 to	 a	 vial	 with	 bi-spirocyclohexylnitroxide-
propyl-azide	 (14.6	mg,	 1.1	 eq)	 and	 3	mL	 of	 dry	 DCM	 under	 N2.	 A	 spatula	 tip	 of	 CuOAc	was	
added.	 The	 mixture	 was	 stirred	 for	 2	 h.	 The	 entire	 reaction	 mixture	 was	 dried	 on	 a	 rotary	
evaporator,	 redissolved	 in	 CHCl3	 and	 cleaned	 using	 preparative	 GPC.	 The	 pure	 fractions	
containing	 chex-PEtOx	MM	were	 condensed	with	 a	 rotary	 evaporator.	 The	 resulting	 residue	
was	dried	overnight	and	analyzed	via	MALDI-ToF	MS,	DMAc	SEC,	and	1H	NMR.	
	
7.2.3. Formation	of	brush	copolymers	using	PEtOx	MM	
All	syntheses	were	performed	in	a	glove	box.	PEtOx	MM	was	added	to	a	2	mL	vial	containing	a	
stir	bar.	THF	was	added	 to	 the	vial	 followed	by	a	 freshly	prepared	solution	of	Ru	catalyst	G3	
bispyridyl	in	THF	(7	mg	mL−1	THF,	amount	added	to	give	desired	PEtOx	MM:G3)	such	that	the	
total	 concentration	 of	 PEtOx	 MM	 was	 0.05	 M.	 For	 kinetic	 studies,	 samples	 were	 taken	 at	
established	 times,	 and	 ethyl	 vinyl	 ether	 (EVE)	 was	 added	 to	 quench	 the	 polymerization.	 To	
screen	 DPs,	 the	 reactions	 ran	 overnight	 and	 then	 were	 quenched	 with	 EVE.	 The	 resulting	
samples	were	analyzed	by	DMAc	SEC.	
	
	 Poly(2-ethyl-2-oxazoline)	macromonomers	for	the	synthesis	of	functional	bottlebrush	polymers	 7.2	
167	
	
7.2.4. Brush-arm	star	polymer	(BASP)	formation	
Here	 is	 a	 representative	 procedure	 for	 BASP	 synthesis	 with	 brush	 length	 of	 7.0	 (m)	 and	 20	
equivalents	(N)	of	cross-linker	Acetal-XL	(BASP,	m	=	7.07,	N	=	20).	Polymers	with	other	degrees	
of	 polymerization	 can	 be	 readily	 prepared	 by	 varying	 the	 crosslinker-to-initiator	 or	
macromonomer-to-initiator	ratios.	In	a	2	mL	vial,	a	suspension	of	acetal-XL	(20.0	eq)	in	THF	was	
prepared	to	afford	a	concentration	of	0.1	M	acetal-XL.	To	a	second	2	mL	vial	containing	a	stir	
bar,	 either	PEtOx	MM	 or	 chex-PEtOx	MM	 (7.0	 eq)	 was	 added.	 In	 a	 third	 vial,	 a	 solution	 of	
Grubbs	 3rd	 generation	 bispyridyl	 catalyst	 (G3,	 7	 mg/mL	 in	 THF)	 was	 freshly	 prepared.	 The	
corresponding	amount	of	THF	from	vial	3	was	then	added	to	the	PEtOx	MM	or	chex-PEtOx	MM	
vial,	to	give	the	desired	MM:G3	ratio	of	7:1		achieving	a	total	MM	concentration	of	0.05	M.	The	
reaction	mixture	was	 stirred	 for	 30	min	 at	 room	 temperature	 before	 an	 aliquot	 (~5	µL)	was	
taken	 out	 and	 quenched	 with	 1	 drop	 of	 ethyl	 vinyl	 ether	 for	 GPC	 analysis.	 The	 acetal-XL	
suspension	was	then	added	dropwise	(in	aliquots	of	5	eq,	or	~70	µL,	every	5	minutes)	over	the	
course	of	20	min	into	the	MM	vial,	and	the	polymerizing	mixture	was	allowed	to	stir	overnight	
at	 room	 temperature.	 To	quench	 the	polymerization,	 a	drop	of	 ethyl	 vinyl	 ether	was	 added.	
The	 reaction	 mixture	 was	 transferred	 to	 a	 5kD	 molecular	 weight	 cutoff	 dialysis	 tubing	
(Spectrum	Laboratories)	in	10	mL	nanopure	water,	and	the	solution	was	dialyzed	against	water	
(500	mL	X	3,	solvent	exchange	every	6	h).	The	resulting	BASPs	were	analyzed	by	SEC	and	DLS.		 	
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7.3. PNAM	and	POEGMA	conjugates	as	alternatives	to	protein	PEGylation	
7.3.1. Materials	and	instrumentation	
Materials	
N-acryloylmorpholine	 (Sigma,	97%),	1,4-dioxane	 (Sigma,	99%),	dichloromethane	 (DCM;	VWR),	
diethyl	ether	(99.5%,	Roth),	sinapic	acid	(Sigma,	98%),	2,2’-azobis(2-methylpropionitrile)	(AIBN,	
Aldrich,	 98%),	 4-cyano-4-(phenylcarbonothioylthio)pentanoic	 acid	 N-succinimidyl	 ester	
(Aldrich),	 oligo(ethylene	glycol)	methyl	 ether	methacrylate	 (OEGMA;	Mn=300	g	mol-1,	 Sigma),	
trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-propenylidene]malononitrile	 (DCTB,	 99%),	 and	
acetonitrile	(anhydrous,	99.8%,	Sigma)	were	used	as	received.	The	used	buffer	substances	were	
sodium	 citrate	 tribasic	 dihydrate	 (Sigma	 Aldrich)	 for	 pH	 3,	 sodium	 acetate	 trihydrate	 (Sigma	
Aldrich)	 for	 pH	5,	 and	 sodium	phosphate	monobasic	 dihydrate	 (Sigma	Aldrich)	 and	disodium	
hydrogen	phosphate	dihydrate	(Merck)	for	pH	7.	
Instrumentation	
1H	nuclear	magnetic	resonance	(NMR)	spectroscopy		
Measurements	were	performed	on	a	Bruker	AM	500	spectrometer	(500	MHz).	All	compounds	
were	dissolved	in	CDCl3	and	the	residual	solvent	peak	was	used	for	shift	correction	(7.26	ppm).		
Matrix-assisted	 laser	 desorption	 ionization	 coupled	 to	 time-of-flight	 (MALDI-ToF)	 mass	
spectrometry	
Mass	spectra	were	acquired	with	a	4800	Proteomics	Analyzer	(Applied	Biosystems,	Foster	City,	
CA,	USA)	in	positive	ion	linear	mode	and	a	mass	range	of	1000	to	40000	Da.	The	laser	intensity	
was	 set	 to	 4800.	 The	 spectra	 obtained	 represent	 the	 average	 of	 laser	 shots	 taken	 by	 an	
automatic	scheme	measuring	spectra	over	the	whole	spot.	The	matrices	used	were	sinapic	acid	
for	 conjugated	 proteins	 and	DCTB	 for	 the	 polymer	 samples.	 Peak	 lists	were	 generated	 using	
Data	Explorer	Software	4.0	(Applied	Biosystems).		
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Size	exclusion	chromatography	(SEC)		
The	measurements	were	performed	on	a	TOSOH	EcoSEC	HLC-8320	GPC	System,	comprising	an	
autosampler,	 a	 SDV	 5	 µm	 bead	 size	 guard	 column	 (50x8	mm,	 PSS)	 followed	 by	 three	 SDV	 5	
µmm	 columns	 (300x7.5	mm,	 subsequently	 100	 Å,	 1000	 Å	 and	 105	 Å	 pore	 size,	 (PSS)),	 and	 a	
differential	 refractive	 index	 (DRI)	 detector	using	THF	as	eluent	 at	 30	 °C	with	a	 flow	 rate	of	 1	
mL/min.	The	SEC	system	was	calibrated	using	linear	polystyrene	standards	ranging	from	266	to	
252x106	g	mol–1.	Before	injection	the	samples	were	filtered	using	a	0.2	µm	filter.	
	
7.3.2. Polymer	synthesis	
RAFT	polymerization	of	N-acryloylmorpholine	
In	 a	 250	 mL	 round-bottom	 flask	 4-cyano-4-(phenylcarbonothioylthio)pentanoic	 acid	 N-
succinimidyl	 ester	were	mixed	with	 AIBN	 (0.3	 equivalents)	 and	NAM	 (34	 or	 68	 equivalents).	
Trioxane	 was	 used	 added	 to	 be	 used	 as	 reference.	 The	 mixture	 was	 then	 dissolved	 in	 1,4-
dioxane	to	a	monomer	final	concentration	of	1.6	M,	and	flushed	with	nitrogen	for	30	minutes.	
The	polymerization	mixture	was	heated	to	70	°C	and	monitored	by	1H	NMR	spectroscopy	until	
the	target	conversion	values	(70%)	were	reached.	The	polymerization	was	stopped	by	cooling	
the	reaction	flask.	After	evaporation	of	the	solvent	under	reduced	pressure	and	dissolving	the	
residue	 in	 DCM,	 the	 polymer	 was	 precipitated	 in	 diethyl	 ether,	 centrifuged,	 separated,	 and	
dried	 under	 vacuum.	 The	 dry	 product	 was	 analyzed	 by	 SEC,	 MALDI-ToF,	 and	 1H	 NMR	
spectroscopy.	
RAFT	Polymerization	of	oligo(ethylene	glycol)	methyl	ether	methacrylate		
In	 a	 250	 mL	 round-bottom	 flask	 4-cyano-4-(phenylcarbonothioylthio)pentanoic	 acid	 N-
succinimidyl	ester	was	mixed	with	AIBN	(0.2	equivalents)	and	OEGMA	(20	or	40	equivalents).	
The	mixtures	were	dissolved	in	acetonitrile	to	a	RAFT	agent	final	concentration	of	16	mM,	and	
flushed	with	nitrogen	for	30	minutes.	The	polymerization	mixtures	were	then	heated	to	70	°C	
and	 monitored	 by	 1H	 NMR	 until	 the	 target	 conversion	 values	 (50%)	 were	 reached.	 The	
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polymerization	 was	 stopped	 by	 cooling	 the	 reaction	 flask.	 After	 evaporation	 of	 the	 solvent	
under	reduced	pressure	and	dissolving	the	residue	in	DCM,	the	polymers	were	precipitated	in	a	
1:1	mixture	of	petroleum	ether	and	diethyl	ether,	separated,	and	dried	under	vacuum.	The	dry	
products	were	analyzed	by	SEC,	MALDI-ToF,	and	1H	NMR	spectroscopy.	
	
7.3.3. Protein	conjugation	
Conjugation	experiments	were	performed	batch-wise	in	50	mL	Falcon	Tubes	(BD	Biosciences).	
For	 conjugation,	 lysozyme	 and	 the	 respective	 polymer	 were	 dissolved	 in	 25	 mM	 sodium	
phosphate	buffer	at	pH	7.2.	The	concentration	of	lysozyme	was	set	to	0.28	mmol	L–1.	PNAM	and	
POEGMA	were	added	based	on	a	molar	polymer-to-protein	ratio	of	2.	For	the	reaction,	the	tube	
was	 continuously	 shaken	 in	 an	 overhead	 shaker	 (LabincoLD79,	 Labinco	 BV)	 for	 1	 h	 at	 room	
temperature.	
	
7.3.4. Protein	purification	
The	 preparative	 separation	 of	 protein	 conjugates	with	 varying	 numbers	 of	 attached	 polymer	
molecules	was	performed	on	an	AKTA	purifier	system	equipped	with	a	fraction	collector	Frac-
950	(GE	Healthcare).	As	stationary	phase,	a	5	ml	prepacked	Toyopearl	GigaCap	S-650M	cation	
exchange	 (CEX)	 column	 (TOSOH	 Bioscience)	 was	 used.	 For	 column	 loading,	 the	 system	 was	
equilibrated	 in	 10	 mM	 sodium	 acetate	 buffer	 (pH	 5).	 In	 order	 to	 reduce	 the	 influence	 of	
unbound	polymer	on	the	binding	behavior	of	the	conjugates	to	the	CEX	resin,	the	conjugation	
batch	was	diluted	1:6	in	10	mM	sodium	acetate	buffer	(pH	5).	Injection	of	the	diluted	batch	was	
performed	using	 a	 50	mL	 super	 loop	 (GE	Healthcare).	 Elution	was	 performed	by	 applying	 an	
NaCl	 step	 gradient	with	 an	 elution	 buffer	 containing	 1	M	 sodium	 chloride	 in	 10	mM	 sodium	
acetate	buffer	(pH	5).	The	NaCl	molarities	used	for	the	step	elution	of	the	different	conjugates	
are	 displayed	 in	 Table	 12	 in	 dependence	 of	 the	 attached	 polymer.	 The	 flow	 rate	 for	
equilibration,	binding,	and	elution	was	set	to	1	ml	min–1.	To	monitor	the	process,	absorption	at	
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wavelengths	 of	 280	 nm	 (for	 protein)	 and	 320	 nm	 (for	 polymer)	 as	well	 as	 conductivity	were	
detected	 continuously.	 From	 each	 chromatographic	 separation,	 fractions	 of	 2	 mL	 were	
collected	into	a	96-well	plate	(VWR,	USA).	To	obtain	sufficient	sample	for	stability	assessment	
of	 the	 different	 conjugate	 species,	 the	 corresponding	 fractions	 of	 multiple	 chromatographic	
runs	 were	 pooled.	 Peak	 allocation	 to	 the	 different	 conjugate	 species	 were	 performed	 by	
MALDI-ToF.	
	
Table	12.	NaCl	eluent	solution	gradient	(in	mol	L–1)	used	for	the	elution	of	different	conjugate	
species	from	Toyopearl	GigaCap	S-650M	at	pH	5	in	dependency	of	the	attached	polymer	
Polymer	used	
Native	
Lysozyme	
Mono-conjugated	
lysozyme	
Di-conjugated	
lysozyme	
PNAM3.5kDa	 1	 0.36	 0.23	
PNAM7.5kDa	 1	 0.4	 0.175	
POEGMA3.5kDa	 1	 0.37	 0.19	
POEGMA7.5kDa	 1	 0.24	 0.12	
	
7.3.5. Conditioning	and	quantification	of	protein	conjugates	
The	 separation	 of	 protein-polymer	 conjugates	 led	 to	 fractions	 containing	 different	 NaCl	
concentrations.	 Characterizing	 the	 isolated	 conjugates	 with	 regard	 to	 activity	 and	 phase	
behavior	thus	required	a	sample	conditioning	consisting	of	buffer	exchange	(resp.	pH	change)	
and	 concentration	 increase.	 Buffer	 exchange	 was	 carried	 out	 using	 Slide-A-Lyzer™	 Dialysis	
Cassettes	(Thermo	Fisher	Scientific)	with	a	molecular	weight	cut-off	of	2	kDa.	Concentrating	of	
protein	 samples	 was	 performed	 by	 evaporation	 using	 a	 vacuum	 concentration	 unit	 RVC	 2-
33CDplus	(Martin	Christ	Gefriertrocknungsanlagen	GmbH)	operated	at	24	mbar.	Concentrations	
of	 unmodified	 lysozyme	 were	 determined	 by	 measuring	 the	 absorption	 at	 280	 nm	 using	 a	
NanoDrop	 2000c	 UV-Vis	 spectroscopic	 device	 (Thermo	 Fisher	 Scientific)	 and	 an	 extinction	
coefficient	 of	 ε280nm,lyzozyme1%	 =	 22.00.326	 To	 convert	 mass	 concentrations	 into	 molar	
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concentrations,	 a	 molecular	 weight	 of	 lysozyme	 of	 14.3	 kDa	 was	 used.330	 Since	 the	 two	
polymers	PNAM	and	POEGMA	also	absorb	at	280	nm,	the	total	absorption	at	280	nm	(A280nm)	is	
described	for	protein-polymer	conjugates	by:		
A280nm	=	A280nm,lysozyme	+	A280nm,polymer	
In	order	to	quantify	the	molar	concentration	of	the	protein-polymer	conjugates,	measurements	
solely	 at	 280	 nm	 are	 therefore	 not	 sufficient.	 For	 the	 quantification	 of	 protein-polymer	
conjugates,	 a	 method	 based	 on	 the	 differences	 in	 the	 spectra	 of	 protein	 and	 polymer	 was	
applied.	At	320	nm,	 the	 two	polymers	absorb	 light	due	 to	 the	RAFT	group,331	while	 lysozyme	
does	not.	 Thus,	 by	measuring	 the	 absorption	 at	 320	nm	and	 comparing	 it	 to	 a	 calibration	of	
polymer	 solutions,	 it	 is	 possible	 to	 quantify	 how	 much	 polymer	 is	 bound	 to	 a	 protein.	 For	
polymer	 calibration,	 absorption	 spectra	 between	 240	 nm	 and	 340	 nm	 were	 recorded	 for	
polymer	 solutions	 (in	 conjugation	buffer)	 at	 10	 concentrations	 between	0.1	 and	1.0	mg	mL–1	
using	 a	 NanoDrop	 2000c	 UV-Vis	 spectroscopic	 device	 (Thermo	 Fisher	 Scientific)	 (Figure	 95).	
Using	 the	 respective	molar	mass	of	 the	polymer,	 the	mass	concentrations	were	converted	 to	
molar	concentrations.	
	
Figure	95.	Absorption	spectra	of	lysozyme,	PNAM7kDa,	and	POEGMA7.5kDa	normalized	to	their	absorption	
maximum.	
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From	the	recorded	polymer	spectra,	the	absorption	values	were	extracted	for	280	nm	and	320	
nm.	By	implementing	the	proportionality	
K	=	A280nm,polymer/A320nm,polymer	
it	is	possible	to	calculate	the	absorption	A280nm,lysozyme	as		
A280nm,lysozyme	=	A280nm	−	K	·	A320nm,polymer	
For	the	K	value,	the	mean	value	of	all	K	values	of	the	10	measured	polymer	concentrations	was	
used.	 In	 order	 to	 convert	 the	 calculated	 absorption	 A280nm,lysozyme	 into	 a	 concentration,	 the	
extinction	 coefficient	 of	 ε280nm,lyzozyme1%	 =	 22.00	 was	 used	 as	 for	 unmodified	 lysozyme.	 All	
concentration	measurements	were	performed	as	triplicates.	
	
7.3.6. Stability	assessment		
Functional	stability	
In	order	 to	evaluate	 the	 residual	activity	of	 the	protein-polymer	conjugates	after	 conjugation	
and	 separation,	 a	Micrococcus	 lysodeikticus-based	 activity	 assay	was	 performed	 according	 to	
Morgenstern	et	al.305	The	kinetic	assay	is	based	on	the	lysis	of	bacterial	cells	by	the	enzyme.	The	
decrease	 in	 cell	 density	 results	 in	a	decrease	 in	 turbidity	over	 time,	which	was	monitored	by	
measuring	the	absorbance	at	450	nm.	To	allow	a	comparison	for	different	conjugated	species,	
the	derived	activities	were	normalized	to	the	activity	of	native	lysozyme.	
Colloidal	stability	
Using	a	protocol	reported	by	Baumgartner	et	al.,323	a	total	of	 five	protein	phase	diagrams	for	
mono-PNAM3.5kDaylated	 lysozyme,	 di-PNAM3.5kDaylated	 lysozyme,	 mono-PNAM7kDaylated	
lysozyme,	monoPOEGMA3.5kDaylated,	and	monoPOEGMA7.5kDaylated	 lysozyme,	were	generated	
on	 an	 automated	 liquid	 handling	 station	 (Freedom	 EVO®200	 from	 Tecan).	 The	 pH	 value	was	
adjusted	 to	 3	 using	 a	 buffer	 system	 of	 citric	 acid	 monohydrate	 (Merck)	 and	 sodium	 citrate	
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tribasic	 dihydrate	 (Sigma	 Aldrich,	 USA)	 and	 a	 total	 buffer	 capacity	 of	 100	mM.	 The	 purified	
conjugated	 species	were	 concentrated	 to	 3.04	 ±	 0.07	mM	 (corresponds	 to	 43.5	 ±	 1	mg	mL–1	
unmodified	protein)	 and	dialyzed	 into	100	mM	citric	buffer	 (pH	3)	 (=	protein	 stock	 solution).	
Eight	protein	dilution	steps	between	0.35	and	3.04	mM	were	prepared	by	mixing	protein	stock	
solution	and	100	mM	citric	buffer	(pH	3)	on	a	protein	plate.	As	precipitant,	sodium	chloride	was	
used.	Twelve	salt	concentrations	between	0	and	5	M	were	created.	Binary	phase	diagrams	were	
generated	by	mixing	12	µL	of	 each	diluted	protein	 solution	with	12	µL	of	 each	prepared	 salt	
concentration	 on	 a	 crystallization	 plate	 (Swissci)	 resulting	 in	 96	 batch	 systems	 with	 varying	
composition.	As	a	result,	the	protein	concentrations	varied	from	0.17	to	1.52	mM	and	the	salt	
concentrations	 from	 0	 M	 to	 2.5	 M.	 Evaluation	 of	 phase	 states	 was	 conducted	 based	 on	
photographs	 taken	 by	 the	 Rock	 Imager	 182/54	 automated	 imaging	 system	 (Formulatrix).	 In	
order	 to	 determine	 solubility	 lines,	 the	 protein	 concentration	 in	 the	 supernatant	 of	 batch	
systems	where	 a	 phase	 transition	 occurred	was	 determined	 after	 40	 days	 using	 a	NanoDrop	
2000c	UV–Vis	spectroscopic	device.	
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MRI		 	 magnetic	resonance	imaging	
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NMR	 	 nuclear	magnetic	resonance	
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PCBMA	 poly(carboxybetaine	methacrylate)	
PEG		 	 polyethylene	glycol	
PEGA	 	 poly(ethylene	glycol	acrylate)		
PEtOx	 	 poly(2-ethyl-2-oxazoline)		
PG		 	 polyglycerol		
PGA	 	 polyglutamic	acid	
PHEA		 	 poly(hydroxyethyl-L-asparagine)	
PHEG		 	 poly(hydroxyethyl-L-glutamine)		
PHPMA		 poly(N-(2-hydroxypropyl)methacrylamide)		
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PLA		 	 polylactic	acid		
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PNAM			 poly(N-acryloyl	morpholine)		
POEGMA		 poly(oligo(ethylene	glycol)	methyl	ether	methacrylate)		
ppm	 	 part	per	million	
PRE	 	 persistent	radical	effect	
PSA	 	 polysialic	acid		
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PSBMA	 poly(sulfobetaine	methacrylate)	
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RNA	 	 ribonucleic	acid	
ROMP			 ring-opening	metathesis	polymerization	
RT	 	 room	temperature	
SEC	 	 size	exclusion	chromatography	
SDS-PAGE	 sodium	dodecyl	sulfate	polyacrylamide	gel	electrophoresis	
TEA	 	 triethylamine	
THF	 	 tetrahydrofuran	
wt%	 	 weight%	
XPS	 	 X-ray	photoelectron	spectroscopy	
δ	 	 chemical	shift	
λ	 	 wavelength		 	
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